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Task of this Thesis 
Palladium catalyzed transformations have gained remarkable importance for C-C bond 
formation; these reactions are being used for the synthesis of a number of natural 
products, pharmaceutical drugs and advanced materials. The aim of this work is to 
enhance the scope of palladium catalyzed reactions. In recent years, site-selective 
palladium(0) catalyzed cross-coupling reactions of di- and trihalogenated molecules or 
the corresponding triflates have been studied. The Langer group has also greatly 
contributed to this. This paragraph outlines the tasks of this thesis. A more detailed 
introduction is given at the beginning of each individual chapter. I studied the site-
selectivity of palladium catalyzed transformations of a number of di- and tribromides 
derived from hetero- and carbacycles. Reactions of bis(triflates) are also included. Site 
selective reactions of the substrates discussed in my thesis have not been previously 
studied by other research groups. In addition, I had the task to apply Heck reactions to 
substrates where these types of reactions have not been previously reported. 
Although a diverse set of substrates were studied, the general topic of this thesis was to 
develope new applications of palladium(0)-catalyzed reactions to polyhalogenated 
substrates or their triflate analogues. 
In continuation of related work in our group, I had the task to apply the concept of 
domino ′twofold Heck / 6π-electrocyclization′ reactions to di- and tribromo- 
benzothiophene. These reactions afforded functionalized dibenzothiophenes. 
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I also had the task to study domino ′twofold Heck / 6π-electrocyclization′ reactions of 
dichloropyrazine and dichloroquinoxaline. While Heck reactions were possible, the 
electrocyclizations failed. 
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Another task was to study regioselective Suzuki-Miyaura cross-coupling reactions of the 
bis-triflate of 7,8-dihydroxyflavone. These reactions afforded mono- and diarylflavones 
with good site selectivity. 
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The Sonogashira reaction is used as key step in the synthesis of many biological active 
compounds. My task was to study hitherto unknown Sonogashira coupling reactions of 
2,4,5,6-tetrachloropyrimidine and of  2,3,4,5-tetrabromofuran. These reactions afforded 
the desired alkynylated heterocycles. Based on this, an important goal was to study the 
fluorescence properties. 
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A significant part of this dissertation has been published (see list of publications). A 
detailed introduction is given at the beginning of each individual chapter.  
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Chapter 1:  Synthesis of functionalized dibenzothiophenes by Heck  reactions
Efficient Synthesis of Functionalized Dibenzothiophenes by Domino 
Twofold Heck/6-Electrocyclization Reaction of 2,3-Dibromobenzo- 
thiophene and 2,3,6-tribromobenzothiophene. 
1.1 General Introduction 
The Heck reaction was discovered by Heck in 1968 1 and then developed by Mizoroki 
and Heck in the 1970’s. It is the palladium catalyzed C-C coupling between aryl halides 
or vinyl halides with activated alkenes in the presence of palladium(0) catalyst and a 
base.2 Palladium(II) acetate or Palladium(II) chloride in combination with different 
ligands, such as triphenyl phosphine (PPh3), S-Phos, X-Phos, tricyclohexylphosphine 
(PCy3), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), were used in this reaction. 
Phosphine ligands stabilize the palladium in its oxidation state zero state in the form of 
stable PdL4 or PdL3 species. There are many choices of base used in this reaction, such as 
triethylamine, diisoproylamine, potassium carbonate, sodium acetate.3 The reactivity 
depends on the substituted olefins: more substituted olefins resulted slower reaction. 
However, electron poor olefins provided higher yields (electron withdrawing groups such 
as ester, ether, carboxylic acid, nitriles, located at the olefin). The type of leaving group 
also plays an important role. The reactivity order is I > Br > Cl.4 The mechanism of the 
Heck reaction involves the oxidative addition, migratory insertion of the olefins and then 
- hydride elimination.5 The Heck reaction was widely used as a key step in the total 
synthesis of natural products, for the preparation of polymers, pharmaceuticals, and 
hydrocarbons.6
In a couple of years, Prof Langer’s research group has extensively studied twofold Heck 
cross coupling reactions of 2,3-dibromobenzofuran (a),7 2,3-dibromothiophene (b),8 2,3-
dibromo-N-methylindole (c),9 2,3-dibromofuran (d), 2,3-dibromoindenone (e),10 2,3-
dibromo naphthaquinone (f).11 (Figure.1). The electrocyclization and dehydrogenation of 
Heck products provided upon heating in the presence of Pd/C a variety of aromatized 
products. 
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Figure 1.  Heck Reaction Studies on vicinal dibromide in Prof Langer’s Group.
1.2 Introduction 
Benzothiophenes are found in drugs, such as raloxifene, zileuton and sertaconozole. 
Benzothiophenes are present in coffee beans and are used in many dyes, such as 
thioindigo and its derivatives. It is also used in crop protection; for example, Mobam is a 
potent insecticide, which inhibits the enzyme acetylcholinsterase. Dibenzothiophenes 
have never been reported as natural products, still, they can be obtained from coal tar. 
Among the various classes and numerous kinds of sulphur-containing organic compounds 
identified in fossil fuels, the most represented are dibenzothiophene (DBT), and its 
derivatives. Therefore, this compound can be considered to be the model substrate of 
organically bonded sulphur in fossil fuels.12 However, they have shown substantial 
pharmacological properties, for example, antimicrobial,13 antileishmanial,14 
antiprotozoal,15 antidiabetic,16 cytotoxic,17 and genotoxic activity.18 In addition, binding 
to the dopamine19 to the estrogen receptor 20 and to neuroblastoma cells,21 inhibition of 
human protein tyrosine phosphotase 1B,22 and of MAOA23 have been studied. 
Dibenzothiophene has been also used as a model S-heterocycle for studying 
desulfurization in a number of microorganisms, Rhodococcus sp. strain IGTS8 is a 
prototype sulfur-specific desulfurization bacterium.24
Presently and during recent years, polyhalogenated heterocycles have been shown to be 
regioselectively functionalized in palladium (0)-catalyzed cross-coupling reactions. To 
determine the regioselectivity in polyhalogenated compounds electronic and steric 
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parameters find key role by activation of single halogen atom.25 Recently, Prof. P. 
Langer`s research group has reported the synthesis of aryl-substituted thiophenes, 
pyrroles,  and selenophenes  based on regioselective Suzuki reactions of tetrabromo- 
thiophene, tetrabromo-N-methylpyrrole, and tetrabromoselenophene, respectively.26 
Sonogashira, Negishi, and Stille coupling reactions of 2,3- and 2,6-dibromobenzofuran 
have been reported to regioselectively occur at position C-2.27
I have studied the Heck reactions of 2,3-dibromobenzothiophene and 2,3,6-tribromo- 
benzothiophene and subsequent 6π-electrocyclizations. Functionalized dibenzothiophene 
were efficiently prepared based on domino twofold Heck / 6π-electrocyclization
reactions.28  
1.3 Results and Discussion 
The reaction of benzothiophene (1) with bromine (2.0 equiv.) and KOAc (2.0 equiv.) in 
CH2Cl2 (reflux, 18 h) resulted in the formation of 2,3-dibromobenzothiophene (2a) in 
84% yield (Scheme 1). During optimization and scale-up of the reaction, I have found 
that more vigorous conditions (reflux, 18 h) were required to avoid the formation of 
mono-brominated by-products. I have also prepared, for the first time, 2,3,6-
tribromobenzothiophene (2b) by using an excess of bromine (4.5 equiv) and KOAc (4.5 
equiv) in CH2Cl2 (reflux, 24 h). 
S
S S
1
2a (84%) 2b (70%)
Br
Br
Br
Br
Br
i ii
Scheme 1. Bromination of benzothiophene (1); conditions: i, Br2 (2.0 equiv.), KOAc (2.0 
equiv.) CH2Cl2, reflux, 18 h ii, Br2 (4.5 equiv.), KOAc (4.5 equiv.), CH2Cl2, reflux, 24 h 
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The Heck reaction of 2a with acrylates 3b,e (2.5 equiv.) afforded the 2,3-
di(alkenyl)benzothiophenes 4b,e in good yields (Scheme 2, Table 1). The best yields 
were obtained when the reactions were carried out using Pd(OAc)2 (5 mol%) and the 
biaryl monophosphine ligand L1 (10 mol%) which was recently developed by Buchwald 
and coworkers (Figure 2).29 The reactions were carried out in DMF at 100 ˚C for 12 h. 
Heating of a xylene solution of 4b,e in the presence of Pd/C resulted in the formation of 
dibenzothiophene 6b,e in 79-81%.  
The Heck reaction of 2a with acrylates 3a,c,d, carried out at 80-130 °C using several 
ligands (PCy3, PPh3) with Pd(OAc)2, failed. I also tried different solvents such as N-
methyl-2-pyrrolidone (NMP), acetonitrile (CH3CN), dimethylsulfoxide (DMSO), 
dimethylacetamide (DMA), but no satisfactory results were obtained. Finally, I tried 
Buchwald ligands with palladium(II) acetate and DMF as solvent and obtained excellent 
results (For optimization, Table 2). The reaction of 2a with acrylates 3a,c,d, carried out at 
130 °C and using biaryl monophosphine ligand L2, afforded the 1,2-
dihydrodibenzothiophenes 5a,c,d as a mixture of two isomers. Their formation can be 
explained by a domino twofold Heck / thermal 6π-electrocyclization cyclization and 
subsequent double bond migration. Heating of a xylene solution of crude 5a,c,d in the 
presence of Pd/C resulted in the formation of dibenzothiophenes 6a,c,d in 74-77% overall 
yields. The reaction of 2a with chlorostyrene 3f directly afforded dibenzothiophene 6f 
(83%) in only one step.  
PCy2
OMe
Cy = Cyclohexyl
MeO
L1 =
PCy2
iPrPri
L2 =
iPr
X-PhosS-Phos
Figure 2. Biaryl monophosphine ligands developed by Buchwald and coworkers 29
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i ii
3a-f
5a,c,d
4b,e
6a-f
i i i
ii i
Scheme 2 Synthesis of 4b,e and 6a–f. Reagents and conditions:(i) Pd(OAc)2 (5 mol-%), 
L2 (10 mol-%), 3 (2.5equiv), Et3N (8.0 equiv), DMF, 100 °C, 12 h; (ii) Pd(OAc)2 (5 
mol%), L1 (10 mol-%), 3 (2.5 equiv), Et3N, DMF, 130 °C, 48 h; (iii) Pd/C (10 mol-%), 
xylene, reflux, 48 h. 
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Table 1. Synthesis of 4b,e and 6a-f 
a Yields of isolated products based on 2a. 
b Experiment was not carried out. 
c Product was directly formed from 2a in one step. 
Table 2. Optimization of the reaction condition for Heck products 
a isolated yield; b No Conversion; c Experiment was not carried out; d isomeric mixture. 
3,4,6 R % (4) a % (6) a
a CO2Et - b 76
b CO2nBu 71 81
c CO2iBu - b 74
d CO2nHex - b 77
e Ph 85 79 
f 4-ClC6H4 - b    83 c
Entry Conditions Temp 
[°C]
(4b) a
% 
(4e) a
% 
(5a) a
% 
(5c) a
% 
(6f) a
% 
1 PPh3(10 mol-%), Pd(OAc)2
(5 mol-%), CH3CN 
80 - b - c - b - c - b
2 PPh3(10 mol-%), Pd(OAc)2
(5 mol-%), DMF 
100 22 31 - b - c 62 
3 PCy3(10 mol-%), Pd(OAc)2
(5 mol-%), DMF
120 - b - c - d - d 47 
4 N(CH2CH2OH)3,  Pd(OAc)2
(5 mol-%) 
100 - c - b - b - c - b
5 Pd(PPh3)4  (10mol-%), DMF, 
K2CO3
120 - b - c - b - b 20 
6 L2 (10 mol-%),  Pd(OAc)2
(5 mol-%), DMF 
100 71 85 - c - c 83 
7 L1 (10 mol-%),  Pd(OAc)2
(5 mol-%), DMF 
130 - c - c - d - d - c
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According to the literature, the Sonogashira, Suzuki and Stille reactions of 2a
regioselectively occurred at carbon atom C-2.27a  Surprisingly, I have found that the Heck 
reaction of 2a with one equivalent of alkenes 3a,b,g,e,h afforded the 3-
(alkenyl)benzothiophenes 7a-e (Scheme 3, Table 3). The best yield (81%) was obtained 
when 7a was reacted with ethyl acrylate (3a) using Pd(OAc)2 (5 mol-%) in combination 
with biaryl monophosphine ligand L1 (10 mol-%). The employment of Pd(OAc)2  in the 
presence of PPh3 or PCy3 did not give good yields. The reaction was carried out in DMF 
at 130 °C for 24 hours. Other solvents, such as N-methyl-2-pyrrolidone (NMP) and 
acetonitrile (CH3CN), proved to be less successful in terms of yield (For Optimization of 
mono Heck products, Table 4). 
The formation of products 7 can be explained by Heck reaction, which occurs at carbon 
atom C-3, and reduction of the bromide function located at carbon C-2. In case of 
benzofuran and indole, carbon atom C-2 is much more electron deficient than C-3. This 
effect is less pronounced in case of benzothiophene and the rate of the oxidative addition 
at C-2 and C-3 should be not too much different. A reduction of carbon C-2 in the first 
step is unlikely because the 2,3-dialkenylbenzothiophenes 4b,e are cleanly formed 
without any reduction. Therefore, the reason for the formation of products 7 remains 
unclear at present. 
S
Br
Br
S
2a
R
i
7a-e
R
3a,b,e,g,h
Scheme 3. Synthesis of 7a-e. Conditions: i, Pd(OAc)2 (2.5-5 mol-%), L1 (for 7a,b,d) or
L2 (for 7c,e) (5-10 mol-%), 3 (1.25 equiv.), NEt3, DMF, 130 ˚C, 24 h. 
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Table 3. Synthesis of 7a-e
a Yields of isolated products 
Table 4. Optimization of the reaction condition for 7a,c,e
a isolated yield; b No Conversion;  
c Experiment was not carried out 
3 7 R % (7) a
a a CO2Et 81
b b CO2nBu 65
g c CN 51
e d Ph 74
h e 4-MeC6H4 76
Entry Conditions Temp 
[°C] 
(7a) a
% 
(7c) a
% 
(7e) a
% 
1 PPh3(10 mol-%), Pd(OAc)2
(5 mol-%), DMF 
80 - b - b - c
2 PCy3(10 mol-%), Pd(OAc)2
(5 mol-%), DMF
90 - b - b - c
3 N(CH2CH2OH)3,  Pd(OAc)2
(5 mol-%) 
100 - b - b - b
4 PCy3(10 mol-%), Pd(OAc)2
(5 mol-%), NMP, K2CO3
120 17 22 42 
5 L2 (10 mol-%),  Pd(OAc)2
(5 mol-%), DMF 
130 61 51 76 
6 L1 (10 mol-%),  Pd(OAc)2
(5 mol-%), DMF 
130 81 47 56 
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The structures of all products were established by spectroscopic methods.The structure of 
7d was idependently confirmed by X-ray crystal structure analysis (Figure 2).30 The X-
ray structure shows that the phenyl group, the alkenyl unit and the benzothiophene 
moiety are in plane. 
Figure 3. Molecular structure of 7d 
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S
Br
Br
Br
S
Ph
Ph
Ph
2b
S
Ph
Ph
S
Ph
Ph
+
Ph
Ph
10 (73%)
S
Ph
Ph
Ph
8
9
ii i
i i i i i i
3e
Ph
Scheme 4. Synthesis of 8,9 and 10. Conditions: i, Pd(OAc)2 (5 mol-%), L1 (10 mol-%), 3 
(3.75 equiv.), NEt3 (8.0 equiv.), DMF, 100 ˚C, 12 h; ii, Pd(OAc)2 (5 mol-%), L1 (10 mol-
%), 3 (3.75equiv.), NEt3, DMF, 130 ˚C, 48 h; iii, Pd/C (10 mol-%), xylene, reflux, 48 h.  
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The Heck reaction of 2,3,6-tribromobenzothiophene (2b) with styrene (3e) afforded the 
2,3,6-tri(alkenyl)benzothiophenes 8  (Scheme 4). The reaction was carried out in DMF at 
100 ˚C for 12 h using Pd(OAc)2/L1 as the catalyst. The Pd(OAc)2/L1-catalyzed reaction 
of 2b with 3e, carried out at 130 °C, afforded 9 as a mixture of two isomers. Heating of a 
xylene solution of 8 and 9, in the presence of Pd/C, afforded the 2,3-diphenyl-7-
styryldibenzothiophenes 10.  
1.4 Conclusion 
I have synthesized 2,3-di(alkenyl)benzothiophenes and dibenzothiophene by the first 
Heck reactions of 2,3-dibromobenzothiophene. I have obtained mono-Heck products 
along with reduction of carbon atom C-2, when 2,3-dibromobenzothiophene was treated 
with one equivalent of different alkenes. In addition, I was successful to prepare 2,3,6-
tribromobenzothiophenes which were subsequently treated with styrenes to give 2,3-
diphenyl-7-styryl-dibenzothiophenes in good yield. The functionalized dibenzo- 
thiophenes were formed by domino ′twofold Heck / 6π-electrocyclization′ reactions. 
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Chapter 2: Synthesis of functionalized pyrazines and quinoxalines by Heck  reactions
Synthesis of 2,3-Disubstituted Pyrazines and Quinoxalines by 
Heck Cross-Coupling Reactions of 2,3-Dichloropyrazine and 
2,3-Dichloroquinoxaline 
2.1 Introduction 
Pyrazine and quinoxaline (benzopyrazine) are heterocyclic compounds which have 
significant biological and physical importance in organic chemistry. They are found in 
various natural products. Examples include various simple alkyl-substituted pyrazine 
derivatives,31 botryllazines A and B,32 or 2,5-bis(3-indolylmethyl)pyrazine.33 Different 
types of quinoxaline analogues have been prepared which show antibiotic activity. 
Quinoxaline antibiotics of bicyclic octadepsipeptide are potent inhibitors of RNA 
synthesis and quinoxaline antibiotics of echinomycin analogues show remarkable 
cytotoxicity against human tumor cell lines.34 Antimicrobial activity has been reported 
also for naturally occurring phenazines (isolated from marine actinomycete).35 Pteridines 
(isolated from Drosophila) represent nucleobase-type natural products which are also 
pharmacologically active (e. g inhibition of tRNA-guanine transglycosylase).36,37 A 
pyrazine derivative has been isolated from the mushroom Albatrellus confluens and 
promotes melanin synthesis by B 16 melanoma cells.38 The cephalostatins  and 
ritterazines  show a strong cytotoxic  and cancerostatic activity.39 
N
N
OHO
Saphenic acid
(phenezine)
N
N
OH
O
HO
Botryllazine B
N
NO
OH
Melanin synthesis promotor
(pyrazine derivative)
Figure 4. Some examples of pyrazine natural products 
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Some pyrazine derivatives, formed by reaction of 2,3-dichloropyrazine with DBU, show 
fluorescence properties.40 2,3-Dichloropyrazine and 2,3-dichloroquinoxaline represent 
useful building blocks for the synthesis of substituted and annulated pyrazines and 
quinoxalines. Condensed heterocycles have been prepared by cyclization of 2,3-
dichloropyrazine with 2-aminobenzenethiol,41 2-aminophenol,42 3-hydroxy-1H-pyridine-
2-thione,43 3-amino-6-methoxy-1H-pyridine-2-thione,44 2-amino-benzeneselenol,45 and 
pyrid-2-yl-acetonitrile.46 Open-chained pyrazines have been prepared by reaction of 2,3-
dichloropyrazine with one equivalent of different enolates,47 two equivalents of thiols,48
and DMAP.49 Transition metal-catalyzed reactions of 2,3-dichloropyrazine have only 
scarcely been reported. 2,3-Diarylpyrazines and 2,3-di(alkynyl)pyrazines have been 
recently prepared by Suzuki 50 and Sonogashira reactions, respectively.51 In my thesis, I 
have studied the first Heck reactions of 2,3-dichloropyrazine and -quinoxaline.52, 53 These 
reactions provide, depending on the reaction conditions, a convenient approach to 2,3-
dialkenyl-, 2-alkenyl-3-alkyl-, and 2,3-dialkylpyrazines and their quinoxaline derivatives. 
2.2 Results and Discussion 
The reaction of 2,3-dichloropyrazine (11a) with ethyl acrylate (3a), in the presence of 
Pd(OAc)2 (5 mol-%) and L2 (10 mol-%), afforded the 2,3-dialkenylpyrazine 12a in 83% 
yield (Scheme 5, Table 5). The employment of Pd(PPh3)4 was less successful in terms of 
yield. The best yields were obtained when 5 mol-% of the catalyst, 10 mol-% of the 
ligand and a slight excess of the alkene (2.5 equiv) were employed and when the reaction 
mixture was stirred at 90 °C for 48 h. Partial hydrogenation was observed when the 
reaction was carried out at higher temperature. On the other hand, the yields also 
decreased when the temperature was decreased, due to lower conversion of the starting 
material (entry 1-6, Table 6).  
The Pd(OAc)2-catalyzed reaction of 11a with styrenes 3e,f,h-j, in the presence of L2 or 
L1, gave the 2,3-dialkenylpyrazines 12b-f in 64-82% yields. The reaction of 2,3-
dichloroquinoxaline (11b) with 3e, i, j, m afforded the 2,3-dialkenylquinoxalines 12g-l in 
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67-83% yields. The synthesis of the quinoxaline derivatives had to be carried out at 120 
instead of 90 °C to obtain good yields.   
N
N Cl
Cl i
11a,b 12a-l
R3
N
N
R3
R3R1
R2
R1
R2
Scheme 5. Synthesis of 2,3-di(alkenyl)pyrazines and quinoxalines 12a-l. Conditions: i, 
3a,e,f,h-m (2.5 equiv.), Pd(OAc)2 (5 mol-%), L2 (for 12a,b,e-l) or L1 (for 12c,d) (10 
mol-%), NEt3, DMF, 90 ˚C. 
Table 5. Synthesis of 12a-l 
11 3 12 R1 R2 R3 % (12) a  T [°C]
a a a H H CO2Et 83 90 
a e b H H Ph 82 90 
a i c H H 4-(MeO)C6H4 78 b 90
a h d H H 4-MeC6H4 82 b 90
a f e H H 4-ClC6H4 66 90
a j f H H 4-(tBuO)C6H4 64 90
b k g 
−(CH=CH)2− CO2Me 78 120 
b l h 
−(CH=CH)2− cHex 67 120 
b e i 
−(CH=CH)2− Ph 72 120 
b j j 
−(CH=CH)2− 4-(tBuO)C6H4 67 120 
b i k 
−(CH=CH)2− 4-(MeO)C6H4 83 120 
b m l 
−(CH=CH)2− 4-tBuC6H4 69 120 
a Yield of isolated products;  
b L1 instead of L2 was used
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Table 6. Optimization of the reaction condition for 12a,b,g,h
Entry T [°C] % (12a) a % (12b) a % (12g) a % (12h) a
1 70 - b - b - b - c
2 80 52 48 - b - c
3 90 83 82 - b - b
4 100 - c - c - b - b
5 110 - c - c 59 36 
6 120 - c - c 78 67 
       
     Reaction condition: L 2 (10 mol-%), Pd(OAc)2 (5 mol-%), DMF 
     a isolated yield; b No Conversion; c Experiment was not carried out 
     
         
The Pd(OAc)2-catalyzed reaction of 2,3-dichloropyrazine (11a) with acrylates 3a-d,k,n,o
(2.5 equiv.), carried out at 110 rather than 90 °C, afforded the 2-alkenyl-3-alkylpyrazines 
13a-g in 69-83% yield (Scheme 6, Table 7). The formation of products 13a-g can be 
explained by partial reduction of the in situ formed 2,3-dialkenylpyrazines. The reaction 
of 2,3-dichloroquinoxaline (11b) with tert-butyl acrylate (3n), carried out at 130 ˚C , 
gave 2-alkenyl-3-alkylquinoxaline 13h. 
N
N Cl
Cl
i
11a,b 13a-h
R3
N
N
R3
R3R1
R2
R1
R2
Scheme 6. Synthesis of 2-alkenyl-3-alkyl-pyrazines and quinoxalines 13a-h. Conditions:
i,: 3a-d, k, n, o (2.5 equiv.), Pd(OAc)2 (5 mol-%), L2 (10 mol-%), NEt3, DMF, 110 ˚C, 
48 h (for 13a-g), 24 h (for 13h) 
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Table 7. Synthesis of 13a-h 
11 3 13 R1 R2 R3 % (13) a T [°C] 
a k a H H CO2Me 78 110 
a a b H H CO2Et 71 110 
a b c H H CO2nBu 74 110
a c d H H CO2iBu 75 110
a n e H H CO2tBu 83 110
a d f H H CO2nHex 79 110
a o g H H CO2R b 69 110 
b n h 
−(CH=CH)2− CO2tBu 75 130 
a Yield of isolated products; 
  b R = CH2CH(Et)(CH2)3CH3
The Pd(OAc)2-catalyzed reaction of 11a with 2.5 equiv. of acrylates 3b,c,n, carried out at 
140 °C, afforded the 2,3-dialkylpyrazines 14a-c in good yields (Scheme 7, Table 8). The 
formation of products 14a-c can be explained by complete reduction, due to the high 
temperature. The reaction of 11b with 3o and 3n, carried out at 150 °C, afforded the 2,3-
dialkylquinoxalines 14d and 14e, respectively. 
N
N Cl
Cl
R1
R2 N
NR1
R2
R3
i
R3
R3
11a,b 14a-e
Scheme 7. Synthesis of 2,3-dialkyl-pyrazines and quinoxalines 14a-e. Conditions: i: 
3b,c,n,o (2.5 equiv.), Pd(OAc)2 (5 mol-%), L2 (10 mol-%), NEt3, DMF, 140 ˚C, 48 h (for 
14a-c), 150 ˚C  24 h (for 14d,e). 
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Table 8. Synthesis of 14a-e 
11 3 14 R1 R2 R3 % (14) a T [°C] 
a b a H H CO2nBu 69 140
a c b H H CO2iBu 76 140
a n c H H CO2tBu 70 140
b o d 
−(CH=CH)2− CO2R
 b 69 150 
b n e 
−(CH=CH)2− CO2tBu 77 150 
a Yield of isolated products; 
b R = CH2CH(Et)(CH2)3CH3
The Pd(OAc)2-catalyzed reaction of 11b with 1.25 rather than 2.5 equiv. of 3l, carried out 
at 120 °C, afforded the 2-alkenylquinoxaline 15 in 70% yield (Scheme 8). The formation 
of product 15 can be explained by partial reduction of the in situ formed 2-chloro-3-
alkenylquinoxaline. 
N
N Cl
Cl
i
N
N
11b 15 (70%)
Scheme 8. Conditions: i, Pd (OAc)2 (5 mol-%), L2 (10 mol-%), 3l (1.25 equiv.) NEt3, 
DMF, 120 ˚C, 48 h. 
2.3 Conclusion 
I have synthesised 2,3-dialkenyl-, 2-alkenyl-3-alkyl-, and 2,3-dialkylpyrazines and their 
quinoxaline derivatives based on Heck cross-coupling reactions of 2,3-dichloropyrazine 
and quinoxaline. An increase of the reaction temperature results in partial or complete 
hydrogenation of the double bond. Electrocyclization reactions of the 2,3-
dialkenylpyrazines and –quinoxalines proved to be unsuccessful (no conversion). 
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Chapter 3:  Synthesis of 7,8-diarylflavones by Suzuki-Miyaura  reactions
Synthesis of 7,8-Diarylflavones by Site-Selective Suzuki-
Miyaura Cross Coupling Reactions of the Bis(triflate) of 7,8-
Dihydroxyflavone 
3.1 General Introduction 
The Suzuki-Miyaura reaction has become a most significant synthetic process for the 
construction of C-C bonds. Among the various cross coupling reactions, the Suzuki-
Miyaura reaction is widely used to prepare compounds which are pharmacological active 
and used in pharmaceutical industries.54 The reactions involve, for example, the 
palladium catalyzed cross coupling between organoboron compounds and aryl halides. 
The scope of the reaction is not restricted to aryl derivatives, but includes also alkyl, 
alkenyl and alkynyl compounds. The reaction also works well with triflates (the OH 
group is converted into OTf with triflic anhydride); thus, phenolic compounds can be 
arylated by this method. Boronic esters, boranes or boronic acids can be used. Among the 
halides, the relative reactivity is I > OTf > Br > Cl.55  
The mechanism of the Suzuki reaction involes three steps.The first step is the oxidative 
addition of organic halides to Pd(0) to form organopalladium halides. In the second step, 
a transmetallation with the boronic acid provides a diorganopalladium complex, which 
undergoes reductive elimination and regeneration of the palladium catalyst. Different 
types of bases are used in this reaction, e.g. potassium carbonate, potassium phosphate 
and cesium carbonate, which enhance the rate of the transmetalation by increasing the 
nucleophilicity of the organoboran compound by formation of an organoborate.54,56
Several catalysts are used for this reaction, e.g. Pd(OAc)2 together with phosphine ligands 
(such as PPh3, PCy3, SPhos and XPhos), Pd(PPh3)2Cl2, or Pd (PPh3)4.57  
Suzuki-Miyaura reactions have prominent applications in various fields. For example, 
non-linear optical (NLO) materials were prepared.58 Terphenyls can be synthesized 
which are structural elements in liquid crystals and fluorescent compounds.59 Poly(2,7-
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carbazole) derivatives, which are active components in photovoltaic devices, have been 
also prepared by Suzuki-Miyaura reactions.60
In a couple of years, Prof. Peter Langer’s research group has studied site-selective 
Suzuki-Miyaura reactions of polyhalogenated heteroaromatic and aromatic compounds or 
their triflates. In this context, regioselective Suzuki-Miyaura reactions of 2,3-
dibromobenzofuran (a),61 tribromopyrazoles (b),62 2,4,5,6-tetrachloropyrimidine (c),63 
tetrabromobenzoquinone (d),64 1,2-dibromo-3,5-difluorobenzene (e),65 1,4-dibromo-2-
fluorobenzene (f),66 2,3,4-tribromothiophene (g),67 and 2,3,5-tribromothiophene (h)68
were reported (Figure 5). 
O
Br
Br
N
N
R
Br
BrBr
N N
Cl
Cl
Cl
Cl
O
O
Br
Br Br
Br
Br
Br
F
F
F
Br
Br
S SBr
BrBr
Br
Br
Br
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 5. Suzuki reactions of vicinal halides studied in Prof. Langer’s group
The Suzuki Miyaura reaction also provided excellent results for dihydroxylated 
substrates. Their OH groups were converted into OTf groups by using triflic anhydride 
and subsequently the site-selctivity of Suzuki reactions was studied. The Langer group 
reported regioselective Suzuki-Miyaura cross coupling reactions of the bis(triflates) of 
dimethyl 4-fluoro-3,5-dihydroxphthalate (i),69 phenyl 1,4-dihydroxnaphthoate (j),70
methyl-2,5-dihydroxbenzoate (k),71 3,4-dihydroxbenzoate (l),72 2,4-bis(hydroxy)di- 
phenylsulfone (m)73 and 1,2-dihydroxyanthraquinone (n)74 (Figure 6). All mentioned 
substrates proceeded with excellent site-selectivities. 
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Figure 6. Suzuki Reaction Studies on Dihydroxy substrate in Prof. Langer’s Group
3.2 Introduction to Flavones
Flavonoids are polyphenolic secondary metabolites that are widely distributed in higher 
plants. Flavones and flavonols are two major classes of flavonoids. Flavonols are present 
in fruits and vegetables, they have a 3-hydroxyflavone backbone.75 Flavonols are potent 
inhibitors of CYP3A4, an enzyme which is responsible for the metabolism of many 
pharmaceutical drugs in the body.76 Flavones are present in flowers, leaves and fruits of 
living plants as flavonoid glycosides. They have a 2-phenyl-1-benzopyran-4-one 
backbone. The difference between flavones and flavonols is the OH group located at C-3 
position; flavonols have an OH group at C-3, while flavones have no OH group at C-3.77
Flavones are of considerable pharmacological relevance and are widespread in nature as 
plant metabolites. Examples include various simple natural products, such as Chrysin, 
Apigenin, Luteolin, Scutellarein, or Wogonin, which have shown CYP2C9 inhibition 
(Figure 7).77,78 Several flavones show activity against neurological disorders. Recently, 
Keqiang Ye and co-workers have revealed the fact that 7,8-dihydroxyflavone acts as a 
selective TrKB (tyrosine kinase receptor B) agonist, which is a powerful therapeutic tool 
for the treatment of various neurological diseases.79 Many studies have shown that 
chrysin has anti-inflammation, anti-cancer and anti-oxidation, and anti-HIV effects.80
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Natural anti-oxidant tangeretin shows significant protective effects against Parkinson’s 
disease.81
O
OOH
HO O
OOH
HO O
OO
O
OH
OH
O
O
O
Chrysin Luteolin Tangeretin
Figure 7.  Some examples of natural product Flavones. 
7,8-Dihydroxyflavone was synthesized starting from 2,3,4-trihydroxyacetophenone and 
benzoyl chloride in two steps via Baker-Venkatarama rearrangement.82 It was also 
prepared by reaction of 2-fluorobenzoyl chloride, followed by cyclization of the 
intermediate benzophenone in the presence of sodium carbonate.83 A new annellated 1,4-
benzodioxane was prepared by reaction of 7,8-dihydroxyflavone with ethyl 2,3-dibromo- 
propanoate.84 Despite the great pharmacological importance of flavones, only a few 
applications of palladium catalyzed cross coupling reactions to flavone-derived halides or 
triflates have been reported.85 Suzuki reactions of halogenated flavones have been 
reported. 86 In my thesis, I have transformed the OH group of 7,8-dihydroxyflavone into 
triflates and then applied Suzuki reactions which proceed with excellent site-selectivity. 
3.3 Results and discussion 
Commercially available 7,8-dihydroxyflavone (16) was transformed to its bis(triflate) 17
in 76% yield (Scheme 9) by using triflic anhydride (2.4 equiv) and pyridine (4 equiv). 
The addition of triflic anhydride was performed at -78 °C. The Suzuki-Miyaura reaction 
of 17 with arylboronic acids 18a-g (2.6 equiv.) afforded the 7,8-diarylflavones 19a-g in 
59-74% yield  (Scheme 10, Table 9). The reaction conditions were systematically 
optimized for derivatives 19a,c,e (Table 10). Both electron-poor and electron-rich 
arylboronic acids could be successfully employed. The best yields were obtained using 
Pd(PPh3)4 (5 mol-%) as the catalyst and K3PO4 (4.0 equiv.) as the base. The reactions 
were carried out in 1,4-dioxane at 100 °C for 4 h (entry 4).The yields dropped when 
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Pd(PPh3)2Cl2 (5 mol-%) or Pd(OAc)2 (5 mol-%) in the presence of L2 or P(OEt)2Ph 
(10mol-%) were employed (entries 1-3). Therefore, the optimized condition given in 
entry allowed to prepare diarylflavones in good yields. 
O Ph
O
OH
HO O Ph
O
OTf
TfO
16 17 (76%)
i
Scheme 9. Synthesis of 17. Reagents and conditions: (i) 16 (1.0 equiv), Tf2O (2.4 equiv), 
pyridine (4.0 equiv), CH2Cl2, -78  0 °C, 4h. 
O Ph
O
OTf
TfO O Ph
O
Ar
Ar
i
17
ArB(OH)2
18a-g
19a-g
Scheme 10. Synthesis of 19a-g. Reagents and conditions: (i), 17 (1.0 equiv), 18a-g (2.6 
equiv), Pd(PPh3)4  (5 mol-%), K3PO4 (4.0 equiv), 1,4-dioxane, 100 °C, 4 h. 
Table 9. Synthesis of 19a-g. 
18,19 R % (19) a
a 4-EtC6H4 70 
b 4-tBuC6H4 59 
c 4-ClC6H4 72 
d 4-FC6H4 62 
e 4-(MeO)C6H4 68 
f 4-MeC6H4 74 
g 3,5-Me2C6H3 71 
a Yields of isolated products 
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Table 10. Optimization of the reaction condition for 19a,c,e
a Yields of isolated products
The Suzuki-Miyaura reaction of 17 with arylboronic acids 18a,c,f,h,i (1.0 equiv.) 
afforded the 7-aryl-8-trifluorosulfonyloxy-flavones 20a-e in 66-76% yield with very 
good site-selectivity (Scheme 11, Table 11). During the optimization, it proved to be 
important to use exactly 1.0 equiv. of the arylboronic acid and to carry out the reaction at 
70 instead of 100 °C. Both electron-poor and electron-rich arylboronic acids were 
successfully used. The reaction conditions were systematically optimized for derivatives 
20a,d (Table 12). The best yields were obtained using Pd(PPh3)4 (5 mol-%) as the 
catalyst and K3PO4 (1.5 equiv.) as the base. The reactions were carried out in 1,4-dioxane 
at 70 °C for 4 h (entry 3, Table 12). The yields were observed lower when Pd(PPh3)2Cl2
(5 mol-%) or Pd(OAc)2 (5 mol-%) in the presence of L2 (10mol-%) were employed 
(entry 1-2). 
O Ph
O
OTf
TfO O Ph
O
OTf
Ar
i
17
ArB(OH)2
18a,c,f,h,i
20a-e
Scheme 11. Synthesis of 20a-e. Reagents and conditions: i; 17 (1.0 equiv.), 18a,c,f,h,i
(1.0 equiv), K3PO4 (1.5 equiv.), Pd(PPh3)4 (5 mol %), 1,4-dioxane, 70 °C, 4 h. 
Entry Conditions Temp 
[°C] 
(19a) a
% 
(19c) a
% 
(19e) a
% 
1 P(OEt)2Ph(10mol-%), 
Pd(OAc)2 (5 mol-%), K3PO4
90 32 26 35 
2 Pd(PPh3)2Cl2(5mol-%), 
K3PO4
100 39 41 44 
3 L2 (10 mol-%),  Pd(OAc)2 (5 
mol-%), K3PO4
90 30 34 27 
4 Pd(PPh3)4 (5mol-%),  K3PO4 100 70 72 68 
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Table 11. Synthesis of 20a-e 
18 20 R % (20) a
a a 4-EtC6H4 72 
c b 4-ClC6H4 66 
f c 4-MeC6H4 76 
h d 4-(CF3)C6H4 69 
i e 4-(HC=CH2)C6H4 74 
a Yields of isolated products 
Table 12. Optimization of the reaction condition for 20a,d
a Yields of isolated products 
The Suzuki-Miyaura reaction of 20c and 20b with arylboronic acids 18a and 18e (1.3 
equiv.) afforded the 7,8-diarylflavones 21a and 21b, respectively (Scheme 12, Table 13). 
The reactions were carried out at 100 °C. 
O Ph
O
OTf
Ar1 O Ph
O
Ar2
Ar1i
20b,c
Ar2B(OH)2
18a,e
21a,b
Scheme 12. Synthesis of 21a,b. Reagents and conditions: (i) 20b,c (1.0 equiv),  18a,e
(1.3 equiv), K3PO4 (1.5 equiv), Pd(PPh3)4 (5 mol %), 1,4-Dioxane,  100 °C, 4h. 
Entry Conditions Temp 
[°C] 
(20a) a
% 
(20d) a
% 
1 Pd(PPh3)2Cl2(5mol-%), 
K3PO4,  Dioxane 
70 55 42 
2 L2 (10 mol-%),  Pd(OAc)2 (5 
mol-%), K3PO4,  Dioxane 
70 33 19 
3 Pd(PPh3)4(5mol-%),  K3PO4,  
Dioxane 
70 72 69 
 27
Table 13. Synthesis of 7,8-diarylflavones 21a,b 
18 20 21 Ar1 Ar2 % (21) a
a c a 4-MeC6H4 4-EtC6H4 66 
e b b 4-ClC6H4 4-(MeO)C6H4 73 
a Yields of isolated products 
All products were characterized by spectroscopic methods. The constitutions of products 
20a-e and 21a,b were proved by 2D NMR experiments (HMBC, NOESY). The structure 
of 19f was independently confirmed by X-ray crystal structure analysis (Figure 8).87 
Inspection of the X-ray structure shows that the flavone unit (including the phenyl group 
located at C2) in plane. The other two phenyl groups are twisted out of plane, due to 
steric reasons. 
   Figure 8. Molecular structure of 19f  
The structure of 20a was confirmed by 2D-NMR correlation using HMQC, HMBC and 
NOESY. The chemical shift values of the carbon atoms were assigned with the help of an 
HMQC experiment,  = 8.18 (125.4, C-5), 7.44 (127.4, C-6). In the HMBC spectrum, the 
aromatic proton of C-6 showed a strong coupling with C-5 (125.4), C-7 (131.6), C-1
(135.1). In the NOESY spectrum, aromatic proton ( = 7.44, C-6) showed an interaction 
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with proton 5-H ( = 8.18). These information show that the 4-(Et)C6H4 moiety is 
attached to carbon atom C-7 (Figure 9). 
O
O
Ph
OTf
H
H
125.4
127.4
131.6
149.0135.1
5
6
7
8
1'
2'
3'
4'
5'
6'
1
2
3
4
9
10
124.2
Figure 9.  HMBC and NOESY correlations of 20a 
The site-selective formation of 20a-e can be explained by steric and by electronic 
reasons. The first attack of palladium(0)-catalyzed cross-coupling reactions generally 
occurrs at the more electronical deficient and sterically less hindered position. Position 7 
of 17 is sterically less hindered than position 8. In addition, position 7 (located meta to 
the ether oxygen atom and para to the carbonyl group) is considerably more electron-
deficient than position 1 (located ortho to the ether oxygen atom and meta to the carbonyl 
group).  
3.4 Conclusion 
I have synthesized 7,8-diarylflavones by Suzuki-Miyaura reactions of the bis(triflate) of 
7,8-dihydroxyflavone. The first attack proceeded with very good site-selectivity at 
position 7. 
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Chapter 4:  Sonogashira coupling  reactions of  2 4,5 6-tetrachloropyrimidine  
Regioselective Sonogashira Cross-Coupling Reactions of 
2,4,5,6-Tetrachloropyrimidine and Fluorescence Properties of 
Bis-, Tris-, and Tetrakis(arylethynyl)pyrimidines 
4.1 General Introduction 
The Sonogashira reaction was developed in 1975. It is the coupling reaction between aryl 
or alkenyl halides or triflates and terminal alkynes. Two catalysts, palladium(0) and co-
catalyst copper(I), are used in this reaction. The reaction requires a basic medium in order 
to deprotonate the alkyne. Several bases are used, such as triethylamine, diethylamine 
and N,N-diisopropylamine. Diisopropylamine and DMF are often used as solvents.88  
The reactivity depends on the type of the aryl or alkenyl halides; the reactivity order is 
vinyl iodide > vinyl bromide > vinyl chloride > aryl iodide > aryl bromide > aryl 
chloride.89 A possible drawback of the Sonogashira reaction is the in situ generation of a 
copper acetylide which may produce homocoupling products (diynes) along with the 
desired products. For Sonogashira reactions copper and ligand free variants have been 
developed.90 The Sonogarshira reaction is the key step in several total syntheses of 
natural products photophysical materials.91 In recent years, Professor Langer’s research 
group has studied regioselective Sonogashira coupling reactions of N-methylpyrrole 
(a),92 tetrabromoselenophene (b)93 and phenyl-1,4-dihydroxynaphthoate (c) (Figure 10).94
N Br
BrBr
Br
CH3
(a)
Se Br
BrBr
Br
(b)
OH
OH
O
O
(c)
Figure 10. Substrates for Sonogashira reactions studied in Prof. Langer’s group 
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4.2 Introduction 
The chemistry of pyrimidine and its derivatives has been intensively studied, due to their 
pharmacological and physical properties. Pyrimidine derivatives, including uracil, 
thymine, cytosine, adenine, and guanine, are fundamental building blocks for 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Vitamin B1 (thiamine) is a 
well-known example of a naturally occurring pyrimidine that is encountered in our daily 
lives. Synthetic pyrimidine-containing compounds are being used in pharmaceutical 
industry as potent drugs. Pyrimethamine and trimethoprim are two prominent pyrimidine-
containing chemotherapeutics. Trimethoprim is widely used as a general systemic 
antibacterial agent in combination with sulfamethoxazole. Pyrimethamine is used as anti-
malarial and anti-protozoal drug in combination with sulfadiazine.95 Multiple 
pharmacological studies for pyrimidine derivatives have shown significant importance 
and have made pyrimidine to a core structure which is important for analgesic, anti-
hypertensive, anti-pyretic, anti-inflammatory, anti-neoplastics, anti-bacterials, anti-
protozoal, anti-fungal, anti-viral and anti-folate drugs. They also play a role as pesticides, 
herbicides, and plant growth regulators.96 Recent studies have shown that bicyclic 
pyrimidine nucleoside analogues are potent and selective inhibitors of Varicella Zoster 
Virus (VZV) replication.97 Tao Wang reported some derivatives of pyrimidine which 
were identified as potent inhibitors of TrK kinase which play a critical role in cell 
signaling and cancer related processes.98 Movassaghi reported a single step synthesis of 
pyrimidine derivative by cycloisomerization of amides and nitriles.99 One-pot syntheses 
of aryl-substituted pyrimidines were performed through a coupling-isomerization 
sequence with subsequent cyclocondensation-aromatization with pyrimidium salts.100
N N
NH2
N S
OH N N
NH2
H2N
Cl
N N
NH2
H2N
O
O
O
Cl
Vitamin B1
TrimethoprimPyrimethamine
Figure 11. Some common examples of pyrimidine derivatives. 
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Monohalogenated pyrimidines have been used in Negishi and Suzuki coupling 
reactions.101 Sonogashira, Negishi and Suzuki reactions of 2,4,6-trichloropyrimidine have 
been reported.102 Recently, Suzuki-Miyaura coupling reactions of 2,4,5,6-tetachloro- 
pyrimidine have been studied by our group.103
Light emitting materials are applied in biological and material sciences. Conjugated 
organic systems have significant applications in various fields, such as LC (liquid 
crystals), FET (field effect transistors), OLED (organic light emitting devices), 
photovoltaic cells, and 3D-optical memory devices.104 When any heterocyclic moiety, 
such as pyridine, pyrazine, pyrimidine, is introduced into extended -systems, it often 
brings extraordinary electronic and optical changes. These changes may result in liquid 
crystalline and fluorescence properties.105 In this chapter, I have synthesized and 
optimized the reaction conditions to achieve convenient synthesis of Sonogashira 
products of bis-, tris- and tetrakis(arylethynyl)pyrimidines and studied their UV-Vis and 
fluorescence properties. 
4.3 Results and Discussion 
The Sonogashira reaction of commercially available 2,4,5,6-tetrachloropyrimidine (22) 
with different substituted aryl acetylenes 23a-d (2.4 equiv) afforded the 4,6-
bis(arylethynyl)pyrimidines 24a-d (Scheme 13, Table 14) in 73-91% yields. Different 
reaction conditions were optimized for derivatives 24a,c (Table 15) . During optimization
Pd(PPh3)4 (10mol-%), Pd(OAc)2 (5 mol-% ) in the presence of PCy3 (10 mol-%) were 
initially employed, but no satisfactory results were obtained.The progress of reactions 
were monitored at lower temperature (20-60°C), as higher temperature increases the 
chances for tri-alkynylated products. Pd(PPh3)2Cl2 (10 mol-%) was found to be the best 
catalyst. Several solvents were tried, but several of them did not work well, while good 
yields were obtained when DIPA was used (entry 1-5, Table 15). Almost all bis-
Sonogashira products were obtained in good to excellent yields. 
The structure of 24c was independently confirmed by X-ray crystal structure analysis 
(Figure 12). Analysis of the structure shows that all three aryl groups are in one plane. 
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N N
Cl
ClCl
Cl
N N
Cl
Cl
RR
R
22
23a-d
24a-d
i
Scheme 13. Synthesis of 24a – d: conditions and reagents: 22(1.0 equiv), 23a – d (2.4 
equiv), CuI (5 mol-%), Pd(PPh3)2Cl2 (10 mol-%), DIPA , 55°C, 2 h. 
Table 14. Synthesis of 24a-d. 
23,24 R % (24) a
a 4-tBuC6H4 76 
b Ph 73 
c 3-(MeO)C6H4 81 
d 6-(MeO)C10H6 91 
a Yields of isolated products 
Figure 12. Molecular structure of 24c
 33
Table 15. Optimization of the reaction condition for 24a,c
a Yields of isolated products 
b No Conversion 
c Experiment was not carried out 
The Sonogashira reaction of 22 with the substituted acetylenes 23a-c, e-g (3.6 equiv.) 
afforded the tris(arylethynyl)pyrimidines 25a-f (Scheme 14, Table 16) in 68-84 % yield. 
N N
Cl
ClCl
Cl
22
R
23a-c,e-g
i
N N
Cl RR
R
25a-f
Scheme 14. Synthesis of 25a–f: conditions and reagents 22(1.0 equiv), 23a–c, e-g (3.6 
equiv), CuI (5 mol-%), Pd(PPh3)2Cl2 (10 mol-%), DIPA, 70°C, 2 h.  
Entry Conditions Temp 
[°C] 
Time 
(h) 
(24a) a
% 
(24c) a
% 
1 PCy3(10mol-%), Pd(OAc)2 (5 
mol-%), CuI, Toluene, Et3N 
50 6 - b - c
2 PCy3(10 mol-%), Pd(OAc)2
(5 mol-%), CuI, Xylene, Et3N
60 6 - b - c
3 Pd(PPh3)4  (10mol-%), CuI, 
DMF, CS2CO3 
60 4 31 26 
4 L2 (10 mol-%),  Pd(OAc)2 (5 
mol-%), CuI, DMF,  Et3N 
60 4 23 19 
5 Pd(PPh3)2Cl2(10mol-%), CuI, 
DIPA 
55 2 76 81 
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Table 16. Synthesis of 25a-f. 
23, 25 R % (25) a
a, a 4-tBuC6H4 80 
b, b Ph 71 
c, c 3-(MeO)C6H4 77 
e, d 4-(Me)C6H4 84 
f, e C7H11 68 
g, f C5H7 69 
a Yields of isolated products 
For the synthesis of tetrakis(arylethynyl)pyrimidines the previously applied reaction 
conditions did not give tetra-alkynylated product. The reaction conditions were optimized 
for derivatives 26a,c (Table 18). Unsuccessful attempts were made to improve the yield 
by varying solvents (DMF, DMA, toluene, xylene) with DIPA, triethylamine and cesium 
carbonate. During the optimization, Pd(OAc)2 was used in the presence of various ligands 
such as PCy3, PPh3, L1, L2, but no satisfactory results were obtained. In fact, L1, L2 
ligands provided the product, but the yields were very low. The effects of the base and of 
the solvent were evaluated and progress of reactions were observed (70-120 °C, 14-18 h) 
(entry 1-6, Table 18).The best yields were obtained when Pd(PPh3)2Cl2 (10 mol-%) was 
used as catalyst, in dioxane with DIPA at 85°C for 16 h (entry 7, Table 18). Therefore, 
the optimized condition given in entry 6 allowed to prepare tetra-alkynylated product in 
good yields. 
 The Sonogashira coupling of 22 with 23a-c, carried out at 85 °C for 16 hours and using 
the base DIPA (3 mL) and the solvent dioxane (7 mL), afforded 26a-c (Scheme 15, Table 
17) in 73-79% yields. It was concluded that the optimal conditons for the synthesis of 
tetra-alkynylated products include a combination of DIPA and dioxane, a temperature of 
85 °C and longer reaction time (16-18 hours). 
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N N
Cl
ClCl
Cl
22
R
23a-c
i
N N
RR
R
26a-c
R
Scheme 15. Synthesis of 26a-c: conditions and reagents 22 (1.0 equiv), 23a-c (6.0 equiv), 
CuI (5 mol-%) Pd(PPh3)2Cl2 (10 mol-%), DIPA (3 mL), Dioxane (7 mL),  85°C,16 h. 
Table 17: Synthesis of 26a-c. 
23, 26 R % (26) a
a 4-tBuC6H4 76 
b Ph 73 
c 3-(MeO)C6H4 79 
a Yields of isolated products 
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Table 18. Optimization of the reaction condition for 26a,c
a Yields of isolated products 
b No Conversion 
c Experiment was not carried out 
The Suzuki-Miyaura reaction of 2,4,5,6-tetrachloropyrimidine (22) with 4-methylphenyl- 
boronic acid (18f) (1.0 equiv.), using 5 mol-% of Pd(PPh3)2Cl2 at 60 °C for 2 hours, 
afforded product  27 in 76% yield. The Sonogashira reaction of 27 with 3-ethynylanisole 
(23c, 1 equiv.) yielded 28 in 59% yield. The reaction of 27 with 2 equiv. of 23c afforded 
product 29 in 67% yields. The same reaction conditions applied with 1-pentyne (23g) 
afforded product 30 in 54% yields. During the optimization of the reaction conditions, the 
temperature played an important role. The mono-Sonogashira reaction of 22 and 27 was 
best carried out at 55 °C, while the bis-Sonogashira reactions of 27 had to be carried out 
at 70 °C. 
Entry Conditions Temp 
[°C] 
(26a) a
% 
(26c) a
% 
1 Pd(PPh3)2Cl2 (10mol-%), CuI, 
DIPA 
70 - b - b
2 PPh3 (10 mol-%), Pd(OAc)2
(5 mol-%), CuI,  DMA 
120 - b - b
3 PPh3 (10 mol-%), Pd(OAc)2
(5 mol-%), CuI,  Toluene 
90 - b - c
4 PCy3 (10 mol-%), Pd(OAc)2
(5 mol-%), CuI,  Xylene
100 - b - c
5 Pd(PPh3)4  (10 mol-%), CuI, 
DMF, 
120 - b - b
6 L2 (10 mol-%),  Pd(OAc)2 (5 
mol-%), CuI, DMF 
100 23 19 
7 Pd(PPh3)2Cl2 (10mol-%), CuI, 
DIPA, Dioxane 
85 76 79 
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C3H7
C3H7
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Scheme 16. Synthesis of 27-30: conditions : (i)  22 (1.0 equiv), 4-Methylphenylboronic 
acid (18f) (1.0 equiv) Pd(PPh3)2Cl2 (5 mol-%), K2CO3 (2M, 1mL), Dioxane, 60 °C, 2 h
(ii) 23c (1.0 equiv),  CuI (5 mol-%), Pd(PPh3)2Cl2  (10 mol-%), DIPA (5 mL), 55 °C, 2 h. 
(iii) 23c (2.0 equiv) CuI (5 mol-%), Pd(PPh3)2Cl2  (10 mol-%), DIPA (5 mL), 70°C, 3 h. 
(iv) 23g (2.0 equiv), CuI (5 mol-%),  Pd(PPh3)2Cl2 (10 mol-%), DIPA , 70°C, 3 h. 
 38
The structures of products 28 and 29 were independently confirmed by X-ray crystal 
structure analyses (Figures 13 and 14). The aryl groups attached to the alkyne unit are in 
plane. In contrast, the aryl moities of the biaryl uni are twisted out of plane, due to steric 
reasons. 
Figure 13. Molecular structure of 28
Figure 14. Molecular structure of 29
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The UV/Vis and fluorescence spectroscopic data of various pyrimidine derivatives, 
measured in chloroform at 25 °C, are summarized in Table 19. All the compounds 
collected in Table 19 contain a pyrimidine core; their absorption wavelengths (abs) are in 
the UV region (297–371 nm) and their emission wavelengths (em) (fluorescence) are in 
the UV or blue region (395–470 nm). Pyrimidines containing methoxy-substituted aryl 
groups exhibit absorptions and emissions in the range of abs= 301–367 nm and em = 
426–470 nm, respectively. For tert-butyl derivatives, the absorptions and emissions are in 
the range of abs = 325–371 nm and em = 426–440 nm.
Table 19. Absorption and emission spectroscopic data for compounds in chloroform 
solution (10–4–10–7) at 25 °C. 
Product 4abs 
[nm] 
Log  5em 
[nm] 
Stokes 
Shift [nm] 
24a 371 3.86 426 55 
24b 354 3.35 395 41 
24c 367 3.74 470 103 
2abs 
[nm] 
Log  4em 
[nm] 
25b 312 4.25 406 94 
25c 301 3.73 426 125 
26a 325 4.01 440 115 
26b 316 4.32 426 110 
26c 302 4.11 438 136 
29 297 4.19 405 108 
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Figure 15. Absorption and emission spectra of compound 24c 
Figure 16. Absorption and emission spectra of compound 25c 
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Figure 17. Absorption and emission spectra of compound 26c 
Figure 18. Absorption and emission spectra of compound 29 
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The symmetrical Sonogashira products 24a and 24b exhibit absorptions abs, max = 298, 
272 nm and emissions em, max = 426, 395 nm; the stokes shift is 55 and 41 nm, 
respectively. Compound 24c showed absorptions abs, max = 276 nm and emissions em, max 
470 nm; the stokes shift is 103 nm. A larger Stokes shift often corresponds to better 
overall fluorescence properties. Thus, compound 24c has been found to possess the best 
fluorescence properties as compared to 24a and 24b. In this context, the presence of the 
strong electron donating group of 24c plays an important role. In case of unsymmetrical 
Sonogashira products, compound 25c shows a higher Stokes shift (125 nm), while 25b
shows a relatively small Stokes shift (94 nm). The same phenomenon can be observed for 
tetrakis(arylethynl)pyrimidines 26a-c. While compound 26c shows a higher Stokes shift 
(136 nm), 26a and 26b show smaller Stokes shifts. The mixed Suzuki-Sonogashira 
product 29 shows a Stokes shift of 108 nm.
4.4 Conclusion 
I have synthesized bis-, tris-, and tetrakis(arylethynyl)pyrimidines by Sonogashira 
reactions. The fluorescence properties of the products have been studied. 
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Chapter 5:  Sonogashira coupling reactions of 2,3,4,5-tetrabromofuran
Regioselective Sonogashira Coupling Reactions of 2,3,4,5- 
Tetrabromofuran and Fluorescence Properties of Bis-, Tris-, 
and Tetrakis(arylethynyl)furans 
5.1 Introduction 
Furan is an important five membered O-heterocycle which represents a versatile building 
block in synthetic organic chemistry. Substituted furans have attracted attention, due to 
their remarkable pharmacological and photo-physical properties.106 Furan is widely found 
in many natural products, e.g. lophotoxin, pukalide, cembranolides, plakorsins A-C, 
rosefuran, kallolide, adociacetylene B, XH-14, perillene and dendrolasin.107 Furan 
derivative ranitidine (brand name Zantac) is used in the treatment of peptic ulcer and 
gastroesophegeal reflux disease. Nitrofurantoin is used for the treatment of urinary tract 
infections and nifuroxazide is suggested for colitis and diarrhea treatment.108 Much 
research efforts revealed the biological significance of furan derivatives, which have also 
shown anti-inflammatory, anti-tuberculosis, anti-cancer, and anti-fungal activities.109
Various methodologies have been developed for the synthesis of furans. In fact, furans 
have been used as a key precursor in the synthesis of many biologically active 
compounds. Furans can be synthesized by cyclodehydrations of 1,4 diketones,110
condensations of –halocarbonyl compounds with 1,3 dicarbonyl compounds,111
cyclizations of ,–epoxyketones,112 cyclodehydrations of –hydroxyl–,-unsaturated 
ketones,113 heteroannulation reactions along with transition metal catalyzed 
cyclizations,114 Feist-Benary cyclocondensations of different phosphoranes with - 
haloketones,115 base-mediated cyclizations of allenylalcohols and epoxides,116 [3+2] 
annulations of alkynes with aldehydes,117 and cyclizations of 1,4-diones in the presence 
of catalytic amounts of p-toluensulfonic acid.118 Furan derivatives not only have 
pharmacological properties, but also they have shown excellent photophysical properties, 
due to which furan has gained attention in material sciences. In recent research, 2,5-
bis(phenylethynyl)furan,119 furan-nucleoside analogues,120 bis-furylethene derivatives 121
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and furopyrimidine derivatives 122 have been reported to show non-linear optical (NLO),  
fluorescence and photochromic properties. 
O
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O
OAc
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O
Lophotoxin
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CH2(CH2)14 CH3O
O
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Plakorsins A Rosefuran
O
5 5
OH OH
Adociacetylene B
Figure 19.  Some examples of furan natural products. 
Sonogashira coupling reactions of 2,3-dibromofuran and 2,5-dibromofuran with site-
selectivity in favour of position C-2 have been reported.123 In my thesis, I have 
synthesized bis-, tris- and tetrakis(arylethnynl)furans by Sonogashira reactions of 2,3,4,5-
tetrabromofuran. I have applied Suzuki reactions on bis-Sonogashira products and 
obtained the corresponding products. Most furan derivatives prepared in my thesis are 
fluorescence active. 
5.2 Results and Discussion 
The Sonogashira reaction of 2,3,4,5-tetrabromofuran (31) with different substituted 
alkynes (23a-d) (2.4 equiv) afforded 2,5-bis(arylethynyl)furans 32a-d (Scheme 17, Table 
20) in 71-81 % yield. 
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31
23a-d
32a-d
Scheme 17. Synthesis of 32a – d: conditions and reagents: 31(1.0 eq), 23a – d (2.4 eq), 
CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol %), DIPA (5mL) , 60°C, 2 h. 
Table 20. Synthesis of 32a-d. 
23,32 R % (32) a
a 4-tBuC6H4 78 
b Ph 71 
c 3-(MeO)C6H4 81 
d 6-(MeO)C10H6 76 
a Yields of isolated products 
The Sonogashira reaction of 31 with different substituted alkynes (23c, g, h) (3.6equiv) 
provided the 2,3,5-tris(arylethynyl)furans 33a-c (Scheme 18, Table 21) in 64-77 % yield. 
O
Br
RR
R
23c,g,h
33a-c
R
O Br
BrBr
Br
31
Scheme 18. Synthesis of 33a-c: conditions and reagents 31(1.0 eq), 23c,g,h (3.6 eq), CuI 
(5 mol %) Pd(PPh3)2Cl2 (10 mol %), DIPA (5mL), 60°C, 2 h. 
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Table 21. Synthesis of 33a-c.
23,33 R % (33) a
c a 3-(MeO)C6H4 77 
h b 3-(Me)C6H4 73 
g c C5H7 64 
a Yields of isolated products 
The Sonogashira reaction of 31 with different substituted alkynes (23a,c,h) (4.8 equiv) 
afforded the 2,3,4,5-tetrakis(arylethynyl)furans 34a-c (Scheme 19, Table 22) in 75-83 %. 
O RR
R
23a,c,h
34a-c
RR
O Br
BrBr
Br
31
Scheme 19. Synthesis of 34a-c: conditions and reagents: 31 (1.0 equiv), 23a,c,h (4.8 
equiv), CuI (5 mol-%) Pd(PPh3)2Cl2 (10 mol-%), DIPA (5 mL), 75°C, 2 h.  
Table 22. Synthesis of 34a-c. 
23,34 R % (34) a
c, a 3-(MeO)C6H4 83 
a, b 4-tBuC6H4 81 
h, c 3-(Me)C6H4 75 
a Yields of isolated products 
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The Suzuki-Miyaura reaction of 2,5-bis(arylethynyl)furans 32a-d with 4-methoxy- 
phenylboronic acid (18e) and 4-methylphenylboronic acid (18f) resulted in the formation 
of 35a-d (Scheme 20, Table 23) in good yields (69-79%). 
35a-d
R1 B(OH)2
18e, f
O
BrBr
RR
32a-d
O
R1R1
RR
Scheme 20. Synthesis of 35a-d: conditions and reagents: 32a-d (1.0 equiv), 18e,f (2.0 
equiv), Pd(PPh3)2Cl2 (10 mol-%), K2CO3 (3equiv), Dioxane (5 mL),  70°C, 2 h. 
Table 23. Synthesis of 35a-d. 
32, 35 18 R R1 % (35) a
a e 4-tBuC6H4 4-(MeO)C6H4 76 
b e Ph 4-(MeO)C6H4 69 
c e 3-(MeO)C6H4 4-(MeO)C6H4 79 
d f 6-(MeO)C10H6 4-(Me)C6H4 74 
a Yields of isolated products 
The structure of 35a was confirmed by X-ray structure analysis (Figure 20). The aryl 
groups are twisted out of plane. 
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Figure 20.  Molecular structure of 35a 
The UV/Vis and fluorescence spectroscopic data of various furan derivatives, measured 
in chloroform at 25 °C, are summerized in Table 24. All the compounds collected in 
Table 24 contain a furan core. Their absorption wavelengths (	abs) are in the UV region 
(303-374 nm) and their emission wavelengths (	em) (fluorescence) are in the UV or blue 
region (418-442 nm). Bis- and tris(arylethynyl)furans 32a-d and 33a-c did not show 
fluorescence. Tetrakis(arylethynyl)furan 34a-c possess excellent fluorescence properties. 
All these compounds show high Stokes shift values (approx. 116-119 nm). Mixed 
Sonogashira-Suzuki products (35a-d) also show good fluorescence properties.  
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Table 24. Compounds in chloroform solution (10–4–10–7) at 25 °C. 
Product 1abs 
[nm] 
Log 
  
4em 
[nm] 
Stokes
Shift[nm]
34a 309 3.83 425 116 
34b 303 4.07 422 119 
34c 304 4.16 420 116 
35a 356 4.06 418 62 
35b 355 4.25 420 65 
35c 356 3.70 420 64 
35d 374 3.47 442 68 
Figure 21. Absorption and emission spectra of compound 34c 
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Figure 22. Absorption and emission spectra of compound 35b 
5.3 Conclusion 
In conclusion, I have synthesized bis-, tris- and tetrakis(arylethynyl)furans by 
Sonogashira coupling reactions in good yields. Suzuki-Miyaura reactions of 
bis(aryethynyl)furans provided the corresponding products. Tetrakis(arylethynyl)furans 
show excellent fluorescence properties, while bis- and tris(arylethynyl)furan did not show 
a considerable fluorescence activity. 
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6 Abstract 
The palladium(0)-catalyzed Heck cross coupling reactions of di- and tribromo 
benzothiophene provided functionalized dibenzothiophenes by domino twofold Heck / 
6-electrocyclization reactions. Heck cross coupling reactions of 2,3-dichloropyrazine 
and 2,3-dichloroquinoxaline provided 2,3-dialkenyl-, 2-alkenyl-3-alkyl- and 2,3- 
dialkylpyrazines and quinoxalines. The effect of the temperature on the product 
distribution was studied. Suzuki-Miyaura cross coupling reactions of the bis(triflate) of 
7,8-dihyroxyflavone with different arylboronic acids afforded aryl-substituted flavones 
with excellent site-selectivity. The first attack occurred at the more electronically 
deficient and sterically less hindered position at C-7. Sonogashira coupling reactions of 
2,4,5,6-tetrachloropyrimidine and 2,3,4,5-tetrabromofuran provided di-, tri- and tetra-
alkynylated products. Mixed Sonogashira-Suzuki products were also prepared. Most 
derivatives show excellent fluorescence properties.
Palladium(0)-katalysierte Heck-Kupplungsreaktionen von Di- bzw. Tribrombenzo- 
thiophen lieferte funktionalisierte Dibrombenzothiophene durch Domino Heck / 6-
Elektrocyclisierungs Reaktionen. Heck-Reaktionen von 2,3-Dichlorpyrazin und 2,3-
Dichlorchinoxalin lieferten 2,3-Dialkenyl-, 2-Alkenyl-3-alkyl- sowie 2,3-Dialkylpyrazine 
bzw. entsprechende Chinoxaline. Der Einfluss der Temperatur auf die Produktverteilung 
wurde für diese Reaktionen untersucht. Die Suzuki-Miyaura-Kupplungsreaktion des 
Bis(triflats) von 7,8-Dihydroxyflavon mit verschiedenen Arylboronsäuren ergab 
Arylflavone mit hervorragender Regioselektivität. Der Primärangriff erfolgte an der 
elektronenärmeren und weniger sterisch gehinderten Position C-7. Sonogashira 
Reaktionen von 2,4,5,6-Tetrachlorpyrimidin sowie 2,3,4,5-Tetrabromfuran lieferten 
entsprechende di-, tri- und tetraalkinyl-substituierte Produkte. Ebenso wurden gemischte 
Sonogashira-Suzuki-Produkte (mit einem Aryl- und einem Alkinylsubstituenten) 
synthetisiert. Die meisten der Derivate, die ausgehend von 2,4,5,6-Tetrachlorpyrimidin 
bzw. 2,3,4,5-Tetrabromfuran dargestellt wurden, zeigten exzellente Fluoreszen- 
zeigenschaften. 
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General Scheme.  Palladium(0)-Catalyzed Reactions developed in this thesis. 
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7 Experimental Section 
7.1    General: Equipment, chemicals and work technique
1H NMR Spectroscopy:  
Bruker: AM 250, Bruker ARX 300, Bruker ARX 500;  = 0.00 ppm for 
Tetramethylsilane;  = 7.26 ppm for (CDCl3); Characterization of the signal fragmen- 
tations: s = singlet, d = doublet, dd = double of doublet, t = triplet, q = quartet, m = 
multiplet, br = broadly. All coupling constants are indicated as (J). 2D NMR techniques 
(NOESY, COSY, HMQC, and HMBC) were used for the confirmation of structure. 
13C NMR Spectroscopy: 
Bruker: AM 250, (62.9 MHz); Bruker: ARX 300, (75 MHz), Bruker: ARX 500, 
(125 MHz) Ref: 29.84 ± 0.01 ppm and 206.26 ± 0.13 ppm  = 77.00 ppm for CDCl3. The 
multiplicity of the carbon atoms was determined by the DEPT 135 and APT technique 
(APT = Attached Proton Test) and quoted as CH3, CH2, CH and C for primary, 
secondary, tertiary and quaternary carbon atoms. Characterization of the signal 
fragmentations: quart = quartet the multiplicity of the signals was determined by the 
DEPT recording technology and/or the APT recording technology. 
Mass Spectroscopy:
AMD MS40, Varian MAT CH 7, MAT 731 (EI, 70 eV), Intecta AMD 402 (EI, 70 eV 
and CI), Finnigan MAT 95 (CI, 200 eV).  
High Resolution mass spectroscopy:  
Finnigan MAT 95 or Varian MAT 311; Bruker FT 
CIR, AMD 402 (AMD Intectra). 
Infrared spectroscopy (IR):  
Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet  Protege 460, Nicolet 360 
Smart Orbit (ATR); KBr, KAP, Nujol, and ATR; Peaks are given following 
assignments: w = weak, m = medium, s = strong, br = broad. 
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Elemental Analysis  
LECO CHNS-932, Thermoquest Flash EA 1112.  
X-ray crystal structure analysis:  
Crystallographic data were collected on a Bruker X8Apex, Diffractometer with CCD-
Kamera (MoKa und Graphit Monochromator, = 0.71073 Å). The structures were solved 
by direct methods using SHELXS-97 and refined against F2 on all data by full matrix 
least-squares with SHELXL-97. 
Melting points:  
Micro heating table HMK 67/1825 Kuestner (Büchi apparatus). 
Column chromatography:  
Chromatography was performed over Merck silica gel 60 (0,063 -0,200 mm, 70 - 230 
mesh) as normal and/or over mesh silica gel 60 (0,040 - 0,063 mm, 200 -400 mesh) as 
Flash Chromatography. All solvent were distilled before use. 
Thin Layer Chromatography (TLC):  
Merck DC finished foils silica gel 60 F254 on aluminum foil and Macherey finished 
foils Alugram® Sil G/UV254. Detection under UV light with 254 nm and/or 366 nm 
without dipping reagent, as well as with anisaldehyde sulfuric acid reagent (1 mL 
anisaldehyde consisting in 100 mL stock solution of 85% methanol, 14% acetic acid and 
1% sulfuric acid).   
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7.2 Synthesis of Functionalized Dibenzothiophenes by Domino 
′Twofold Heck / 6π-Electrocyclization′ Reactions of    2, 3-
Dibromobenzothiophene and 2,3,6-Tribromobenzothiophene. 
  
Synthesis of 2,3-Dibromobenzothiophene (2a); To a CH2Cl2 solution (50 mL) of 
benzo[b]thiophene (1, 5.00 g, 37.3 mmol) and KOAc (7.30 g, 74.6 mmol) was added Br2
(3.8 mL, 74.6 mmol) at 20 °C, and the solution was heated under reflux for 24 h. To the 
solution was added a sat. solution of Na2S2O3 and NaHCO3. The organic and the aqueous 
layer were separated, and the latter was extracted with CH2Cl2 (3 x 30 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo. The 
residue was purified by flash silica column chromatography (pure heptanes) to yield 2a 
as a white solid (9.1 g, 84%).
Synthesis of 2,3,6-Tribromobenzothiophene (2b); To a CH2Cl2 solution (50 mL) of 
benzo[b]thiophene (1, 5.00 g, 37.3 mmol) and KOAc (16.5 g, 167.9 mmol) was added
Br2 (8.6 mL, 167.9 mmol) at 20 °C, and the solution was heated under reflux for 24 h. To 
the solution was added a sat. solution of Na2S2O3 and NaHCO3. The organic and the
aqueous layer were separated, and the latter was extracted with CH2Cl2 (3 x 30 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo. The
residue was purified by flash silica column chromatography (pure heptanes) to yield 2b 
as a white solid (9.7 g, 70%).
General procedure A for the synthesis of (6a-f); In a pressure tube (glass bomb) a 
suspension of Pd(OAc)2 (12 mg, 0.05 mmol, 2.5 mol% per Br atom) and dicyclohexyl-
(2',6'-dimethoxybiphenyl-2-yl) phosphine (L1) (41 mg, 10 mol%)  in DMF (5 mL) was 
flushed with Ar and stirred at 20 °C to give a yellowish or brownish transparent solution. 
To the stirred solution were added the 2,3-dibromobenzothiophene (2a, 292 mg, 1.0 
mmol), Et3N (1.1 mL, 8.0 mmol), and the acrylate (1.25 equiv per Br). The reaction 
mixture was stirred at 100-130 °C for 12-48 h. The solution was cooled to 20 °C, poured 
into H2O and CH2Cl2 (25 mL each), and the organic and the aqueous layer were 
separated. The latter was extracted with CH2Cl2 (3 x 25 mL). The combined organic 
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layers were washed with H2O (3 × 20 mL), dried (Na2SO4), concentrated in vacuo, and 
passed through a column (silica gel). To a xylene solution (3 mL) of the crude product 
was added Pd/C (30 mg, 10 mol %). The solution was stirred under reflux for 48 h under 
argon atmosphere. The reaction mixture was filtered, and the filtrate was concentrated in 
vacuo. The residue was purified by chromatography (flash silica gel, heptanes–EtOAc) to 
yield the product. 
Diethyl Dibenzo [b,d]thiophene-2,3- dicarboxylate (6a);  
Compound 6a was prepared starting with 2a (292 mg, 1.0
mmol) as an amorphous white solid (249 mg, 76%); m.p. 
118–119 °C. 1H NMR (300 MHz, CDCl3):  = 1.33 (t, 3H, J = 
7.76 Hz, CH3), 1.35 (t, 3H, J = 7.76 Hz, CH3), 4.31–4.40 (m, 
4H, 2 CH2O), 7.41–7.48 (m, 2H, ArH), 7.79–7.82 (m, 1H, ArH), 8.12 (s, 1H, ArH), 8.13–
8.15 (m, 1H, ArH), 8.43 (s, 1H, ArH). 13C NMR (62 MHz, CDCl3):  = 14.2 (2CH3),
61.7, 61.8 (CH2O), 122.3, 122.4, 123.0, 123.6, 125.1, 128.0 (CH), 128.5, 130.4, 134.4, 
137.1, 140.7, 141.9 (C), 167.5, 167.7 (CO). IR (KBr): ν~ = 3053 (w), 2975 (w), 2931 (w), 
2896 (w), 2867 (w), 1706 (s), 1632 (w), 1603 (w), 1540 (w), 1483 (w), 1469 (w), 1440 
(m), 1366 (m), 1314 (m), 1247 (s), 1229 (s), 1098 (s), 1021 (s), 913 (w), 885 (w), 873 
(w), 853 (w), 765 (s), 757 (s), 708 (s), 642 (w), 583 (w), 552 (w) cm–1. MS (EI, 70 eV): 
m/z (%) = 328 (40) [M]+, 284 (06), 257 (54), 229 (19), 211 (58), 185 (100); HRMS (EI, 
70 eV): m/z calcd for C18H16O4S [M]+: 328.08715; found: 328.08765. 
Dibutyl dibenzo[b,d]thiophene-2,3-dicarboxylate (6b): 
Compound 6b was prepared starting with 2a (292 mg, 
1.0 mmol) as a highly viscous oil (311 mg, 81%). 1H 
NMR (300 MHz, CDCl3):  = 0.91 (t, 3H, J = 7.3 Hz, 
CH3), 0.92 (t, 3H, J = 7.4 Hz, CH3), 1.34–1.47 (m, 4H ), 
1.64–1.74 (m, 4H), 4.28 (t, 2H, J = 6.7 Hz,  OCH2), 4.30 
(t, 2H, J = 6.6Hz, OCH2), 7.44–7.48 (m, 2H, ArH), 7.80-7.83(m, 1H, ArH), 8.13 (s, 1H, 
ArH), 8.15-8.17 (m, 1H, ArH), 8.43 (s, 1H, ArH). 13C NMR (62 MHz, CDCl3):  = 12.7 
(2CH3), 18.2, 29.6, 64.7 (CH2), 121.3, 121.4, 122.0, 122.6, 124.0, 127.0 (CH), 127.5, 
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129.4, 133.4, 136.1, 139.7, 140.8 (C), 166.5, 166.8 (CO). IR (KBr): ν~  = 2957 (m), 1717 
(s), 1459 (m), 1263 (s), 1119 (m), 1092 (m), 1018 (w), 760 (m), 731 (m) cm–1. MS (EI, 
70 eV): m/z (%) = 384 (20) [M]+, 328 (06), 311 (04), 272 (31), 255 (100), 228 (10), 211 
(05), 171 (12). HRMS (EI, 70 eV): m/z calcd for C22H24O4S [M]+: 384.13898; found: 
384.139182. 
Diisobutyl dibenzo[b,d]thiophene-2,3-dicarboxylate (6c);  
Compound 6c was prepared starting with 2a (292 mg, 1.0
mmol) as highly viscous oil (284 mg, 74%). 1H NMR (300 
MHz, CDCl3):  = 0.94 (d, 6H, J = 1.6 Hz, CH3), 0.96 (d, 
6H, J = 1.6 Hz, CH3), 1.94–2.06 (m, 2H ), 4.06 (d, 2H, J = 
6.5 Hz, OCH2), 4.08 (d, 2H, J = 6.7 Hz, OCH2), 7.44–7.47 
(m, 2H ), 7.80–7.83 (m, 1H ), 8.13 (s, 1 H, ArH), 8.15–
8.16 (m, 1H ), 8.43 (s, 1H, ArH). 13C NMR (62 MHz, CDCl3):  = 19.2 (CH3), 71.9 
(OCH2), 27.7 122.3, 122.4, 123.0, 123.6, 125.0, 128.0 (CH), 128.6, 130.4, 134.4, 137.1, 
140.7, 141.8 (C), 167.5, 167.8 (CO). IR (KBr): ν~ = 2959 (m), 2873 (w), 1717 (s), 1604 
(w), 1468 (m), 1263 (s), 1120 (m), 1091 (m), 982 (m), 759 (m), 730 (m) cm–1. MS (EI, 70
eV): m/z (%) = 384 (20) [M]+, 328 (06), 311 (02), 272 (56), 255 (100), 228 (11), 211 
(05). 171 (12). HRMS (EI, 70 eV): m/z calcd for C22H24O4S [M]+: 384.13898; found: 
384.13901. 
Dihexyl dibenzo[b,d]thiophene-2,3-dicarboxylate (6d);  
Compound 6d was prepared starting with 2a (292 mg, 
1.0 mmol) as highly viscous oil (338 mg, 77%). 1H 
NMR (300 MHz, CDCl3):  = 0.83 (t, 3H, J = 6.1 Hz, 
CH3), 0.84 (t, 3H, J = 5.4 Hz, CH3), 1.23–1.39 (m, 12H 
), 1.64–1.74 (m, 4H ), 4.27(t, 2H, J = 6.8 Hz, OCH2), 
4.28 (t, 2H, J = 6.9 Hz, OCH2), 7.43–7.46 (m, 2H ), 
7.79–7.82 (m, 1H ), 8.12 (s, 1 H, ArH), 8.13–8.15 (m, 1H ), 8.42 (s, 1H, ArH). 13C NMR 
(75 MHz, CDCl3):  = 14.0 (2CH3), 22.5, 25.6, 28.5, 31.5 (CH2), 66.0 (OCH2), 122.3, 
122.4, 123.0, 123.6, 125.0, 128.0 (CH), 128.6, 130.4, 134.4, 137.1, 140.7, 141.9 (C), 
S
O
O
O
O
S
O
O
O
O
 58
167.6, 167.8 (CO). IR (KBr): ν~ = 2953 (m), 2927 (m), 1718 (s), 1459 (w), 1263 (s), 1120 
(m), 1092 (m), 760 (m), 729 (m) cm–1. MS (EI, 70 eV): m/z (%) = 440 (14) [M]+, 356 
(06), 272 (33), 255 (100), 228 (09), 182 (07). HRMS (EI, 70 eV): m/z calcd for
C26H32O4S [M]+: 440.20158; found: 440.20186. 
2,3-Diphenyldibenzo[b,d]thiophene (6e);  
Compound 6e was prepared starting with 2b (292 mg, 1.0 mmol) 
as a brownish semisolid (265 mg, 79%). 1H NMR (300 MHz, 
CDCl3):  = 7.11–7.34 (m, 10H), 7.44–7.50 (m, 4H), 7.70 (d, 1H, 
J = 8.3 Hz, ArH), 7.89 (s, 1H, ArH). 13C NMR (75 MHz, 
CDCl3):  = 120.7, 122.7, 123.6, 123.7, 126.5, 126.7 127.6, 
128.6, 128.7, 128.8 (CH), 130.3, 133.8, 137.4, 139.1, 140.4 (C). IR (KBr): ν~  = 2926 (w), 
2850 (w), 1665 (m), 1594 (m), 1446 (m), 1246 (m), 1107 (m), 958 (w), 746 (m), 691 (s), 
595 (w) cm–1. MS (EI, 70 eV): m/z (%) = 336 (15) [M]+, 321 (06), 302 (03), 261 (32), 
184 (04), 167 (05). HRMS (EI, 70 eV): m/z calcd for C24H16S [M]+: 336.09672; found: 
336.09660. 
2,3-Bis(4-chlorophenyl)dibenzo[b,d]thiophene (6f);  
Compound 6f was prepared starting with 2b (292 mg, 1.0 
mmol) as a brown semisolid (336 mg, 83%). 1H NMR
(300 MHz, CDCl3):  = 7.24–7.43 (m, 10H), 7.60–7.93 
(m, 4H). 13C NMR (75 MHz, CDCl3):  = 121.3, 121.9, 
122.2, 123.0, 124.4, 124.6, 124.9, 127.6, 127.7, 128.9 
(CH), 133.3, 133.6, 133.8, 135.1, 135.9, 137.2, 137.7, 
140.1, 140.5,142.5 (C). IR (KBr): ν~  =3058 (w), 1708 (s), 1587 (m), 1489 (m), 1421 (w), 
1358 (w), 1219 (m), 1090 (m), 1012 (m), 828 (m), 756 (s) cm–1. MS (EI, 70 eV): m/z (%) 
= 404 (40) [M]+, 384 (67), 368 (08), 351 (08), 334 (07), 307 (12), 266 (12), 224 (15), 202 
(07), 161 (34). HRMS (EI, 70 eV): m/z calcd for C24H14Cl2S [M]+: 404.01878; found: 
404.01880. 
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General Procedure B for the Synthesis of (7a-e); In a pressure tube (glass bomb) a 
suspension of Pd(OAc)2 (06 mg, 0.025 mmol) and dicyclohexyl-(2',6'-
dimethoxybiphenyl-2-yl) phosphine (L1, 21 mg, 0.05 mmol) in DMF (5 mL) was flushed 
with Ar and stirred at 20 °C to give a yellowish or brownish transparent solution. To the 
stirred solution were added the 2,3-dibromobenzothiophene (2a, 292 mg, 1.0 mmol), 
Et3N (1.1 mL, 8.0 mmol), and the acrylate (1.25 mmol). The reaction mixture was stirred 
at 130 °C for 24 h. The solution was cooled to 20 °C, poured into H2O and CH2Cl2 (25 
mL each), and the organic and the aqueous layer were separated. The latter was extracted 
with CH2Cl2 (3 × 25 mL). The combined organic layers were washed with H2O (3 × 20 
mL), dried (Na2SO4), concentrated in vacuo, and passed through a column (flash silica 
gel, heptanes–EtOAc) to yield the product.
(E)-Ethyl 3-(benzo[b]thiophen-3-yl)acrylate (7a): 
Compound 7a was prepared starting with 2a (292 mg, 1.0mmol) 
as a colorless viscous oil (188 mg, 81%). 1H NMR (250 MHz, 
CDCl3):  = 1.28 (t, 3H, J = 7.1 Hz, CH3), 4.21 (q, 2H, J = 7.2, 
14.3 Hz, OCH2), 6.45 (d, 1H, J = 16.1 Hz), 7.25–7.40 (m, 2 H), 
7.66 (s, 1H, ArH), 7.78–7.81 (m, 1H), 7.88 (d, 1H, J = 16.1 Hz), 
7.91–7.95 (m, 1H). 13C NMR (62 MHz, CDCl3):  = 14.3 (CH3), 60.5 (OCH2), 118.7, 
122.1, 123.0, 124.9, 125.0, 128.0 (CH), 131.6 (C), 136.3 (CH), 137.1, 140.5 (C), 167.1 
(CO). IR (KBr): ν~ = 2978 (w), 1703 (s), 1627 (s), 1503 (w), 1368 (m), 1257 (m), 1158 
(s), 1093 (w), 1043 (m), 971 (m), 731 (s) cm–1. GC-MS (EI, 70 eV): m/z (%) = 232 (92) 
[M]+, 217 (02), 204 (09), 187 (100), 175 (04), 160 (29) 147 (07) 115 (67). HRMS (EI, 70 
eV): m/z calcd for C13H12O2S [M]+: 232.05525; found: 232.05530. 
(E)-Butyl 3-(benzo[b]thiophen-3-yl)acrylate (7b): 
Compound 7b was prepared starting with 2a (292 mg, 
1.0mmol) as a colorless viscous oil (169 mg, 65%). 1H NMR 
(300 MHz, CDCl3):  = 0.89 (t, 3H, J = 7.4 Hz, CH3), 1.30–
1.42 (m, 2H), 1.57–1.69 (m, 2H), 4.16 (t, 2H, J = 6.7 Hz, 
OCH2), 6.45 (d, 1H, J = 15.9 Hz),  7.25–7.41 (m, 2 H), 7.66 (s, 
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1H, ArH), 7.77–7.81 (m, 1H), 7.88 (d, 1H, J = 16.1 Hz), 7.91–7.95 (m, 1H). 13C NMR 
(75 MHz, CDCl3):  = 12.7 (CH3), 18.2, 29.7 (CH2), 63.4 (OCH2), 117.7, 121.1, 121.9, 
123.9, 124.0, 126.9 (CH), 130.6 (C), 135.2 (CH), 136.1, 139.4 (C), 166.2 (CO). IR (KBr): 
ν~ = 2956 (m), 1719 (s), 1542 (w), 1459 (m), 1316 (m), 1262 (s), 1119 (m), 1092 (m), 
1018 (w), 898 (w), 760 (m), 731 (m) cm–1. GC-MS (EI, 70 eV): m/z (%) = 260 (90) [M]+, 
245 (14), 231 (20), 217 (40), 204 (27), 187 (100) 175 (18) 160 (29). HRMS (EI, 70 eV): 
m/z calcd for C15H16O2S [M]+: 260.09110; found: 260.09136.
(E)-3-(Benzo[b]thiophen-3-yl)acrylonitrile (7c): 
Compound 7c was prepared starting with 2a (292 mg, 1.0mmol) as 
light brown semisolid (94 mg, 51%). 1H NMR (300 MHz, CDCl3):  
= 5.63 (d, 1H, J = 16.3 Hz), 7.26–7.41 (m, 1 H), 7.49 (d, 1H, J = 16.2 
Hz), 7.68–7.73 (m, 3H), 7.78–7.84 (m, 1H). 13C NMR (62 MHz, 
CDCl3):  = 96.9 (CH), 117.7 (C), 122.5, 124.8, 125.2, 127.0 (CH), 128.5 (C), 129.2 
(CH), 138.1, 139.2 (C), 143.3 (CH). IR (KBr). ν~ = 2921 (m), 2213 (w), 1611 (m), 1457 
(m), 1365 (w), 1107 (m), 952 (m), 745 (s), 618 (m) cm–1. GC-MS (EI, 70 eV): m/z (%) = 
260 (90) [M]+, 185 (100), 158 (09), 140 (10), 126 (01), 114 (05). HRMS (EI, 70 eV): m/z 
calcd for C11H7NS [M]+: 185.02937; found: 185.02874. 
(E)-3-Styrylbenzo[b]thiophene (7d): 
Compound 7d was prepared starting with 2a (292 mg, 1.0mmol) 
as a colorless crystalline solid (174 mg, 76%); m.p. 93–95 °C. 1H 
NMR (300 MHz, CDCl3):  = 7.12–7.23 (m, 2 H), 7.28–7.36 (m, 
5H), 7.46 (s, 1H, ArH), 7.46–7.49 (m, 2H, ArH), 7.77–7.83 (m, 
1H, ArH), 7.91–7.94 (m, 1H, ArH). 13C NMR (62 MHz, CDCl3): 
= 120.7, 121.8, 122.0, 123.0, 124.33, 124.6, 126.4, 127.7, 128.8, 130.3 (CH), 134.2, 
137.4, 137.8, 140.5 (C). IR (KBr): ν~  = 2921 (s), 2851 (s), 1667 (m), 1598 (m), 1492 (m), 
1454 (m), 1446 (m), 1434 (m), 1377 (w), 1365 (w), 1346 (w), 1260 (w), 1243 (w), 1204 
(w), 1176 (w), 1156 (w), 1029 (w), 1019 (w), 948 (w), 907 (w), 887 (w), 864 (w), 757 
(s), 748 (s), 730 (s), 696 (s), 623 (w), 591 (w), 555 (w), 538 (w) cm–1. GC-MS (EI, 70 
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eV): m/z (%) = 236 (100) [M]+, 221 (18), 202 (16), 189 (05), 117 (08). HRMS (EI, 70 
eV): m/z calcd for C16H12S [M]+: 236.06542; found: 236.064490. 
(E)-3-(4-Methylstyryl)benzo[b]thiophene (7e): 
Compound 7e was prepared starting with 2a (292 mg, 1.0mmol) as a 
white crystalline solid (190 mg, 76%); m.p. 107–109 °C. 1H NMR 
(300 MHz, CDCl3):  =2.29 (s, 3H, CH3), 7.11–7.38 (m, 6H), 6.88 
(d, 1H, J = 16.0 Hz), 7.79 (d, 2H, J = 7.3 Hz), 7.92 (d, 2H, J = 7.2 
Hz). 13C NMR (62 MHz, CDCl3):  = 21.3 (CH3), 119.7, 121.4, 
121.9, 123.0, 124.2, 124.5, 126.3, 129.4, 130.2 (CH), 134.3, 134.6, 137.6, 137.8, 140.5 
(C). IR (KBr): ν~ = 2919 (m), 1642 (w), 1425 (m), 1234 (m), 1109 (w), 962 (m), 805 (s), 
754 (s), 730 (s), 709 (w) cm–1. GC-MS (EI, 70 eV): m/z (%) = 250 (75) [M]+, 235 (100), 
221 (06), 202 (11), 189 (04), 158 (02), 139 (02). HRMS (EI, 70 eV): m/z calcd for 
C17H14S [M]+: 250.08107; found: 250.08125.
Synthesis of (E)-2,3-Diphenyl-7-styryldibenzo[b,d]thiophene (10); In a pressure tube 
(glass bomb) a suspension of Pd(OAc)2 (12 mg, 0.05 mmol, 1.7 mol% per Br atom) and 
dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl) phosphine (L1, 41 mg, 0.10 mmol) in DMF 
(5 mL) was flushed with Ar and stirred at 20 °C to give a yellowish or brownish 
transparent solution. To the stirred solution were added the 2,3,6-
tribromobenzothiophene (2b, 371 mg, 1.0 mmol), Et3N (1.1 mL, 8.0 mmol), and the 
acrylate (1.25 equiv per Br). The reaction mixture was stirred at 130 °C for 48 h. The 
solution was cooled to 20 °C, poured into H2O and CH2Cl2 (25 mL each), and the organic 
and the aqueous layers were separated. The latter was extracted with CH2Cl2 (3 × 25 
mL). The combined organic layers were washed with H2O (3 × 20 mL), dried (Na2SO4), 
concentrated in vacuo, and passed through a column (silica gel). To a xylene solution (3 
mL) of the crude product was added Pd/C (30 mg, 10 mol %). The solution was stirred 
under reflux for 48 h under argon atmosphere. The reaction mixture was filtered, and the 
filtrate was concentrated in vacuo. The residue was purified by chromatography (flash 
silica gel, heptanes–EtOAc) to yield the product. 
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(E)-2,3-Diphenyl-7-styryldibenzo[b,d]thiophene (10);  
Compound 10 was prepared starting with 2b (371 
mg, 1.0 mmol) as a brownish semisolid (319 mg, 
73%). 1H NMR (300 MHz, CDCl3):  = 7.01–7.20 
(m, 7H), 7.24–7.34 (m, 7H), 7.40–7.47 (m, 6H), 
7.75–7.86 (m, 2H, ArH). 13C NMR (62 MHz, 
CDCl3):  = 120.7, 121.3, 122.1, 122.3, 122.9,
125.6, 126.5, 126.6, 127.5, 128.6, 128.7, 128.8 (CH), 129.7, 130.3 (C), 130.4 (CH), 
137.3, 137.4, 137.4, 137.5, 139.9, 140.5, 141.2, 142.1 (C). IR (KBr): ν~  = 3054 (w), 3023 
(w), 291 (w), 1681 (m), 1596 (m), 1493 (m), 1445 (m), 1178 (w), 1155 (w), 1072 (w), 
1026 (w), 956 (s), 908 (w), 876 (w), 812 (w), 747 (s), 733 (s), 688 (s) cm–1. MS (EI, 70 
eV): m/z (%) = 438 (19) [M]+, 368 (31), 338 (100), 259 (20), 234 (16), 202 (10), 105 
(15). HRMS (EI, 70 eV): m/z calcd for C32H22S [M]+: 438.14422; found: 438.144012. 
7.3 Synthesis of 2,3-Disubstituted Pyrazines and Quinoxalines by 
Heck Cross-Coupling Reactions of 2,3-Dichloropyrazine and 2,3-
Dichloroquinoxaline. 
  
General procedure for the two-fold Heck cross-coupling reactions; In a pressure tube 
(glass bomb) a suspension of Pd(OAc)2 (12 mg, 0.05 mmol, 2.5 mol% per Cl) and 
dicyclohexyl (2’,4’,6’-triisopropylbiphenyl-2-yl)phosphine (Xphos) (47 mg, 0.10 mmol) 
in DMF (5 mL) was purged with Ar and stirred at 20 °C to get a yellowish or brownish 
transparent solution. To the stirred solution were added 2,3-dichloropyrazine (11a) (149 
mg, 1.0 mmol), NEt3 (1.1 mL, 8.0 mmol) and  the acrylate or styrene (1.25 equiv. per Br). 
The reaction mixture was stirred at the indicated temperature for 48 h. The solution was 
cooled to 20 °C, poured into H2O and CH2Cl2 (25 mL each), and the organic and the 
aqueous layer were separated. The latter was extracted with CH2Cl2 (3 x 25 mL). The 
combined organic layers were washed with H2O (3 x 20 mL), dried (Na2SO4), and 
concentrated in vacuo. The residue was purified by chromatography (flash silica gel, 
heptanes/EtOAc).  
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(2E,2’E)-Diethyl 3,3’-(pyrazine-2,3-diyl)diacrylate (12a): 
Compound 12a was prepared from 11a (149 mg, 1.0 mmol) as a 
light brown highly viscous oil (229 mg, 83%). Reaction 
temperature: 90 °C. 1H NMR (300 MHz, CDCl3): δ  = 1.28 (t, 6H,
J = 7.2 Hz, 2CH3), 4.23 (q, 4H, J = 7.1, 14.2 Hz, 2CH2O), 7.05 (d, 
2H, J = 15.2 Hz, 2CH), 7.94 (d, 2H, J = 15.2 Hz, 2CH), 8.48 (s, 2H, ArH). 13C NMR 
(62.9 MHz, CDCl3):  δ = 14.2 (CH3), 60.9 (CH2O), 126.8, 136.3, 145.0 (CH), 146.3 (C), 
166.0 (CO). IR (KBr): ν~ = 2978 (m), 2934 (w), 1715 (s), 1638 (w), 1400 (m), 1294 (s), 
1266 (m), 1177 (s), 1033 (m), 974 (m), 911 (w), 797 (w) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 276 (11) [M]+, 231 (42), 186 (5), 175 (44), 157 (34), 131 (73). HRMS (EI, 70 eV):
calcd for C14H16N2O4 [M]+ : 276.11046; found: 276.11092.
2,3-Distyrylpyrazine (12b);  
Compound 12b was prepared from 11a (149 mg, 1.0 mmol) as a 
light yellow solid (233 mg, 82%); m.p. 105-107 °C. Reaction 
temperature: 90 °C. 1H NMR (300 MHz, CDCl3):  δ = 7.28-7.35 (m, 
6H, ArH), 7.41 (d, 2H, J = 15.6), 7.54-7.57 (m, 4H, ArH), 7.76 (d, 
2H, J = 15.6 Hz), 8.34 (brs, 2H, ArH). 13C NMR (75.5 MHz, CDCl3):  δ = 121.9, 127.4, 
128.8, 128.9 (CH), 136.5 (C), 136.6, 142.5 (CH), 147.8 (C). IR (KBr): ν~  = 3369 (w), 
3024 (w), 1626 (m), 1599 (w), 1575 (w), 1493 (m), 1447 (m), 1392 (m), 1154 (m), 1072 
(m), 962 (m), 744 (s), 687 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 283 (100) [M-1]+,  
268 (2), 226 (2), 207 (24), 141 (18). HRMS (EI, 70 eV): calcd for C20H15N2 [M-1]+: 
283.12298; found: 283.12297.  
2,3-Bis(4-methoxystyryl)pyrazine (12c);  
Compound 12c was prepared from 11a (149 mg, 1.0 mmol) as 
a light brown highly viscous oil (268 mg, 78%). Reaction 
temperature: 90 °C. 1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 
6H, 2OCH3), 6.95 (d, 4H, J = 8.6 Hz, ArH), 7.36 (d, 2H, J = 
15.6 Hz), 7.59 (d, 4H, J = 8.6 Hz, ArH), 7.80 (d, 2H, J = 15.6 
Hz), 8.38 (brs, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 55.3 (CH3), 114.2, 119.8, 
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128.8 (CH), 129.4 (C), 135.8, 141.9 (CH), 147.9 I, 160.2 (C). IR (KBr): ν~ = 3400 (w), 
3033 (w), 2954 (m), 1708 (m), 1601 (s), 1508 (s), 1440 (m), 1399 (w), 1301 (m), 1243 
(s), 1028 (s), 970 (m), 823 (s), 708 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 344 (100) 
[M]+, 329 (12), 313 (4), 299 (4), 237 (30), 172 (05). HRMS (EI, 70 eV): calcd for 
C22H20N2O2 [M]+: 344.15193; found: 344.15154. 
2,3-Bis(4-methylstyryl)pyrazine (12d);  
Compound 12d was prepared from 11a (149 mg, 1.0 mmol) as a 
yellow solid (256 mg, 82%); m.p. 111-113 °C. Reaction 
temperature: 90 °C. 1H NMR (300 MHz, CDCl3): δ = 2.30 (s, 6H, 
2CH3), 7.12 (d, 4H, J = 8.1 Hz, ArH), 7.34 (d, 2H, J = 15.4), 7.44 
(d, 4H, J = 8.0 Hz, ArH), 7.72 (d, 2H, J = 15.7 Hz), 8.30 (brs, 2H, ArH). 13C NMR (75.5 
MHz, CDCl3): δ = 21.4 (CH3), 121.0, 127.3, 129.5 (CH), 133.8 (C), 136.4 (CH), 139.0 
(C), 142.2 (CH), 147.9 (C). IR (KBr): ν~ = 3046 (w), 3023 (w), 2920 (w), 2860 (w), 1710 
(m), 1444 (m), 1414 (m), 1391 (w), 1360 (w), 1220 (m), 1180 (m), 1153 (m), 971 (s), 905 
(w), 866 (w), 845 (w), 803 (s), 750 (w), 656 (w), 596 (w) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 311 (100) [M-1]+, 297 (8), 281 (2), 221 (24), 195 (7), 141 (13). HRMS (EI, 70 eV):
calcd for C22H19N2 [M-1]+: 311.15428; found: 311.15432. 
2,3-Bis(4-chlorostyryl)pyrazine (12e);  
Compound 12e was prepared from 11a (149 mg, 1.0 mmol), 
following the general procedure, as a light yellowish highly 
viscous oil (232 mg, 66 %). Reaction temperature: 90 °C. 1H 
NMR (300 MHz, CDCl3): δ = 7.27-7.38 (m, 6H), 7.45-7.56 (m, 
4H), 7.69-7.79 (m, 2H), 8.35 (brs, 2H, ArH). 13C NMR (62.9 
MHz, CDCl3): δ = 122.7, 128.5, 129.0 (CH), 134.9, 134.6 (C), 135.3, 142.6 (CH), 147.4 
(C). IR (KBr): ν~  = 3026 (w), 2927 (s), 2854 (m), 1706 (s), 1603 (w), 1490 (s), 1090 (s), 
1013 (m), 966 (m), 827 (m), 765 (w), 700 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 351 
(100) [M-1]+, 317 (10), 280 (02), 241 (48), 227 (07). HRMS (EI, 70 eV): calcd for 
C20H13N2Cl2 [M-1]+: 351.04503; found: 351.04518. 
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2,3-Bis(4-tert-butoxystyryl)pyrazine (12f);  
Compound 12f was prepared from 11a (149 mg, 1.0 mmol) 
as a brownish solid (274 mg, 64%); m.p. 125-127 °C. 
Reaction temperature: 90 °C. 1H NMR (300 MHz, CDCl3): 
δ = 1.30 (s, 18H, 6CH3), 6.94 (d, 4H, J = 8.2 Hz, ArH), 
7.30 (d, 2H, J = 15.9 Hz), 7.45 (d, 4H, J = 8.6 Hz, ArH), 
7.71 (d, 2H, J = 15.5 Hz), 8.30 (brs, 2H, ArH). 13C NMR 
(62.9 MHz, CDCl3): δ = 28.9 (CH3), 79.02 (C), 120.6, 124.0, 128.1 (CH), 131.6 (C), 
135.9, 142.1 (CH), 147.8, 156.4 (C). IR (KBr): ν~  = 3029 (w), 2972 (m), 2928 (w), 1600 
(m), 1503 (s), 1445 (m), 1388 (m), 1363 (m), 1234 (s), 1154 (s), 1089 (w), 975 (m), 892 
(s), 848 (m), 713 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 428 (09) [M]+, 372 (4), 316 
(100), 285 (3), 223 (30), 210 (15). HRMS (EI, 70 eV): calcd for C28H32N2O2  [M]+: 
428.24583; found: 428.24676. 
Dimethyl 3,3’-(quinoxaline-2,3-diyl)diacrylate (12g);  
Compound 12g was prepared from 11b (199 mg, 1.0 mmol) as 
a  light yellow solid (232 mg, 78%); m.p.  134-136 °C. 
Reaction temperature: 120 °C. 1H NMR (300 MHz, CDCl3): δ  
= 3.90 (s, 6H, 2CH3O), 7.30 (d, 2H, J = 15.2 Hz), 7.80-7.83 (m, 
2H, ArH), 8.08-8.11 (m, 2H, ArH , 8.20 (d, 2H, J = 15.2 Hz). 13C NMR (62.9 MHz, 
CDCl3):  δ  = 52.0 (CH3O), 127.1, 129.5, 131.2, 137.2 (CH), 142.4, 146.4 (C), 166.4 
(CO). IR (KBr): ν~  = 3303 (w), 2956 (w), 2920 (w), 1710 (s), 1638 (w), 1433 (m), 1308 
(m), 1269 (s), 1170 (s), 1027 (m), 969 (m), 757 (s), 717 (m), 611 (w), 543 (w) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 298 (08) [M]+, 283 (3), 267 (26), 239 (100), 223 (8), 207 (25), 
195 (38). HRMS (EI, 70 eV): calcd for C16H14N2O4 [M]+: 298.0951; found: 298.0954. 
2,3-Bis(E-2-cyclohexylvinyl)quinoxaline (12h);  
Compound 12h was prepared from 11b (199 mg, 1.0 mmol) 
as a light yellow highly viscous oil (222 mg, 64%). Reaction 
temperature: 120 °C. 1H NMR (300 MHz, CDCl3): δ  = 1.62-
1.86 (m, 20H), 2.16-2.28 (m, 2H ), 6.77 (d, 2H, J = 15.4 
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Hz), 6.96 (dd, 2H, J = 6.7, 15.4 Hz ), 7.52-7.55 (m, 2H), 7.87-7.91 (m, 2H ). 13C NMR 
(62.9 MHz, CDCl3):  δ  = 25.9, 26.1, 32.5 (CH2), 41.5, 122.7, 128.7, 128.8 (CH), 141.3 
(C), 146.7 (CH), 149.4 (C). IR (KBr): ν~  = 3065 (w), 2922 (s), 2850 (m), 1700 (m), 1447 
(m), 1259 (s), 1091 (s), 1019 (s), 798 (m), 758 (s), 698 (w), 589 (w) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 346 (35) [M]+, 303 (6), 263 (100), 251 (7), 169 (20). HRMS (EI, 70 eV):
calcd for C24H30N2 [M]+: 346.24035; found: 346.23992. 
2, 3-Distyrylquinoxaline (12i);  
Compound 12i was prepared from 11b (199 mg, 1.0 mmol) as a 
yellow solid (240 mg, 72%); m.p. 143-145 °C. Reaction 
temperature: 120 °C. 1H NMR (300 MHz, CDCl3): δ = 7.24-
7.37 (m, 6H), 7.55 (d, 2H, J = 15.5 Hz), 7.58-7.61 (m, 6H 
), 7.91 (d, 2H, J = 15.5 Hz ), 7.94-7.98 (m, 2H ). 13C NMR (62.9 MHz, CDCl3):  δ = 
122.6, 127.6, 128.8, 128.9, 129.0, 129.5 (CH), 136.5 (C), 137.9 (CH), 141.6, 149.0 (C). 
IR (KBr): ν~  = 3060 (w), 3029 (w), 2930 (w), 2853 (w), 1706 (m), 1682 (w), 1491 (w), 
1320 (m), 1106 (m), 981 (w), 763 (s), 697 (s), 601 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) 
= 334 (93)[M]+, 333 (100), 257 (62), 243 (19), 204 (32), 167 (17). HRMS (EI, 70 eV):
calcd for C24H18N2 [M]+: 334.14645; found: 334.14539. 
2,3-Bis(4-tert-butoxystyryl)quinoxaline (12j);  
Compound 12j was prepared from 11b (199 mg, 1.0 
mmol) as a yellow highly viscous oil (319 mg, 67%). 
Reaction temperature: 120 °C. 1H NMR (300 MHz, 
CDCl3): δ  = 1.27 (s, 18H, 6CH3), 6.92 (d, 4H, J = 8.5 
Hz, ArH), 7.43 (d, 2H, J = 15.5 Hz), 7.49-7.54 (m, 6H), 
7.84 (d, 2H, J = 15.6 Hz), 7.86-7.91 (m, 2H). 13C NMR 
(62.9 MHz, CDCl3):  δ = 28.9 (CH3), 79.1 (C), 121.3, 124.0, 128.3, 128.8, 129.2 (CH), 
131.5 (C), 137.7 (CH), 141.5, 149.2, 156.6 (C). IR (KBr): ν~  = 3031 (w), 2922 (s), 2851 
(m), 1677 (w), 1601 (m), 1504 (s), 1459 (m), 1364 (m), 1237 (m), 1156 (s), 1014 (w), 
972 (w), 893 (m), 759 (m), 607 (w), 537 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 478 
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(03)[M]+, 422 (4), 366 (61), 273 (22), 260 (12), 212 (05). HRMS (EI, 70 eV): calcd for 
C32H34N2O2 [M]+: 478.26148; found: 478.26059. 
2,3-Bis(4-methoxystyryl)quinoxaline (12k);  
Compound 12k was prepared from 11b (199 mg, 1.0 
mmol) as a yellow highly viscous oil (327 mg, 83%). 
Reaction temperature: 120 °C. 1H NMR (300 MHz, 
CDCl3): δ = 3.76 (s, 6H, 2OCH3), 6.85 (d, 4H, J = 8.8 Hz, 
ArH), 7.42 (d, 2H, J = 15.5 Hz), 7.52-7.57 (m, 6H, ArH), 
7.85 (d, 2H, J = 15.6 Hz), 7.90-7.94 (m, 2H, ArH). 13C NMR (62.9 MHz, CDCl3):  δ = 
55.35 (OCH3), 114.2, 120.4, 128.7, 129.0, 129.1 (CH), 129.3 (C), 137.3 (CH), 141.5, 
149.3 (C), 160.4 (CO). IR (KBr): ν~  = 3004 (w), 2963 (w), 2838 (w), 1598 (s), 1541(w), 
1508 (s), 1460 (m), 1420 (m), 1299 (w), 1247 (s), 1172 (s), 1109 (m), 1022 (s), 969 (s), 
829 (s), 760 (s), 610 (m), 535 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 394 (61)[M]+, 379 
(15), 335 (4), 288 (11), 275 (41), 227 (13), 191 (8). HRMS (EI, 70 eV): calcd for 
C26H22N2O2 [M]+: 394.16758; found: 394.16667. 
2,3-Bis(4-tert-butylstyryl)quinoxaline (12l);  
Compound 12l was prepared from 11b (199 mg, 1.0 
mmol) as a highly viscous brownish oil (321 mg, 72%). 
Reaction temperature: 120 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.28 (s, 18H, 6CH3), 7.28 (d, 2H, J = 16.3 
Hz), 7.37 (d, 4H, J = 8.5 Hz, ArH), 7.59-7.70 (m, 4H), 
7.78 (d, 2H, J = 16.3 Hz), 7.96-8.01 (m, 4H). 13C NMR 
(75.5 MHz, CDCl3): δ = 31.3 (CH3), 33.7 (C), 125.9, 127.3, 129.1, 130.3 (CH), 135.3 
(C), 136.3 (CH), 143.4 (C), 144.4 (CH), 149.8, 151.6 (C). IR (KBr): ν~  = 3059 (w), 2922 
(s), 2852 (m), 1632 (m), 1512 (w), 1457 (m), 1362 (m), 1267 (m), 1202 (m), 1106 (s), 
971 (m), 820 (m), 759 (s), 610 (w), 562 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 446 
(13)[M]+, 433 (8), 391 (12), 301 (40), 285 (7), 245 (8). HRMS (EI, 70 eV): calcd for 
C32H34N2 [M]+: 446.28869; found: 446.28780. 
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(E)-Methyl 3-(3-(3-methoxy-3-oxopropyl)pyrazin-2-yl)acrylate (13a);   
Compound 13a was prepared from 11a (149 mg, 1.0 mmol) as a 
brown highly viscous oil (195 mg, 78%). Reaction temperature: 110 
°C.  1H NMR (300 MHz, CDCl3): δ  = 2.80 (t, 2H, J = 7.2 Hz, CH2 ), 
3.23 (t, 2H, J = 7.1 Hz, CH2 ), 3.61 (s, 3H, OCH3), 3.76 (s, 3H, 
OCH3), 7.02 (d, 1H, J = 15.2 Hz, CH), 7.87 (d,1H, J = 15.3 Hz, CH), 8.35-8.38 (m, 2H, 
ArH). 13C NMR (62.9 MHz, CDCl3): δ = 28.4, 31.3 (CH2), 51.7, 51.9 (OCH3), 125.2, 
137.6, 142.3, 144.2 (CH), 146.4, 153.8 (C), 166.8, 173.0 (CO). IR (KBr): ν~  = 2953 (m), 
2932 (w), 1713 (s), 1530 (w), 1436 (m), 1361 (m), 1294 (m), 1171 (m), 1103 (w), 1032 
(w), 977 (w), 858 (w), 711 (w) cm-1.  GC-MS (EI, 70 eV): m/z (%) = 250 (02)[M]+, 235 
(2), 219 (32), 191 (100), 159 (44), 131 (63). HRMS (EI, 70 eV): calcd for C12H14N2O4 
[M]+: 250.09481; found: 250.09556. 
(E)-Ethyl 3-(3-(3-ethoxy-3-oxopropyl)pyrazin-2-yl)acrylate (13b); 
 Compound 13b was prepared from 11a (149 mg, 1.0 mmol) as a 
light yellow highly viscous oil (196 mg, 71%). Reaction 
temperature: 110 °C. 1H NMR (300 MHz, CDCl3): δ  = 1.15 (t, 
3H, J = 7.2 Hz, CH3), 1.26 (t, 3H, J = 7.2 Hz, CH3), 2.78 (t, 2H, J
= 7.2 Hz, CH2), 3.22 (t, 2H, J = 7.1 Hz, CH2), 4.05 (q, 2H, J = 7.1, 14.3 Hz, CH2O), 4.21 
(q, 2H, J = 7.1, 14.3 Hz, CH2O), 7.01 (d, 1H, J = 15.4 Hz, CH), 7.86 (d, 1H, J = 15.4 
Hz), 8.34-8.37 (m, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 14.1, 14.2 (CH3), 28.4, 
31.6 (CH2), 60.5, 60.8 (CH2O), 125.6, 137.4, 142.2, 144.1 (CH), 146.4, 154.0 (C), 166.3, 
172.5 (CO). IR (KBr): ν~  = 2981 (m), 2934 (w), 1712 (s), 1640 (w), 1446 (w), 1404 (m), 
1368 (m), 1290 (s), 1174 (s), 1099 (m), 1031 (s), 974 (m), 857 (m), 710 (w) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 278 (03)[M]+, 249 (4), 233 (46), 205 (100), 159 (54), 131 
(60). HRMS (EI, 70 eV): calcd for C14H18N2O4 [M]+: 278.12611; found: 278.126717. 
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(E)-Butyl 3-(3-(3-butoxy-3-oxopropyl)pyrazin-2-yl)acrylate (13c);  
Compound 13c was prepared from 11a (149 mg, 1.0 mmol) 
as a light yellow highly viscous oil (247 mg, 74%). Reaction 
temperature: 110 °C. 1H NMR (300 MHz, CDCl3): δ  = 0.84 
(t, 3H, J = 7.3 Hz, CH3), 0.89 (t, 3H, J = 7.4 Hz, CH3), 1.23-
1.40 (m, 4H, 2CH2), 1.48-1.65 (m, 4H, 2CH2), 2.79 (t, 2H, J = 7.2 Hz, CH2), 3.22 (t, 2H, 
J = 7.0 Hz, CH2), 4.00 (t, 2H, J = 6.8 Hz, CH2O), 4.16 (t, 2H, J = 6.8 Hz, CH2O), 7.02 (d, 
1H, J = 15.3 Hz, CH), 7.9 (d, 1H, J = 15.2 Hz, CH), 8.35-8.37 (m, 2H, ArH). 13C NMR 
(75.5 MHz, CDCl3): δ = 13.7 (CH3), 19.0, 19.1, 28.4, 30.6, 30.7, 31.6 (CH2), 64.5, 64.7 
(CH2O), 125.7, 137.4, 142.2, 144.1 (CH), 146.5, 154.0 (C), 166.4, 172.7 (CO). IR (KBr):
ν~ = 2958 (m), 2933 (w), 1720 (s), 1455 (m), 1405 (m), 1263 (w), 1170 (s), 1063 (m), 
1021, 975 (m), 857 (w), 754 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 334 (05)[M]+, 277 
(03), 261 (31), 233 (100), 177 (16), 159 (47). HRMS (EI, 70 eV): calcd for C18H26N2O4 
[M]+: 334.18871; found: 334.18877. 
(E)-Isobutyl 3-(3-(3-isobutoxy-3-oxopropyl)pyrazin-2-yl)acrylate (13d);  
Compound 13d was prepared from 11a (149 mg, 1.0 mmol) as 
a brown highly viscous oil (251 mg, 75%). Reaction 
temperature: 110 °C. 1H NMR (300 MHz, CDCl3): δ = 0.81 (d, 
6H, J = 6.7 Hz, 2CH3 ), 0.91 (d, 6H, J = 6.9 Hz, 2CH3), 1.76-
1.99 (m, 2H, CH), 2.80 (t, 2H, J = 7.1 Hz, CH2), 3.2 (t, 2H, J = 7.1 Hz, CH2), 3.78 (d, 2H, 
, J = 6.7 Hz, CH2O), 3.94 (d, 2H, J = 6.4 Hz, CH2O), 7.0 (d, 1H, J = 15.3 Hz, CH), 7.9 (d, 
1H, J = 15.3 Hz, CH), 8.35-8.37 (m, 2H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 19.0 
(CH3), 27.6, 27.7 (CH), 28.4, 31.5 (CH2), 70.7, 70.9 (CH2O), 125.7, 137.4, 142.2, 144.2 
(CH), 146.5, 153.9 (C), 166.4, 172.6 (CO). IR (KBr): ν~  = 2960 (m), 2874 (w), 1716 (s), 
1640 (w), 1469 (m), 1405 (m), 1166 (s), 1008 (m), 854 (w), 710 (w) cm-1. GC-MS (EI, 
70 eV): m/z (%) = 334 (07)[M]+, 277 (4), 261 (51), 233 (100), 205 (12), 177 (44). HRMS 
(EI, 70 eV): calcd for C18H26N2O4 [M]+: 334.18871; found: 334.18918. 
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(E)-Tert-Butyl 3-(3-(3-tert-butoxy-3-oxopropyl)pyrazin-2-yl)acrylate (13e);  
Compound 13e was prepared from 11a (149 mg, 1.0 mmol) as a 
light yellow highly viscous oil (277 mg, 83%). Reaction 
temperature: 110 °C. 1H NMR (300 MHz, CDCl3): δ  = 1.34 (s, 
9H, 3CH3), 1.46 (s, 9H, 3CH3), 2.68 (t, 2H, J = 7.2 Hz, 
CH2), 3.16 (t, 2H, J = 7.2 Hz, CH2 ), 6.93 (d, 1H, J = 15.2 Hz, CH), 7.76 (d, 1H, J = 15.3 
Hz, CH), 8.33-8.35 (m, 2H, ArH). 13C NMR (62.9 MHz, CDCl3):  δ = 28.0 (CH3), 28.6, 
32.8, (CH2), 80.2, 80.9 (C), 127.6, 136.5, 142.1, 143.9 (CH), 146.6, 154.1 (C), 165.6, 
171.7 (CO). IR (KBr): ν~  = 2976 (m), 2931 (w), 1708 (s), 1638 (w), 1455 (w), 1366, 
1295 (m), 1144 (s), 975 (m), 847 (m), 758 (w), 711 (w) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 334 (01)[M]+, 261 (31), 222 (23), 205 (64), 177 (100), 159 (22). HRMS (EI, 70 
eV): calcd for C18H26N2O4 [M]+: 334.18871; found: 334.18930. 
(E)-Hexyl 3-(3-(3-(hexyloxy)-3-oxopropyl)pyrazin-2-yl)acrylate (13f);  
Compound 13f was prepared from 11a (149 mg, 1.0 
mmol as light yellow highly viscous oil (308 mg, 79%). 
Reaction temperature: 110 °C. 1H NMR (300 MHz, 
CDCl3): δ  = 0.78-0.85 (m, 6H, 2CH3), 1.20-1.27 (m, 
12H, 6CH2), 1.47-1.65 (m, 4H, 2CH2), 2.79 (t, 2H, J = 7.4 Hz, CH2), 3.22 (t, 2H, J = 7.0 
Hz, CH2), 3.99 (t, 2H, J = 6.7 Hz, CH2O), 4.15 (t, 2H, J = 6.7 Hz, CH2O), 7.02 (d, 1H, J
= 15.3 Hz), 7.86 (d, 1H, J = 15.3 Hz), 8.35-8.37 (m, 2H, ArH). 13C NMR (62.9 MHz, 
CDCl3): δ = 14.0 (CH3), 22.4, 22.5, 25.5, 25.6, 28.4, 28.5, 28.6, 31.3, 31.4, 31.6 (CH2), 
64.7, 65.0 (CH2O), 125.7, 137.3, 142.2, 144.1, (CH), 146.5, 154.0 (C), 166.4, 172.6 
(CO). IR (KBr): ν~  = 2928 (m), 2857 (w), 1716 (s), 1530 (w), 1404 (m), 1358 (w), 1289 
(m), 1168 (s), 976 (m), 854 (w), 725 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 390 (17) 
[M]+, 289 (22), 261 (100), 205 (9), 177 (18), 159 (35). HRMS (EI, 70 eV): calcd for 
C22H34N2O4 [M]+: 390.25131; found: 390.25141. 
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(E)-2-Ethylhexyl 3-(3-(3-(2-ethylhexyloxy)-3-oxopropyl) pyrazin-2-yl)acrylate (13g);
Compound 13g was prepared from 11a (149 mg, 1.0 
mmol) as a light yellow highly viscous oil (306 mg, 
69%). Reaction temperature: 110 °C. 1H NMR (300 
MHz, CDCl3): δ  = 0.86-0.93 (m, 12H, 4CH3), 1.24-
1.35 (m, 16H), 1.50-1.68 (m, 2H), 2.87 (t, 2H, J = 7.1 Hz), 3.30 (t, 2H, J = 7.1 Hz), 3.99 
(d, 2H, J = 7.7 Hz), 4.15 (d, 2H, J = 7.1 Hz), 7.10 (d, 1H, J = 15.2 Hz), 7.94 (d, 1H, J = 
15.7 Hz), 8.42-8.44 (m, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ  = 10.9, 13.9 (CH3), 
22.9, 22.9, 23.6, 23.8, 28.3, 28.8, 28.9, 30.3, 30.4, 31.5 (CH2), 38.6, 38.8 (CH), 66.9, 67.2 
(CH2O), 125.7, 137.3, 142.2, 144.1 (CH), 146.5, 153.9, 166.5 (C), 172.7 (CO). IR (KBr):
ν~ = 2957 (m), 2872 (w), 1717 (s), 1461 (m), 1404 (m), 1264 (m), 1168 (s), 975 (m), 771 
(w), 710 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 446 (59)[M]+, 417 (8), 389 (5), 335 
(45), 317 (73), 289 (100). HRMS (EI, 70 eV): calcd for C26H42N2O4 [M]+: 446.31391; 
found: 446.314336.
(E)-Tert-Butyl 3-(3-(3-tert-butoxy-3-oxopropyl) quinoxalin-2-yl) acrylate (13h);
Compound 13h was prepared from 11b (199 mg, 1.0 mmol) 
as a light brown viscous oil (288 mg, 75%). Reaction 
temperature: 130 °C. 1H NMR (300 MHz, CDCl3): δ = 1.36 
(s, 9H, 3CH3), 1.49 (s, 9H, 3CH3), 2.82 (t, 2H, J = 7.1 Hz, 
CH2), 3.35 (t, 2H, J = 7.1 Hz, CH2), 7.10 (d, 1H, J = 15.4 Hz), 7.61-7.65 (m, 2H), 7.89-
7.98 (m, 3H). 13C NMR (62.9 MHz, CDCl3): δ = 27.5, 28.1 (CH3), 29.6, 32.3 (CH2), 
80.4, 81.1 (C), 128.6, 128.7, 129.4, 129.5, 130.2, 136.7 (CH), 141.1, 142.0, 147.2, 154.0 
(C), 165.5, 172.0 (CO). IR (KBr): ν~  = 3062 (w), 2976 (m), 2931 (m), 1710 (s), 1482 
(m), 1456 (w), 1366 (m), 1247 (m), 1147 (s), 975 (w), 845 (m), 760 (s), 611 (w) cm-1. 
GC-MS (EI, 70 eV): m/z (%) = 384 (01)[M]+, 328 (9), 311 (25), 272 (15), 255 (25), 227 
(100), 209 (13), 181 (32). HRMS (EI, 70 eV): calcd for C22H28N2O4 [M]+: 384.20436; 
found: 384.20525.  
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Dibutyl 3,3’-(pyrazine-2,3-diyl)dipropanoate (14a);
 Compound 14a was prepared from 11a (149 mg, 1.0 mmol) 
as a light yellow highly viscous oil (232 mg, 69%). Reaction 
temperature: 140 °C. 1H NMR (300 MHz, CDCl3): δ  = 0.83 
(t, 6H, J = 7.4 Hz, 2CH3), 1.23-1.31 (m, 4H, 2CH2), 1.49-
1.54 (m, 4H, 2CH2), 2.79 (t, 4H, J = 7.2 Hz, 2CH2 ), 3.09 (t, 4H, J = 7.1 Hz, 2CH2), 4.00 
(t, 4H, J = 6.7 Hz, 2CH2O),  8.21 (s, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 13.6 
(CH3), 19.0, 28.4, 30.6, 31.2 (CH2), 64.3(CH2O), 141.1(CH), 153.5 (C), 173.0 (CO). IR 
(KBr): ν~  = 2958 (m), 2873 (w), 1729 (s), 1536 (w), 1456 (w), 1412 (m), 1165 (s), 1109 
(m), 1020 (w), 944 (w), 849 (w), 738 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 336 
(66)[M]+, 2263 (65), 235 (100), 207 (6), 188 (12), 161 (71). HRMS (EI, 70 eV): calcd for 
C18H28N2O4 [M]+: 336.20436; found: 336.20440. 
Isobutyl 3,3’-(pyrazine-2,3-diyl)dipropanoate (14b);  
Compound 14b was prepared from 11a (149 mg, 1.0 mmol) as 
a light brown highly viscous oil (255 mg, 76%). Reaction 
temperature: 140 °C. 1H NMR (300 MHz, CDCl3): δ  = 0.82 (d, 
12H, J = 6.9 Hz, 4CH3), 1.77-1.88(m, 2H, 2CH), 2.81 (t, 4H, J
= 7.3 Hz, 2CH2), 3.10 (t, 4H, J = 6.9 Hz, 2CH2), 3.79 (d, 4H, J = 6.9 Hz, 2CH2O), 8.20 
(s, 2H, Ar-H). 13C NMR (62.9 MHz, CDCl3): δ = 18.9 (CH3), 27.6(CH), 28.4, 31.1 
(CH2), 70.6 (CH2O), 141.2 (CH), 153.4 (C), 173.0 (CO). IR (KBr): ν~  = 2959 (m), 2874 
(w), 1729 (s), 1535 (w), 1469 (m), 1411 (m), 1379 (m), 1160 (s), 1109 (m), 992 (m), 851 
(w), 796 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 336 (49)[M]+, 279 (23), 261 (52), 233 
(100), 219 (15), 177 (51), 159 (46). HRMS (EI, 70 eV): calcd for C18H28N2O4 [M]+: 
336.20436; found: 336.20453. 
Tert-Butyl 3,3’-(pyrazine-2,3-diyl)dipropanoate (14c);  
Compound 14c was prepared from 11a (149 mg, 1.0 mmol) as a 
light yellow highly viscous oil (235 mg, 70%). Reaction 
temperature: 140 °C. 1H NMR (300 MHz, CDCl3): δ = 1.35 (s, 
18H, 6CH3), 2.68 (t, 4H, J = 7.1 Hz, 2CH2), 3.04 (t, 4H, J = 7.1 
N
N
O
O
O
O
N
N
O
O
O
O
N
N
O
O
O
O
 73
Hz, 2CH2), 8.21 (s, 2H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 28.2 (CH3), 28.6, 32.5 
(CH2), 80.3 (C), 141.1 (CH), 153.7 (CH), 172.3 (C). IR (KBr): ν~  = 2976 (m), 2931 (w), 
1723 (s), 1456 (w), 1392 (w), 1366 (m), 1248 (w), 1146 (s), 978 (w), 846 (m), 755 (w) 
cm-1. GC-MS (EI, 70 eV): m/z (%) = 336 (02) [M]+, 280 (27), 263 (60), 224 (98), 207 
(92), 188 (29), 180 (100), 161 (30). HRMS (EI, 70 eV): calcd for C18H28N2O4 [M]+: 
336.20436; found: 336.20490. 
Bis(2-ethylhexyl) 3,3’-(quinoxaline-2,3-diyl) dipropanoate (14d);  
Compound 14d was prepared from 11b (199 mg, 
1.0 mmol) as a light brown highly viscous oil (344 
mg, 69%). Reaction temperature: 150 °C. 1H 
NMR (300 MHz, CDCl3): δ  = 0.77-0.80 (m, 12H 
), 1.16-1.22 (m, 16H ), 1.42-1.52 (m, 2H ), 2.95 (t, 4H, J = 7.1 Hz ), 3.26 (t, 4H, J = 6.9 
Hz), 3.93 (d, 4H, J = 5.8 Hz, 2CH2O), 7.54-7.58 (m, 2H, ArH), 7.86-7.89 (m, 2H, ArH). 
13C NMR (75.5 MHz, CDCl3): δ = 10.9, 14.0 (CH3), 22.9, 23.7, 28.9, 29.1, 30.4, 30.9 
(CH2), 38.7 (CH), 66.9 (CH2O), 128.5, 128.7 (CH), 140.7, 153.8 (C), 173.3 (CO). IR 
(KBr): ν~  = 3063 (w), 2958 (s), 2928 (s), 2860 (m), 1731 (s), 1654 (m), 1545 (s), 1458 
(m), 1418 (m), 1378 (m), 1169 (s), 1079 (w), 758 (s), 608 (m), 541 (w) cm-1. GC-MS (EI, 
70 eV): m/z (%) = 498 (52)[M]+, 469 (30), 441 (69), 385 (56), 356 (100), 313 (18), 226 
(40), 184 (33). HRMS (EI, 70 eV): calcd for C30H46N2O4 [M]+: 498.27568; found: 
498.27498. 
Tert-Butyl 3,3’-(quinoxaline-2,3-diyl)dipropanoate (14e);  
Compound 14e was prepared from 11b (199 mg, 1.0 mmol) 
as a light yellow highly viscous oil (297 mg, 77%). Reaction 
temperature: 150 °C. 1H NMR (300 MHz, CDCl3): δ = 1.36 
(s, 18H, 6CH3), 2.83 (t, 4H, J = 7.2 Hz, 2CH2), 3.21 (t, 4H, 
J = 7.0 Hz, 2CH2), 7.54-7.57 (m, 2H), 7.86-7.89 (m, 2H). 13C NMR (62.9 MHz, CDCl3): 
δ = 28.1 (CH3), 29.3, 32.0 (CH2), 80.2 (C), 128.5, 128.6 (CH), 140.6, 154.1 (C), 172.4 
(CO). IR (KBr): ν~  = 2977 (w), 2930 (w), 1722 (s), 1488 (w), 1365 (m), 1314 (m), 1256 
(m), 1143 (s), 953 (w), 846 (m), 760 (s), 662 (w), 609 (w) cm-1. GC-MS (EI, 70 eV): m/z
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(%) = 386 (16)[M]+, 330 (34), 313 (37), 274 (84), 257 (74), 230 (100), 211 (31), 183 
(36). HRMS (EI, 70 eV): calcd for C22H30N2O4 [M]+: 386.22001; found: 386.22006. 
(E)-2- (2-Cyclohexylvinyl)quinoxaline (15);  
Compound 15 was prepared starting with 11b (199 mg, 1.0 
mmol) as a light yellow solid (167 mg, 70%). 1H NMR (300 
MHz, CDCl3): δ = 1.46-1.85 (m, 10H), 2.18-2.27 (m, 1H), 6.61 
(d, 1H, J = 15.91Hz ), 6.91 (dd, 1H, J = 6.8, 16.1 Hz, CH), 7.57-7.68 (m, 2H), 7.94-7.99 
(m, 2H ), 8.86 (s, 1H). 13C NMR (75.5 MHz, CDCl3): δ  = 25.9, 26.0, 32.3 (CH2), 41.4, 
125.3, 128.9, 129.0, 130.2 (CH), 141.3 (C), 143.9, 146.1 (CH), 151.1, 158.1 (C). IR 
(KBr): ν~  = 3060 (w), 2923 (s), 2850 (m), 1708 (m), 1590 (w), 1544 (w), 1447 (m), 1361 
(m), 1247 (m), 1109 (s), 974 (w), 759 (s), 565 (m), 537 (m) cm-1. GC-MS (EI, 70 eV): 
m/z (%) = 238 (100)[M]+, 223 (17), 209 (19), 195 (24), 195 (24), 181 (34), 169 (16). 
HRMS (EI, 70 eV): calcd for C16H18N2 [M]+: 238.14700; found: 238.14701. 
7.4 Synthesis of 7, 8-Diarylflavones by Site-Selective Suzuki-Miyaura 
Cross Coupling Reactions of 7, 8-dihydroxyflavone. 
General procedure for Suzuki-Miyaura cross-coupling reactions: A 1,4-dioxane 
solution (3-4 mL) of 17 (1.0 equiv.), arylboronic acid 18 (1.0-1.3 equiv. per desired 
cross-coupling reaction), K3PO4 (1.5-2.0 equiv. per desired cross-coupling reaction), and
Pd(PPh3)4 (5 mol%) was heated at 70-100 °C for 4 h. After cooling to 20 °C, a saturated 
aqueous solution of NH4Cl was added, the organic and aqueous layers were separated and 
the latter was extracted with CH2Cl2. The combined organic layers were dried (Na2SO4), 
filtered and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography. 
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 4-Oxo-2-phenyl-4H-chromene-7,8-diyl-bis(trifluoromethanesulfonate) (17):  
To a CH2Cl2 solution (10 mL) of 16 (254 mg, 1.0 mmol) was 
added pyridine (0.32 mL, 4.0 mmol) at – 78 °C under argon 
atmosphere. After stirring for 10 min, Tf2O (0.40 mL, 2.4 
mmol) was added at −78 °C. The mixture was allowed to warm 
to 0 °C and stirred for 4 h. The reaction mixture was filtered and the filtrate was 
concentrated in vacuo. Product 17 was isolated by rapid column chromatography (flash 
silica gel, heptanes/EtOAc) as a white solid (393 mg, 76%); m.p. 142-143 °C. 1H NMR 
(300 MHz, CDCl3): δ = 6.82 (s, 1H), 7.43-7.52 (m, 4H, ArH), 7.88-7.91 (m, 2H, ArH), 
8.25 (d, J = 9.4 Hz, 1H). 13C NMR (75.5 MHz, CDCl3): δ = 108.3 (CH), 118.6 (q, JF,C = 
321.6 Hz, CF3), 118.7 (q, JF,C = 320.4 Hz, CF3), 118.9 (CH), 124.7 (C), 126.6, 126.7, 
129.3 (CH), 129.9, 130.2 (C), 132.6 (CH), 143.9, 149.5, 164.5, 175.3 (C) . 19F NMR (282 
MHz, CDCl3): δ = −72.6, −72.8. IR (KBr): ν~ = 3080 (w), 1660 (s), 1613 (m), 1427 (s), 
1359 (m), 1210 (s), 1126 (s), 1053 (m), 996 (m), 955 (m), 836 (m), 794 (m), 756 (m), 733 
(w), 684 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 518 (95) [M]+, 385 (7), 357 (15), 321 
(29), 293 (100), 219 (66), 191 (79). HRMS (EI, 70 eV): calcd for C17H8F6O8S2 [M+]: 
517.95700; found 517.95651. 
7,8-Bis(4-ethylphenyl)-2-phenyl-4H-chromen-4-one (19a):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 2.0 
mmol), Pd(PPh3)4 (5 mol%), 4-ethylphenylboronic acid 
(18a) (195 mg, 1.3 mmol) and 1,4-dioxane (5 mL), 19a
was isolated as a crystalline white  solid (150 mg, 70%); 
m.p. 148-150 °C. 1H NMR (300 MHz, CDCl3): δ = 1.11 
(t, 3H, J = 7.8 Hz, CH3), 1.18 (t, 3H, J = 7.4 Hz, CH3), 
2.50 (q, 2H, J = 7.4,15.3 Hz ), 2.59 (q, 2H, J = 7.4,15.3 Hz ), 6.76 (s, 1H), 6.93-7.07 (m, 
8H, ArH), 7.22-7.35 (m, 3H, ArH), 7.41 (d, 1H, J = 8.3 Hz, ArH), 7.46-7.50 (m, 2H, 
ArH), 8.16 (d, 1H, J = 8.3 Hz, ArH). 13C NMR (62MHz, CDCl3): δ = 15.3, 15.8 (CH3), 
28.4, 28.7 (CH2), 106.6 (CH), 122.7 (C), 124.3, 126.2, 127.3, 127.4, 127.5, 128.8, 129.7  
(CH), 130.3 (C), 131.1, 131.4 (CH), 131.6, 132.0, 137.2, 143.3, 143.5, 146.6, 154.0, 
163.1, 178.7 (C). IR (KBr): ν~ = 3064 (w), 2966 (w), 1643 (s), 1510 (m), 1394 (m), 1370 
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(m), 1147 (m), 1016 (m), 919 (m), 823 (s), 772 (s), 689 (s) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 430 (100) [M]+, 415 (09), 401 (51), 373 (03), 344 (02), 313 (09), 239 (09), 156 
(03). HRMS (EI) calcd for C31H26O2 [M+]: 430.19273; found 430.19288.
7,8-Bis(4-tert-butylphenyl)-2-phenyl-4H-chromen-4-one (19b):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 
2.0 mmol), Pd(PPh3)4 (5 mol%), 4-tert-butylphenyl 
boronic acid (18b) (231 mg, 1.3 mmol) and 1,4-dioxane 
(5 mL), 19b was isolated as a white  solid (143 mg, 
59%); m.p. 162-164 °C. 1H NMR (300 MHz, CDCl3): δ
= 1.20 (s, 9H, 3CH3), 1.28 (s, 9H, 3CH3), 6.80 (s, 1H), 
7.03-7.17 (m, 7H, ArH), 7.23-7.30 (m, 4H, ArH), 7.44-
7.51 (m, 3H, ArH),  8.18 (d, 1H, J = 8.1 Hz, ArH). 13C NMR (75MHz, CDCl3): δ = 31.2, 
31.4 (CH3), 34.4, 34.6 (C), 106.6 (CH), 122.7 (C), 124.3, 124.7, 124.8, 126.2, 127.2, 
128.8, 129.5 (CH), 130.4 (C), 130.8, 131.4 (CH), 131.6, 131.8, 136.8, 146.5, 150.3, 
150.4, 154.0, 163.0, 178.7 (C). IR (KBr): ν~ = 3059 (w), 2958 (m), 1635 (s), 1372 (m), 
1258 (m), 1142 (w), 1090 (m), 1014 (m), 919 (w), 794 (s), 684 (s) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 486 (95) [M]+, 471 (100), 455 (02), 429 (06), 415 (86), 387 (05), 373 
(19), 339 (04), 313 (07), 228 (14), 200 (08), 177 (15). HRMS (EI) calcd for C35H34O2 
[M+]: 486.25533; found 486.25569.
7,8-Bis(4-chlorophenyl)-2-phenyl-4H-chromen-4-one (19c):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 
2.0 mmol), Pd(PPh3)4 (5 mol%), 4-chlorophenylboronic 
acid (18c) (203 mg, 1.3 mmol) and 1,4-dioxane (5 mL), 
19c was isolated as a light yellow  solid (160 mg, 72%); 
m.p. 192-194 °C. 1H NMR (300 MHz, CDCl3): δ = 6.82 
(s, 1H), 7.01 (d, 2H, J = 8.8 Hz, ArH) 7.10-7.18 (m, 5H, 
ArH), 7.29 (d, 2H, J = 8.6 Hz, ArH) 7.37-7.43 (m, 3H, ArH), 7.48-7.53 (m, 2H, ArH),  
8.23 (d, 1H, J = 8.2 Hz, ArH). 13C NMR (62MHz, CDCl3): δ = 107.0 (CH), 123.2 (C), 
125.2, 126.1, 127.1, 128.4, 128.5, 129.1, 131.0 (CH), 131.3 (C), 131.6, 132.4 (CH), 
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132.8, 133.8, 133.9, 137.9, 143.0, 145.4, 154.0, 163.4, 178.2 (C). IR (KBr): ν~ = 3055 
(w), 1682 (w), 1587 (w), 1486 (m), 1248 (w), 1088 (m), 1009 (m), 940 (m), 820 (m), 742 
(s), 723 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 442 (100) [M]+, 407 (23), 378 (01), 339 
(09), 305 (12), 249 (27), 213 (27), 172 (14). HRMS (EI) calcd for C27H16O2Cl2 [M+]: 
442.05219; found 442.05234.
7,8-Bis(4-fluorophenyl)-2-phenyl-4H-chromen-4-one (19d):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 2.0 
mmol), Pd(PPh3)4 (5 mol%), 4-fluorophenylboronic acid 
(18d) (182 mg, 1.3 mmol) and 1,4-dioxane (5 mL), 19d
was isolated as a  white  solid (127 mg, 62%); m.p. 233-
235 °C. 1H NMR (300 MHz, CDCl3): δ = 6.84 (s, 1H), 
6.89 (d, 2H, J = 8.7 Hz, ArH), 7.01-7.07 (m, 4H, ArH), 
7.12-7.18 (m, 2H, ArH),  7.34 (d, 2H, J = 8.1 Hz, ArH), 7.42 (d, 2H, J = 8.2 Hz, ArH)  
7.50-7.53 (m, 2H, ArH), 8.22 (d, 1H, J = 8.2 Hz, ArH). 13C NMR (62MHz, CDCl3): δ = 
107.0 (CH), 115.2 (d, JCF = 21.3 Hz, CH),  123.1 (C),  125.0, 126.1, 127.2, 129.0, (CH), 
129.3 (C), 130.4 (d, JCF = 3.5 Hz, C), 131.3 (CH),  131.4 (C),  131.5 (d, JCF = 20 Hz, CH), 
132.7, 132.8 (CH), 135.6 (d, JCF = 3.2 Hz, C), 145.8, 153.7, 163.4 (C), 162.8 (d, JCF = 247 
Hz, CF), 162.9 (d, JCF = 247 Hz, CF), 178.3 (C). 19F NMR (282 MHz, CDCl3): δ = -113.3 
(ArF), -112.4 (ArF). IR (KBr): ν~ = 3062 (w), 1630 (s), 1602 (m), 1509 (s), 1449 (m), 
1415 (m), 1373 (s), 1219 (s), 1159 (s), 1093 (m), 1014 (m), 834 (s), 771 (s) cm-1. GC-MS 
(EI, 70 eV): m/z (%) = 410 (100) [M]+, 382 (16), 351 (02), 307 (17), 280 (06), 262 (09), 
251 (40), 225 (03). HRMS (EI) calcd for C27H16O2F2 [M+]: 410.11129; found 410.11046.
7,8-Bis(4-methoxyphenyl)-2-phenyl-4H-chromen-4-one (19e):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 
2.0mmol), Pd(PPh3)4 (5 mol%), 4-methoxphenyl 
boronic acid (18e) (197 mg, 1.3 mmol) and 1,4-dioxane 
(5 mL), 19e was isolated as a white crystalline (147 mg, 
68%); m.p.172-174 °C. 1H NMR (300 MHz, CDCl3): δ
= 3.71 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 6.70 (d, 2H,
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J = 8.8 Hz, ArH), 6.80 (s, 1H), 6.82 (d, 2H, J = 8.8 Hz, ArH), 7.02 (d, 2H, J = 8.8 Hz, 
ArH), 7.10 (d, 2H, J = 8.8 Hz, ArH), 7.32-7.36 (m, 3H, ArH), 7.42 (d, 1H, J = 8.2 Hz, 
ArH), 7.54-7.58 (m, 2H, ArH)  8.17 (d, 1H, J = 8.2 Hz, ArH). 13C NMR (75MHz, 
CDCl3): δ = 55.2, 55.3 (OCH3), 106.7, 113.4, 113.5 (CH), 121.7, 123.3 (C), 124.3 (CH), 
126.0 (C), 126.2, 127.3, 128.9 (CH), 130.4, 130.7 (C), 131.0, 131.4, 132.4 (CH), 145.5, 
153.0, 157.8, 157.9, 162.2, 177.7 (C). IR (KBr): ν~ = 2922 (w), 1635 (s), 1512 (m), 1423 
(m), 1372 (m), 1285 (m), 1243 (s), 1177 (m), 1112 (w), 1017 (m), 916 (w), 822 (s), 769 
(s), 687 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 434 (100) [M]+, 403 (07), 331 (04), 281 
(09), 253 (05), 207 (17), 189(11). HRMS (EI) calcd for C27H14O6 [M+]: 434.07849; found 
434.07952. 
2-Phenyl-7,8-di(p-tolyl)-4H-chromen-4-one (19f):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 2.0 
mmol), Pd(PPh3)4 (5 mol%), 4-methylphenylboronic acid 
(18f) (177 mg, 1.3 mmol) and 1,4-dioxane (5 mL), 19f
was isolated as a crystalline light yellow solid (148 mg, 
74%); m.p. = 248-249 °C. 1H NMR (300 MHz, CDCl3): δ
= 2.19 (s, 3H, CH3), 2.29 (s, 3H, CH3), 6.75 (s, 1H), 6.90-
7.04 (m, 8H, ArH), 7.24-7.33 (m, 3H, ArH), 7.39 (d, 1H, J = 8.2 Hz, ArH), 7.48-7.51 (m, 
2H, ArH), 8.16 (d, 1H, J = 8.2 Hz, ArH). 13C NMR (75MHz, CDCl3): δ = 21.2, 21.4 
(CH3), 106.7 (CH), 122.8 (C), 124.4, 126.2, 127.4, 128.6, 128.7, 128.9, 129.7 (CH), 
130.2 (C), 131.0, 131.4 (CH), 131.6, 131.7, 137.0, 137.1, 146.7, 153.9, 163.2, 178.6 (C). 
IR (KBr): ν~ = 2917 (w), 1631 (m), 1592 (w), 1446 (m), 1371 (m), 1238 (w), 1145 (m), 
1016 (m), 917 (w), 816 (s), 773 (s), 690 (s), 665 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 
402 (100) [M]+, 387 (34), 359 (03), 331 (4), 299 (4), 285 (07), 243 (09), 229 (12). HRMS 
(EI) calcd for C29H22O2 [M+]: 402.16143; found 402.161442.
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7,8-Bis(3,5-dimethylphenyl)-2-phenyl-4H-chromen-4-one (19g):  
Starting with 17 (259 mg, 0.5 mmol), K3PO4 (424 mg, 2.0 
mmol), Pd(PPh3)4 (5 mol%), 3,5-dimethylphenylboronic 
acid (18g) (195 mg, 1.3 mmol) and 1,4-dioxane (5 mL), 
19g was isolated as a colorless crystalline (152 mg, 71%); 
m.p. 233-235 °C. 1H NMR (300 MHz, CDCl3): δ = 2.13 
(s, 6H, 2CH3), 2.19 (s, 6H, 2CH3), 6.73 (Brs, 2H), 6.77 (Brs, 1H), 6.80 (Brs, 2H), 6.82 (s, 
1H), 6.87 (Brs, 1H), 7.28-7.37 (m, 3H, ArH), 7.43 (d, 1H, J = 8.2 Hz, ArH), 7.56-7.59 
(m, 2H, ArH), 8.24 (d, 1H, J = 8.2 Hz, ArH). 13C NMR (75MHz, CDCl3): δ = 21.2 
(CH3), 106.5 (CH), 122.7 (C), 124.2, 126.2, 127.3, 127.7, 128.8, 128.9, 129.0 (CH), 
130.4 (C), 131.4 (CH), 131.7, 134.4, 137.0, 137.2, 139.8, 147.0, 153.8, 163.2, 178.8 (C). 
IR (KBr): ν~ = 2951 (w), 1709 (m), 1663 (m), 1629 (s), 1593 (m), 1435 (m), 1366 (m), 
1332 (m), 1272 (m), 1190 (s), 1024 (m), 849 (w), 819 (m), 764 (m), 680 (m) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 430 (100) [M]+, 415 (73), 402 (07), 355 (05), 313 (09), 285 
(06), 239 (07), 164 (17). HRMS (EI) calcd for C31H26O2 [M+]: 430.19273; found 
430.19366.
7-(4-Ethylphenyl)-4-oxo-2-phenyl-4H-chromen-8-yl Trifluoromethanesulfonate (20a): 
Starting with 17 (156 mg, 0.30 mmol), K3PO4 (96 mg,  
0.45 mmol), Pd(PPh3)4 (5 mol%), (4-ethylphenyl) 
boronic acid (18a) (45 mg, 0.30 mmol) and 1,4-dioxane 
(3mL), 20a was isolated as a white solid (102 mg, 
72%), m.p. 167-168 °C. 1H NMR (500 MHz, CDCl3): δ = 1.22 (t, 3H, J = 7.7 Hz, CH3), 
2.66 (q, 2H, J = 7.5 Hz, CH2), 6.83 (s, 1H), 7.27 (d, 2H, J = 8.0 Hz, ArH), 7.38 (d, 2H, J
= 8.3 Hz, ArH), 7.44 (d, 1H, J = 8.3 Hz, ArH), 7.46-7.50 (m, 3H, ArH), 7.95-7.97 (m, 
2H, ArH), 8.18 (d, 1H, J = 8.3 Hz, ArH). 13C NMR (125.76 MHz, CDCl3): δ = 15.5 
(CH3), 28.7 (CH2), 108.2 (CH), 118.0 (q, JF,C = 320 Hz, CF3), 124.2 (C), 125.1, 126.7, 
127.4, 128.3, 129.1, 129.2 (CH), 130.8, 131.6 (C), 132.1 (CH), 135.1, 140.7, 145.9, 
149.0, 163.8, 176.7 (C). 19F NMR (282 MHz, CDCl3): δ = −74.3. IR (KBr): ν~ = 2916 
(w), 2850 (w), 1622 (m), 1568 (m), 1447 (m), 1386 (s), 1271 (m), 1164 (s), 1041 (m), 
906 (w), 811 (s), 767 (s), 681 (s), 634 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 474 (40) 
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[M]+, 410 (28), 395 (18), 366 (03), 341 (100), 326 (08), 313 (20), 281 (04). HRMS (EI) 
calcd for C24H17F3O5S [M+]: 474.07471 found 474.07492. 
7-(4-Chlorophenyl)-4-oxo-2-phenyl-4H-chromen-8-yl trifluoromethanesulfonate (20b) 
Starting with 17 (156 mg, 0.30 mmol), K3PO4 (96 mg, 
0.45 mmol), Pd(PPh3)4 (5 mol%), (4-chlorophenyl 
boronic acid (18c) (47 mg, 0.30 mmol) and 1,4-dioxane 
(3mL), 20b was isolated as a light yellow amorphous 
solid (95 mg, 66%); m.p. 143-145 °C. 1H NMR (300 MHz, CDCl3): δ = 6.84 (s, 1H), 
7.39-7.43 (m, 5H, ArH), 7.48-7.52 (m, 3H, ArH), 7.93-7.96 (m, 2H, ArH), 8.20 (d, 1H, J
= 8.3 Hz, ArH). 13C NMR (62 MHz, CDCl3): δ = 108.2 (CH), 118.2 (q, JCF = 321 Hz, 
CF3), 124.7 (C), 125.4, 126.7, 127.0, 129.1, 129.2, 130.6 (CH), 130.7 (C), 132.2 (CH), 
132.8, 135.8, 139.2, 145.5, 149.0, 164.0, 176.5 (C). 19F NMR (282 MHz, CDCl3): δ = 
−74.1. IR (KBr): ν~ = 2928 (w), 1656 (s), 1426 (m), 1359 (m), 1212 (s), 1134 (s), 1090 
(m), 1015 (m), 966 (m), 880 (w), 803 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 480 (16) 
[M]+, 347 (100), 332 (02), 284 (05), 345 (08), 210 (08), 189 (10). HRMS (EI) calcd for 
C22H12F3O5S [M+]: 480.00406 found 480.00345. 
4-Oxo-2-phenyl-7-p-tolyl-4H-chromen-8-yl trifluoromethanesulfonate (20c):  
Starting with 17 (156 mg, 0.30 mmol), K3PO4 (96 mg, 
0.45 mmol), Pd(PPh3)4 (5 mol%), 4-methylphenylboronic 
acid (18f) (41 mg, 0.30 mmol) and 1,4-dioxane (3mL), 
20c was isolated as a amorphous white solid (105 mg, 
76%); m.p. 156-158 °C. 1H NMR (300 MHz, CDCl3): δ =  2.37 (s, 3H, CH3), 6.78 (s, 
1H), 7.26-7.30 (m, 3H, ArH), 7.42-7.49 (m, 4H, ArH), 7.74 (d, 1H, J = 8.3 Hz, ArH), 
7.84-7.88 (m, 2H, ArH) 8.24 (d, 1H, J = 8.3 Hz, ArH). 13C NMR (75 MHz, CDCl3): δ = 
21.3 (CH3), 107.8, 116.4 (CH), 118.2 (q, JCF = 320 Hz, CF3), 124.7 (C), 126.4, 126.5, 
128.9, 129.2, 129.8 (CH), 130.6 (C), 131.7 (CH), 131.8, 132.7, 135.0, 145.1, 149.6, 
164.0, 176.8 (C). 19F NMR (282 MHz, CDCl3): δ = −74.3. IR (KBr): ν~ = 2917 (m), 1623 
(s), 1389 (m), 1248 (m), 1167 (s), 1019 (m), 811 (m), 767 (m), 682 (s) cm-1. GC-MS (EI, 
70 eV): m/z (%) = 460 (40) [M]+, 418 (03), 380 (02), 355 (14), 328 (100), 300 (04), 262 
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(02), 226 (73), 211 (22), 198 (10). HRMS (EI) calcd for C23H15F3O5S [M+]: 460.06230 
found 460.06350. 
4-Oxo-2-phenyl-7-(4-(trifluoromethyl)phenyl)-4H-chromen-8-yl 
trifluoromethanesulfonate (20d):  
Starting with 17 (156 mg, 0.30 mmol), K3PO4 (96 mg, 
0.45 mmol), Pd(PPh3)4 (5 mol%), 4-(trifluoromethyl) 
phenylboronic acid (18h) (57 mg, 0.30 mmol) and 1,4-
dioxane (3mL), 20d was isolated as a  white solid (107 
mg, 69%); m.p. 176-178 °C. 1H NMR (300 MHz, 
CDCl3): δ =  6.85 (s, 1H), 7.42 (d, 2H, J = 8.3 Hz, ArH), 7.49-7.51 (m, 2H, ArH), 7.60(d, 
2H, J = 8.0 Hz, ArH), 7.72 (d, 2H, J = 8.2 Hz, ArH), 7.94-7.97 (m, 2H, ArH) 8.24 (d, 1H, 
J = 8.3 Hz, ArH). 13C NMR (62 MHz, CDCl3): δ = 108.3, (CH), 118.3 (q, JCF = 319 Hz, 
CF3), 124.2 (q, JCF = 280 Hz, CF3), 125.1 (C), 125.5 (q, JCF = 3.6 Hz, 2CH), 125.8, 126.7, 
127.0, 129.2, 129.7 (CH), 130.1 (q, JCF = 34.2 Hz, C), 130.6, 132.0 (C), 132.3 (CH), 
139.0, 145.3, 149.2, 164.1, 176.4 (C). 19F NMR (282 MHz, CDCl3): δ = −74.2, −62.8 . IR 
(KBr): ν~ = 2923 (w), 1649 (m), 1421 (m), 1326 (m), 1205 (m), 1115 (s), 1070 (m), 1017 
(m), 963 (m), 829 (m), 802 (s), 763 (m), 682 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 
514 (19) [M]+, 381 (100), 325 (02), 279 (08), 251 (08), 223 (13), 183 (06). HRMS (EI) 
calcd for C23H12F6O5S [M+]: 514.03041 found 514.03132. 
4-Oxo-2-phenyl-7-(4-vinylphenyl)-4H-chromen-8-yl trifluoromethanesulfonate (20e):  
Starting with 17 (156 mg, 0.30 mmol), K3PO4 (96 mg, 
0.45 mmol), Pd(PPh3)4 (5 mol%), 4-vinylphenylboronic 
acid (18i) (44 mg, 0.30 mmol) and 1,4-dioxane (3mL), 
20e was isolated as a amorphous white solid (105 mg, 
74%); m.p. 113-115 °C. 1H NMR (300 MHz, CDCl3): δ = 5.30 (d, 1H, J = 11.6 Hz ), 5.80 
(d, 1H, J = 16.9 Hz ), 6.71 (dd, 1H, J = 10.8, 17.6 Hz ), 6.84 (s, 1H), 7.42-7.50 (m, 8H, 
ArH), 7.94-7.97 (m, 2H, ArH), 8.19 (d, 1H, J = 8.4 Hz, ArH). 13C NMR (62 MHz, 
CDCl3): δ = 115.4 (CH2), 108.2 (CH), 117.8 (q, JCF = 319 Hz, CF3), 124.4 (C), 125.2, 
126.6, 126.7, 127.2, 129.1, 129.5 (CH), 130.8 (C), 132.1 (CH), 133.6, 135.0 (C), 136.0 
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(CH), 138.6, 140.2, 149.5, 163.9, 176.7 (C). 19F NMR (282 MHz, CDCl3): δ = −74.2. IR 
(KBr): ν~ = 2923 (w), 1645 (s), 1484 (w), 1423 (s), 1354 (s), 1216 (s), 1128 (s), 1017 (m), 
963 (m), 803 (m), 763 (m), 681 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 472 (16) [M]+, 
339 (100), 311 (01), 383 (11), 237 (07), 210 (03), 181 (07). HRMS (EI) calcd for 
C24H15F3O5S [M+]: 472.05868 found 472.05988. 
8-(4-Ethylphenyl)-2-phenyl-7-(p-tolyl)-4H-chromen-4-one (21a):  
Following the general procedure starting with 20c (101 
mg, 0.22 mmol), K3PO4 (93 mg, 0.44 mmol), Pd(PPh3)4
(5 mol%), 4-ethylphenylboronic acid (44 mg, 0.29 
mmol) and 1,4-dioxane (3 mL), 21a was isolated as a 
yellow solid (60 mg, 66%); m.p. 198-199 °C.1H NMR 
(500 MHz, CDCl3): δ  = 1.20 (t, 3H, J = 7.9 Hz, CH3 ), 
2.23 (s, 3H, CH3), 2.62 (q, 2H, J = 7.5 Hz), 6.79 (s, 1H), 6.95-7.01 (m, 4H, ArH), 7.07-
7.12 (m, 4H, ArH), 7.26-7.38 (m, 3H, ArH), 7.43 (dd, 1H, J = 3.4, 8.3 Hz, ArH), 7.50-
7.54 (m, 2H, ArH), 8.18 (d, 1H, J = 8.3 Hz, ArH). 13C NMR (125.75 MHz, CDCl3): δ = 
15.8, 21.1 (CH3), 28.7 (CH2), 122.8 (C), 124.3, 126.2, 127.4, 128.6, 128.7, 128.8, 128.9, 
129.6, 131.0, 131.3 (CH), 131.6, 131.7, 132.0, 137.0, 143.5, 146.5, 146.7, 153.9, 136.1, 
178.7 (C). IR (KBr): ν~ = 2962 (s), 2923 (s), 1644 (s), 1597 (w), 1371 (m), 1202 (w), 
1096 (w), 1016 (w), 815 (m), 771 (m), 688 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 416 
(100) [M]+, 402 (16), 387 (49), 313 (06), 285 (14), 271 (05), 253 (06), 239 (09). HRMS 
(EI) calcd for C30H24O2 [M+]: 416.17783; found 416.17762. 
7-(4-Chlorophenyl)-8-(4-methoxyphenyl)-2-phenyl-4H-chromen-4-one (21b):  
Following the general procedure starting with 20b 
(101 mg, 0.22 mmol), K3PO4 (93 mg, 0.44 mmol), 
Pd(PPh3)4 (5 mol%), 4-methoxyphenylboronic acid 
(44 mg, 0.29 mmol) and 1,4-dioxane (3 mL), 21b
was isolated as a yellow solid (60 mg, 73%), m.p. 
152-154 °C. 1H NMR (300 MHz, CDCl3): δ = 3.81 
(s, 3H, OCH3 ), 6.82 (s, 1H), 6.96 (d, 2H, J = 8.8 Hz ), 7.01-7.10 (m, 3H ), 7.40  (d, 5H, J
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= 8.5 Hz, ArH), 7.47-7.49 (m, 2H ), 7.93-7.97 (m, 2H ), 8.16 (d, 1H, J = 8.3 Hz, ArH). 
13C NMR (62 MHz, CDCl3): δ = 55.4 (OCH3), 108.1, 114.3 (CH), 124.0 (C), 125.0, 
126.2, 126.7, 127.2, 128.3, 129.1 (CH), 129.5 (C), 130.6 (CH), 130.8, 131.3 (C), 132.1 
(CH), 135.0, 140.3, 145.5, 149.1, 160.6, 163.8, 176.7. IR (KBr): ν~ = 3066 (w), 1649 (s), 
1519 (m), 1438 (s), 1357 (m), 1246 (m), 1216 (s), 1134 (m), 963 (m), 802 (s), 684 (m) 
cm-1. GC-MS (EI, 70 eV): m/z (%) = 438 (100) [M]+, 407 (05), 360 (02), 335 (05), 301 
(03), 249 (03), 202 (16). HRMS (EI) calcd for C28H19ClO3 [M+]: 438.10230; found 
438.10250. 
7.5 Regioselective Sonogashira coupling reactions of 2,4,5,6-tetra 
chloropyrimidine. 
General Procedure for Sonogashira coupling Reaction
A suspension of 2,4,5,6–tetrachloropyrimidine (22), Pd(PPh3)2Cl2 (10 mol %), CuI (5 
mol %) in Diisopropylamine was degassed three time in ace pressure tube. Acetylene (1.2 
eq per chlorine atom) were added using a syringe. The mixture was heated at the 
indicated temperature (60–80 °C) for 4-10 h. The reaction mixture was filtered and 
residue washed with CH2Cl2. The filtrate was washed with saturated solution of 
ammonium chloride (2 x 25mL), water (2 x 25mL) and dried over anhydrous Na2SO4. 
Solvent was removed in vacuo. The product was purified by column chromatography on 
silica gel.  
General Procedure for Suzuki cross coupling Reaction  
The reaction was carried out in a pressure tube. To a dioxane suspension (3-5 mL) of 
2,4,5,6–tetrachloropyrimidine (22), Pd(PPh3)2Cl2 (3-5 mol %) and arylboronic acid was 
added an aqueous solution of K2CO3 (2M, 1-2 mL ). The mixture was heated at the 
indicated temperature (60-100 °C) for the indicated period of time (2-8 h). The reaction 
mixture was diluted with water and extracted with CH2Cl2 (3 x 25mL). The combined 
organic layers were dried over Na2SO4, filtrated and the filtrate was concentrated in 
vacuo the residue was purified by flash chromatography (silica gel, ethyl acetate / 
heptanes)  
 84
4,6-Bis((4-tert-butylphenyl)ethynyl)-2,5-dichloropyrimidine (24a):  
starting with 22 (217 mg; 1mmol), 4-(tert-
butyl)phenylacetylene (23a) (0.4mL; 2.4mmol) 
CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol %) and 
diisopropylamine (5mL), 24a was isolated as 
yellowish highly viscous oil (350 mg; 76 %). 
1H-NMR (250 MHz, CDCl3): δ = 1.24 (s, 18H, 
6CH3), 7.34 (d, 4H, J = 8.5 Hz), 7.52 (d, 2H, J = 8.5 Hz), 7.54 (d, 2H, J = 8.4 Hz). 13C 
NMR (75 MHz, CDCl3): δ = 31.0 (CH3), 35.1, 84.0, 102.6, 117.4 (C), 125.7, 125.8, 
132.5, 132.7 (CH), 133.1, 151.3, 154.6, 158.0 (C). IR (KBr): ν~ = 2960 (w), 2208 (s), 
1516 (s), 1362 (m), 1259 (s), 1106 (m), 1016 (m), 922 (m), 832 (s), 774 (w) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 460 (33) [M]+, 445 (100), 417 (07), 364 (03), 305 (07), 273 
(05), 245 (06), 215 (45), 202 (33). HRMS (EI, 70 eV): calcd for C28H26Cl2N2 [M+] ; 
460.14685; found 460.14730.  
2,5-Dichloro-4,6-bis(phenylethynyl)pyrimidine (24b): 
starting with 22 (217 mg; 1mmol), phenylacetylene 
(23b) (0.2mL; 2.4mmol) CuI (5 mol %), Pd(PPh3)2Cl2
(10 mol %) and diisopropylamine (5mL), 24b was 
isolated as light brown solid (254 mg; 73 %); m.p. 
197–199 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.32–
7.41 (m, 6H), 7.59–7.62 (m, 4H). 13C NMR (62 MHz, CDCl3): δ = 84.1, 102.0, 120.4 
(C), 128.6, 130.8, 132.8 (CH), 137.1, 151.2, 158.0 (C). IR (KBr): ν~ = 2961 (w), 2209 (s), 
1517 (s), 1471 (m), 1261 (s), 1025 (m), 927 (m), 770 (m), 751 (s), 679 (s) cm-1. GC-MS 
(EI, 70 eV): m/z (%) = 348 (100) [M]+, 331 (01), 315 (02), 276 (04), 251 (08), 226 (03), 
186 (02), 160 (20). HRMS (EI, 70 eV): calcd for C20H10Cl2N2 [M+] ; 348.02156; found 
348.02110.  
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2, 5- Dichloro-4,6-bis (3-methoxyphenyl)ethynyl pyrimidine (24c): 
starting with 1 (217 mg; 1mmol), 3-ethynylanisole(23c) 
(0.3mL; 2.4mmol) CuI (5 mol %), Pd(PPh3)2Cl2 (10 
mol %) and diisopropylamine (5mL), 24c was isolated 
as brown solid (331 mg; 81 %); m.p. 177–179 °C. 1H-
NMR (250 MHz, CDCl3): δ = 3.76 (s, 6H, 2OCH3), 
6.93–6.97 (m, 2H), 7.09–7.10 (m, 2H), 7.17-7.25 (m, 
4H). 13C NMR (62.8 MHz, CDCl3): δ = 55.4 (OCH3), 83.8, 101.9 (C), 117.2, 117.6 (CH), 
121.3 (C), 125.4, 129.8 (CH), 132.1, 151.2, 158.0, 159.4 (C). IR (KBr): ν~ = 2974 (w), 
2207 (m), 1596 (m), 1518 (m), 1268 (s), 1151 (m), 1035 (m), 955 (w), 850 (m), 772 (s), 
673 (s), 541 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 408 (M+, 87), 379 (04), 356 (02), 
331 (05), 281 (23), 253 (17), 207 (100), 170 (05), 147 (08). HRMS (EI, 70 eV): calcd for 
C22H14Cl2N2O2 [M+] ; 408.04370; found 408.04320.  
2,5-Dichloro-4,6-bis((6-methoxynaphthalen-2-yl)ethynyl)pyrimidine (24d):  
Starting with 22 (217 mg; 1mmol), 
2-ethynyl-6-methoxynaphthalene      
(23d) (436 mg; 2.4mmol) CuI (5 
mole %),  Pd(PPh3)2Cl2 (10mol%) 
and diisopropylamine (5mL), 24d
was isolated as light yellow solid 
(463 mg; 91 %); m.p. 206–208 °C. 1H-NMR (300 MHz, CDCl3): δ = 3.87 (s, 6H, 
2OCH3), 7.07 (s, 2H), 7.13 (d, 2H, J = 8.9 Hz), 7.54 (d, 2H, J = 8.5 Hz), 7.67 (d, 2H, J = 
8.5 Hz), 7.69 (d, 2H, J = 8.9 Hz), 8.07 (s, 2H). 13C NMR (75 MHz, CDCl3): δ = 55.4 
(OCH3), 84.2, 104.2 (C), 106.0 (CH), 114.7 (C), 120.1, 127.3 (CH), 128.1 (C), 128.8 
(CH), 129.5 (C), 130.0, 134.1 (CH), 135.7, 152.0, 157.0, 159.6 (C). IR (KBr): ν~ = 2934 
(w), 2199 (s), 1626 (m), 1515 (m), 1476 (s), 1394 (w), 1266 (s), 1225 (m), 1192 (m), 
1176 (m), 1032 (m), 969 (m), 849 (m), 798 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 508 
(100) [M]+, 493 (03), 465 (22), 422 (12), 362 (03), 325 (06), 281 (04), 254 (10), 211 (21). 
HRMS (EI, 70 eV): calcd for C30H18Cl2N2O2 [M+] ; 508.07428; found 508.07450. 
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2,4,6-Tris((4-tert-butylphenyl)ethynyl)-5-chloropyrimidine (25a)
starting with 22 (217 mg; 1mmol), 4-(tert-
butyl)phenylacetylene (23a) (0.6mL; 3.6mmol) 
CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol %) and 
diisopropylamine (5mL), 25a was isolated as 
dark yellow solid (468 mg; 80 %); m.p. 227– 
229 °C. 1H-NMR (250 MHz, CDCl3): δ = 1.24 
(s, 9H, 3CH3), 1.29 (s, 18H, 6CH3), 6.99 (d, 
3H, J = 8.3 Hz), 7.29 (d, 3H, J = 8.5 Hz ), 7.33 
(d, 3H, J = 8.4 Hz ) 7.45 (d, 3H, J = 8.5 Hz ). 
13C NMR (62 MHz, CDCl3): δ = 31.1, 31.4 (CH3), 34.7, 34.9, 84.9, 93.2, 97.4, 118.6, 
124.8 (C), 125.4, 125.5, 127.4, 132.1 (CH), 134.0, 146.9, 151.6, 153.1, 156.0 (C). IR 
(KBr): ν~ = 2959 (m), 1504 (s), 1432 (s), 1356 (m), 1292 (m), 1263 (s), 1133 (s), 1036 
(s), 931 (m), 816 (s), 767 (m), 735 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 582 (70) 
[M]+, 567 (16), 552 (38), 537 (46), 518 (100), 482 (03), 462 (02), 447 (02), 410 (12), 382 
(02), 344 (31). HRMS (EI, 70 eV): calcd. for C40H39ClN2 [M+] ; 582.28004 found 
582.28020. 
5-Chloro-2,4,6-tris(phenylethynyl)pyrimidine (25b):
starting with 22 (217 mg; 1mmol), phenylacetylene 
(23b) (0.4mL; 3.6mmol) CuI (5 mol %), Pd(PPh3)2Cl2
(10 mol %) and diisopropylamine (5mL), 25b was 
isolated as light brown solid (294 mg; 71 %); m.p. 220–
222 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.30–7.40 
(m, 10H), 7.58–7.63 (m, 5H). 13C NMR (62 MHz, 
CDCl3): δ = 84.4, 87.1, 89.2, 100.5, 120.8, 121.1 (C), 
128.4, 128.6, 129.9, 130.5 (CH), 132.0 (C), 132.7 (CH), 149.8, 150.4 (C). IR (KBr): ν~ = 
3054 (w), 2215 (s), 1512 (s), 1490 (m), 1363 (s), 1229 (m), 1177 (m), 1025 (m), 970 (m), 
918 (w), 842 (w), 751 (s), 686 (s) cm-1.GC-MS (EI, 70 eV): m/z (%) = 414 (89) [M]+, 377 
(60), 346 (20), 315 (12), 250 (27), 238 (23), 189 (33). HRMS (EI, 70 eV): calcd. for 
C28H15ClN2 [M+] ; 414.09215 found 414.09240. 
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5-Chloro-2,4,6-tris((3-methoxyphenyl)ethynyl)pyrimidine (25c)
starting with 22 (217 mg; 1mmol), 3-ethynyl 
anisole (23c) (0.45mL; 3.6mmol) CuI (5 mol 
%), Pd(PPh3)2Cl2 (10 mol %) and diisopropyl 
amine (5mL), 25c was isolated as dark brown 
solid (388 mg; 77 %); m.p. 163–165 °C. 1H-
NMR (250 MHz, CDCl3): δ = 3.74 (s, 3H, 
OCH3), 3.76 (s, 6H, 2OCH3), 6.87–6.96 (m, 
3H ), 7.11–7.13 (m, 3H ), 7.18–7.25 (m, 6H ). 
13C NMR (75 MHz, CDCl3): δ = 55.3, 55.4 (OCH3), 84.2, 86.8, 89.2, 100.4 (C), 117.0, 
117.1, 117.2, 117.4 (CH), 121.7, 122.0 (C), 125.3, 129.5, 129.7 (CH), 132.0, 149.8, 
150.4, 159.3, 159.4 (C). IR (KBr): ν~ = 2940 (w), 2214 (s), 1573 (m), 1513 (s), 1483 (m), 
1368 (m), 1261 (s), 1162 (m), 1039 (s), 848 (m), 769 (s), 677 (s) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 504 (100) [M]+, 473 (03), 431 (02), 389 (04), 355 (12), 312 (22), 252 
(31), 190 (31). HRMS (EI, 70 eV): calcd. for C31H21ClN2O3 [M+] ; 504.12392 found 
504.12410. 
5- Chloro -2,4,6-tris(P-tolylethynyl) pyrimidine (25d)
starting with 22 (217 mg; 1mmol), P-tolylacetylene 
(23e) (0.4mL; 3.6mmol) CuI (5 mol %),  
Pd(PPh3)2Cl2 (10 mol %) and diisopropylamine 
(5mL), 25d was isolated as yellow solid (383 mg; 84 
%); m.p.102–104°C. 1H-NMR (300 MHz, CDCl3): δ
= 2.30 (s, 3H, CH3), 2.32 (s, 6H, 2CH3), 7.09–7.15 
(m, 8H), 7.50 (d, 4H, J = 8.1 Hz ). 13C NMR (62.8 
MHz, CDCl3): δ = 21.6, 21.7 (CH3), 84.2, 86.8, 
89.5, 100.9, 117.5, 118.1 (C), 129.2, 129.3, 132.6 (CH), 140.3, 141.1,149.8, 150.5 (C). IR 
(KBr): ν~ = 2918 (w), 2208 (s), 1682 (w), 1510 (s), 1479 (s), 1361 (m), 1226 (w), 1176 
(m),1019 (m), 969 (m), 907 (m), 810 (s), 727 (m) cm-1.GC-MS (EI, 70 eV): m/z (%) = 
456 (100) [M]+, 422 (04), 280 (07), 264 (05), 230 (11), 174 (36), 139 (54). HRMS (EI, 70 
eV): calcd. for C31H21ClN2 [M+] ; 456.13971 found 456.13930. 
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5-Chloro-2,4,6-tri(hept-1-ynyl)pyrimidine (25e)
starting with 22 (217 mg; 1mmol), 1-Heptyne 
(23e) (0.5mL; 3.6mmol) CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %) and diisopropyl 
amine (5mL), 25e was isolated as yellowish 
highly viscous oil (270 mg; 68 %). 1H-NMR 
(250 MHz, CDCl3): δ = 0.84 (t, 6H, J = 7.1 
Hz, CH3), 1.07 (t, 3H, J = 7.0 Hz, CH3), 
1.21–1.43 (m, 12H), 1.53–1.64 (m, 6H), 2.33 
(t, 2H, J = 7.1 Hz ), 2.41 (t, 4H, J = 7.2 Hz). 13C NMR (62 MHz, CDCl3): δ = 12.9, 13.9 
(CH3), 19.7, 22.1, 27.7, 28.2, 29.5, 30.9, 40.8, 41.7 (CH2), 80.2, 91.2, 99.0, 131.5, 149.6, 
150.2 (C). IR (KBr): ν~ = 2930 (m), 2232 (w), 1604 (s), 1455 (m), 1165 (m), 1079 (m), 
783 (m), 760 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 396 (90) [M]+, 382 (60), 368 (41), 
344 (100), 330 (40), 316 (07), 301 (04), 287 (06), 231 (04), 209 (04). HRMS (EI, 70 eV): 
calcd. for C25H33ClN2 [M+] ; 396.23160 found 396.23176. 
5-Chloro-2,4,6-tri(pent-1-ynyl)pyrimidine (25f)
starting with 22 (217 mg; 1mmol), 1-Pentyne (23f) 
(0.3mL; 3.6mmol) CuI (5 mol %), Pd(PPh3)2Cl2 (10 
mol %) and diisopropylamine (5mL), 25f was isolated 
as brownish highly viscous oil (216 mg; 69 %). 1H-
NMR (300 MHz, CDCl3): δ = 0.95 (t, 6H, J = 7.3 Hz, 
CH3), 0.99 (t, 3H, J = 7.4 Hz, CH3), 1.53–1.64 (m, 6H), 
2.32 (t, 2H, J = 7.1 Hz ), 2.42 (t, 4H, J = 7.0 Hz ). 13C 
NMR (62 MHz, CDCl3): δ = 13.5, 13.6 (CH3), 21.4, 21.7, 29.6, 30.1 (CH2), 79.1, 91.4, 
103.1, 131.5, 149.7, 150.1 (C). IR (KBr): ν~ = 2926 (m), 2228 (m), 1727 (w), 1515 (s), 
1489 (s), 1359 (s), 1172 (m), 1080 (w), 962 (m), 790 (m) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 312 (100) [M]+, 297 (21), 282 (40), 267 (13), 254 (15), 225 (23), 211 (33), 183 
(43). HRMS (EI, 70 eV): calcd. for C19H21ClN2 [M+] ; 312.14321 found 312.14336. 
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2,4,5,6-Tetrakis((4-tert-butylphenyl)ethynyl)pyrimidine (26a) 
starting with 22 (217 mg; 1mmol), 4-(tert-
butyl) phenylacetylene (23a) (1.0mL; 6.0 
mmol ) CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol 
%), Dioxane (7mL) and diisopropylamine 
(3mL), 26a was isolated as dark brown solid 
(535 mg; 76 %); m.p. 110–112 °C; 1H-NMR 
(300 MHz, CDCl3): δ = 1.25 (s, 9H, CH3), 
1.26 (s, 18H, CH3), 1.28 (s, 9H, CH3),  7.31–
7.37 (m, 8H), 7.49–7.56 (m, 8H). 13C NMR 
(75 MHz, CDCl3): δ = 30.0, 30.1 (CH3), 33.9, 
34.0,  82.2, 85.0, 86.7, 89.2, 98.2, 102.4, 
117.3 (C), 124.4, 124.6, 130.5, 131.4, 131.6 
(CH), 149.2, 151.2, 151.9, 152.3, 152.8 (C). IR (KBr): ν~ = 2959 (w), 2209 (w), 1483 
(m), 1398 (m), 1264 (m), 1106 (m), 1016 (m), 831 (s), 634 (w), 560 (s) cm-1. GC-MS (EI, 
70 eV): m/z (%) = 704 (100) [M]+, 644 (09), 471 (02), 337 (12), 281 (02), 207 (04), 173 
(39). HRMS (EI, 70 eV): calcd. for C52H52N2 [M+] ; 704.41250 found 704.41482. 
2,4,5,6-Tetrakis(phenylethynyl)pyrimidine (26b) 
starting with 22 (217 mg; 1mmol), phenylacetylene 
(23b) (0.62mL; 6.0 mmol) CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %), Dioxane (7mL) and 
diisopropylamine (3mL), 26b was isolated as light 
brown solid (349 mg; 73 %); m.p. 188–190 °C. 1H-
NMR (300 MHz, CDCl3): δ = 6.77–6.86 (m, 12H), 
7.02 – 7.11 (m, 8H). 13C NMR (62.8 MHz, CDCl3): 
δ = 83.5, 86.2, 87.9, 90.0, 98.9, 103.4, 121.2, 121.3,     
122.3 (C), 128.4, 128.6, 128.7, 129.5, 129.8,  130.3,  
131.7, 132.6, 132.7 (CH), 150.3, 152.3 (C). IR (KBr): ν~ = 2918 (w), 2213 (m), 1479 (s), 
1398 (s), 1211 (w), 1067 (w), 970 (w), 797 (m), 767 (m), 748 (s),  680 (s)  cm-1. GC-MS  
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(EI, 70 eV): m/z (%) = 480 (92) [M]+, 375 (40), 330 (20), 305 (10), 260 (18), 218 (23). 
HRMS (EI, 70 eV): calcd. for C36H20N2 [M+] ; 480.16292 found 480.16260. 
2,4,5,6-Tetrakis((3-methoxyphenyl)ethynyl)pyrimidine (26c) 
starting with 22 (217 mg; 1mmol), 3-ethynyl 
anisole (23c) (0.76mL; 6.0 mmol) CuI (5 mol 
%), Pd(PPh3)2Cl2 (10 mol %), Dioxane (7mL) 
and diisopropylamine (3mL), 26c was isolated 
as dark brown solid (474 mg; 79 %); m.p. 152–
154 °C.1H-NMR (300 MHz, CDCl3): δ = 3.72 
(s, 6H, 2OCH3), 3.74 (s, 3H, OCH3), 3.77 (s, 
3H, OCH3), 6.81–6.85 (m, 2H), 6.93–6.97 (m, 
4H) 7.00–7.03 (m, 2H), 7.12–7.23 (m, 8H). 13C 
NMR (75 MHz, CDCl3): δ = 55.2, 55.3, 55.4 
(OCH3), 83.5, 84.2, 86.8, 89.2, 100.4, 102.7 (C), 115.4, 116.9, 117.0, 117.1, 117.2, 117.3 
(CH), 121.7, 122.0, 123.1 (C), 124.6, 125.3, 129.4, 129.5, 129.7 (CH), 149.8, 150.4, 
159.2, 159.3, 159.4 (C). IR (KBr): ν~ = 2939 (w), 2213 (s), 1574 (m), 1513 (s), 1483 (m), 
1367 (m), 1315 (m), 1261 (s), 1161 (m), 1039 (s), 848 (m), 769 (s), 677 (s) cm-1. GC-MS 
(EI, 70 eV): m/z (%) = 600 (80) [M]+, 569 (60), 538 (34), 507 (100), 470 (51), 440 (12), 
410 (17), 380 (32), 304 (56), 280 (40), 204 (12). HRMS (EI, 70 eV): calcd. for 
C40H28N2O4 [M+] ; 600.20221 found 600.20246. 
2,5-Dichloro-4-[(3-methoxyphenyl)ethynyl]-6-P-tolylpyrimidine (28) 
Starting with 27 (100 mg; 0.36mmol), 3-ethynylanisole 
(23c) (0.05 mL, 0.36 mmol), CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %), and diisopropylamine (5mL), 
28 was isolated as crystalline light brown solid (79 mg; 
59 %); m.p. 110–112 °C. 1H-NMR (300 MHz, CDCl3): δ
= 2.36 (s, 3H, CH3), 3.75 (s, 3H, OCH3), 6.91–6.95 (m, 1H), 7.09–7.10 (m, 1H), 7.17–
7.25 (m, 4H), 7.72 (d, 2H, J = 8.2 Hz). 13C NMR (75 MHz, CDCl3): δ = 21.5 (CH3), 55.4 
(OCH3), 84.4, 100.7 (C), 117.2, 117.4 (CH), 121.6 (C), 125.3 (CH), 128.5 (C), 129.1, 
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129.6, 129.7 (CH), 131.9, 141.6, 152.2, 158.1, 159.4, 165.8 (C). IR (KBr): ν~ = 3013 (w), 
2935 (w), 2213 (w), 1578 (m), 1481 (m), 1255 (s), 1151 (s), 1035 (s), 914 (m), 838 (m), 
775 (s), 676 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 368 (100) [M]+, 333 (10), 325 (02), 
303 (02), 290 (12), 227 (20), 184 (26), 140 (40). HRMS (EI, 70 eV): calcd. for 
C20H14ON2Cl2 [M+] ; 368.04777 found 368.04752. 
5-Chloro-2,4-bis((3-methoxyphenyl)ethynyl)-6-p-tolylpyrimidine(29) 
Starting with 27 (100 mg; 0.36mmol), 3-ethynylanisole 
(23c) (0.1 mL, 0.72 mmol), CuI (5 mol %),  Pd(PPh3)2Cl2
(10 mol %), and diisopropylamine (5mL), 29 was isolated 
as crystalline brown solid (114 mg; 67 %); m.p. 167–169 
°C. 1H-NMR (300 MHz, CDCl3): δ = 2.34 (s, 3H, CH3), 
3.72 (s, 3H, OCH3), 3.74 (s, 3H, OCH3),  6.85–6.93 (m, 
2H), 7.10–7.12 (m, 2H), 7.19–7.25 (m, 6H), 7.69 (d, 2H, J
= 8.2 Hz). 13C NMR (75 MHz, CDCl3): δ = 21.5 (CH3), 55.3 (OCH3), 55.4 (OCH3),  
84.7, 87.3, 88.6, 99.3 (C), 116.8, 117.0, 117.1, 117.2 (CH), 121.9, 122.2 (C), 125.2 (CH), 
128.5 (C), 129.0, 129.3, 129.5, 129.6, 129.7 (CH), 132.7, 141.0, 150.2, 150.6, 159.3, 
159.4, 164.1 (C). IR (KBr): ν~ = 3008 (w), 2214 (m), 1573 (w), 1525 (m), 1486 (s), 1357 
(s), 1287 (m), 1255 (s), 1180 (m), 1043 (m), 859 (m), 774 (s), 683 (s) cm-1. GC-MS (EI, 
70 eV): m/z (%) = 464 (100) [M]+, 424 (61), 389 (09), 272 (02), 232 (27), 190 (10), 150 
(06). HRMS (EI, 70 eV): calcd. for C29H21O2N2Cl [M+] ; 464.12926 found 464.12920. 
5-Chloro-2,4-di(pent-1-ynyl)-6-p-tolylpyrimidine (30)
starting with 27 (100 mg; 0.36mmol), 1-Pentyne (23f) 
(0.07mL; 0.72mmol) CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol 
%), and diisopropylamine (5mL), 30 was isolated as light 
yellow semisolid (66 mg; 54 %). 1H-NMR (300 MHz, 
CDCl3): δ = 0.95 (t, 3H, J = 7.4 Hz, CH3), 0.98 (t, 3H, J = 
7.3 Hz, CH3), 1.53–1.64 (m, 4H), 2.31 (s, 3H, CH3) 2.34 (t, 
2H, J = 7.1 Hz ), 2.42 (t, 2H, J = 7.0 Hz ), 7.19 (d, 2H, J = 
8.1 Hz ) 7.62 (d, 2H, J = 8.3 Hz ). 13C NMR (62 MHz, CDCl3): δ = 13.5, 13.7 (CH3), 
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21.3 (CH2), 21.4 (CH3), 21.5, 21.7 (CH2), 80.0, 90.7, 102.3 (C), 128.8, 129.5 (CH), 
129.9, 132.8, 133.5, 150.2, 150.8, 163.7 (C). IR (KBr): ν~ = 2961 (w), 2232 (m), 1611 
(w), 1529 (m), 1492 (s), 1355 (s), 1179 (m), 1149 (m), 1035 (m), 821 (m), 795 (m), 756 
(w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 336 (20) [M]+, 321 (04), 308 (100), 292 (03), 
279 (03), 256 (01), 229 (20), 243 (10), 208 (15), 178 (21). HRMS (EI, 70 eV): calcd. for 
C21H21ClN2 [M+] ; 336.13915 found 336.13930. 
7.6 Regioselective Sonogashira coupling reactions of 2, 3, 4, 5- tetra 
bromofuran. 
General Procedure for  Sonogashira coupling Reaction  
A suspension of tetrabromofuran (31), Pd(PPh3)2Cl2 (10 mol %), CuI (5 mol %) in 
Diisopropylamine was degassed three time in ace pressure tube. Acetylene (1.2 eq per 
bromine atom) were added using a syringe. The mixture was heated at the indicated 
temperature (60–80 °C) for 2-4 h. The reaction mixture was filtered and residue washed 
with  CH2Cl2 . The filtrate was washed with saturated solution of ammonium chloride (2 x 
25ml), water (2 x 25ml) and dried over anhydrous Na2SO4. Solvent was removed in 
vacuo. The product was purified by column chromatography on silica gel.  
General Procedure for Suzuki cross coupling Reaction  
The reaction was carried out in a pressure tube. To a dioxane suspension (3-5 ml) of di 
sonogashira product of tetrabromofuran, Pd(PPh3)2Cl2 (3-5 mol %), arylboronic acid (1.0 
eq per bromine atom) and K2CO3 (3eq) was added. The mixture was heated at the 
indicated temperature (60-100 °C) for the indicated period of time (2-4 h). The reaction 
mixture was diluted with water and extracted with CH2Cl2 (3 x 25ml). The combined 
organic layers were dried over Na2SO4, filtrated and the filtrate was concentrated in 
vacuo the residue was purified by flash chromatography (silica gel, ethyl acetate / 
heptanes)  
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3,4-Dibromo-2,5-bis((4-tert-butylphenyl)ethynyl)furan(32a)
starting with 31 (150 mg; 0.40mmol), 4-
ter-butylphenylacetylene(23a) (0.16mL; 
0.94mmol), CuI (5 mol %),Pd(PPh3)2Cl2
(10 mol %), and diisopropylamine 
(5mL), 32a was isolated as white solid 
(163 mg; 78 %);  m.p. 197–199 °C. 1H-NMR (300 MHz, CDCl3): δ = 1.36 (s, 18H, CH3), 
7.40 (d, 4H, J = 8.6Hz), 7.51 (d, 4H, J = 8.6Hz). 13C NMR (75.4MHz, CDCl3): δ = 31.1 
(CH3), 34.9, 81.5, 98.8, 109.3, 118.8 (C), 125.5, 132.3 (CH), 136.7, 152.6 (C). IR (KBr): 
ν~ = 2952 (w), 1497 (m), 1461 (m), 1362 (m), 1266 (m), 1102 (m), 1013 (m), 923 (w), 
833 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 536 (M+, [79Br, 79Br], 30), 538 (M+, [79Br, 
81Br], 100), 540 (M+, [81Br, 81Br], 62), 523 (52), 508 (02), 493 (04), 467 (03), 350 (03), 
314 (18), 299 (26), 254 (15), 226 (09). HRMS (EI, 70 eV): calcd for C28H26Br2O (M+, 
[79Br, 79Br]: 536.03449; found 536.03353; calcd for C28H26Br2O (M+, [79Br, 81Br]: 
538.03245; found 538.03238; calcd for C28H26Br2O (M+, [81Br, 81Br]: 540.03040; found 
540.03176. 
3,4-Dibromo-2,5-bis(phenylethynyl)furan (32b)
starting with 31 (150 mg; 0.40mmol), phenylacetylene 
(23b) (0.10mL; 0.94mmol), CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %), and diisopropylamine (5mL), 
32b was isolated as brown semisolid (118 mg; 71 %). 
1H-NMR (300 MHz, CDCl3): δ = 7.23–7.33 (m, 6H), 7.43–7.50 (m, 4H). 13C NMR (75 
MHz, CDCl3): δ = 81.6, 98.5, 109.6, 121.3 (C), 128.4, 128.5, 132.5 (CH), 136.7 (C). IR 
(KBr): ν~ = 3045 (w), 2214 (w), 1557 (m), 1494 (m), 1440 (m), 1342 (w), 1177 (w), 1043 
(w), 1010 (m), 914 (w), 746 (s), 681 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 424 (M+, 
[79Br, 79Br], 53), 426 (M+, [79Br, 81Br], 100), 428 (M+, [81Br, 81Br], 49), 397 (10), 345 
(20), 319 (29), 299 (21), 266 (23), 238 (36), 213 (06), 185 (02), 158 (01), 137 (12), 129 
(25). HRMS (EI, 70 eV): calcd for C20H10Br2O (M+, [79Br, 79Br]: 424.01121; found 
424.01081; calcd for C20H10Br2O (M+, [79Br, 81Br]: 426.02136; found 426.02087; calcd 
for C20H10Br2O (M+, [81Br, 81Br]: 428.31251; found 428.31202. 
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3,4-Dibromo-2,5-bis((3-methoxyphenyl)ethynyl)furan (32c):
starting with 31 (150 mg; 0.40mmol), 3-ethynyl 
anisole (23c) (0.12mL; 0.94mmol), CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %) and diisopropylamine 
(5mL), 32c was isolated as white solid (154 mg; 81 
%); m.p. 181–183 °C. 1H-NMR (250 MHz, CDCl3): δ
= 3.76 (s, 6H, 2OCH3), 6.79–6.86 (m, 3H), 6.93–6.97 (m, 3H), 7.03 (Brs, 2H ). 13C NMR 
(62 MHz, CDCl3): δ = 55.3 (OCH3), 81.5, 98.5, 109.7, 122.7 (C), 116.0, 117.1, 125.1, 
129.6 (CH), 136.6, 159.4 (C). IR (KBr): ν~ = 2958 (w), 2206 (w), 1579 (m), 1482 (m), 
1415 (m), 1312 (m), 1258 (m), 1224 (m), 1152 (m), 1034 (s), 1012 (m), 838 (m), 776 (s), 
676 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 484 (M+, [79Br, 79Br], 55), 486 (M+, [79Br, 
81Br], 11), 488 (M+, [81Br, 81Br], 443 (01), 379 (20), 326 (02), 298 (24), 262 (13), 243 
(08), 224 (03), 159 (11). HRMS (EI, 70 eV): calcd for C22H14Br2O3 (M+, [79Br, 79Br]: 
483.93042; found 483.93122; calcd for C22H14Br2O3 (M+, [79Br, 81Br]: 485.92837; found 
485.92982; calcd for C22H14Br2O3 (M+, [81Br, 81Br]: 487.92633; found 487.92704. 
3,4-Dibromo-2,5-bis((6-methoxynaphthalen-2-yl)ethynyl)furan (32d):
starting with 31 (150 mg; 0.40mmol), 
2-ethynyl-6-methoxynaphthalene     
(23d) (171 mg; 0.94mmol), CuI (5 mol 
%), Pd(PPh3)2Cl2 (10 mol %), and 
diisopropylamine (5mL), 32d was isolated as light yellow solid (174 mg; 76 %); m.p. 
198–200 °C. 1H-NMR (300 MHz, CDCl3): δ = 3.86 (s, 6H, 2OCH3), 7.03–7.15 (m, 5H), 
7.60–7.68 (m, 5H),  7.90 (Brs, 2H ). 13C NMR (62 MHz, CDCl3): δ = 55.3 (OCH3), 82.2, 
99.3 (C), 105.7 (CH), 109.3, 116.7 (C), 119.4, 126.8, 129.1, 129.3, 132.0 (CH), 132.7, 
134.6, 136.8, 158.7 (C). IR (KBr): ν~ = 2935 (w), 1619 (m), 1593 (m), 1478 (m), 1381 
(m), 1266 (m), 1227 (s), 1164 (s), 1025 (s), 898 (m), 853 (s), 823 (s), 808 (m) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 584(M+, [79Br, 79Br], 49), 586 (M+, [79Br, 81Br], 100), 588 
(M+, [81Br, 81Br], 51), 562(20), 493 (29), 429 (37), 362 (100), 347 (22), 319 (20), 304 
(06), 276 (19), 207 (01), 181 (12). HRMS (EI, 70 eV): calcd for C30H18Br2O3 (M+, [79Br, 
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79Br]: 583.96172; found 583.96297; calcd for C30H18Br2O3 (M+, [79Br, 81Br]: 585.95967; 
found 585.96120; calcd for C30H18Br2O3 (M+, [81Br, 81Br]: 587.96014; found 587.95966. 
3-Bromo-2,4,5-tris((3-methoxyphenyl)ethynyl)furan (33a)
starting with 31 (150 mg; 0.40mmol), 3-ethynyl 
anisole (23c) (0.18mL; 1.44mmol), CuI (5 mol 
%), Pd(PPh3)2Cl2 (10 mol %), and diiso 
propylamine (5mL), 33a was isolated as brown 
highly viscous oil (161 mg; 77 %). 1H-NMR (300 
MHz, CDCl3): δ = 3.73 (s, 3H, OCH3), 3.74 (s, 
6H, 2OCH3), 6.82–6.88 (m, 3H), 6.99–7.03 (m, 
3H), 7.07–7.12 (m, 3H), 7.17–7.22 (m, 3H). 13C 
NMR (75.4 MHz, CDCl3): δ = 55.3, 55.4 (CH3), 77.8, 77.9, 97.7, 98.0, 99.0, 108.6, 113.6 
(C), 115.3, 115.5, 115.9, 116.2, 116.3, 116.4, 116.6 (CH), 122.3, 123.4 (C), 124.2, 124.3, 
124.4, 129.5, 129.6 (CH), 136.5, 139.6, 159.3, 159.4 (C). IR (KBr): ν~ = 2935 (w), 1594 
(m), 1571 (s), 1422 (m), 1282 (m), 1228 (s), 1036 (s), 849 (m), 774 (s), 680 (s) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 536 (M+, [79Br], 90), 538 (M+, [81Br], 100), 458 (38), 429 
(97), 386 (19), 343 (07), 300 (18), 269 (11). HRMS (EI, 70 eV): calcd for C31H21BrO4
(M+, [79Br]: 536.06177; found 536.06195; calcd for C31H21BrO4 (M+, [81Br]: 538.05973; 
found 538.06091. 
3-Bromo-2,4,5-tris(m-tolylethynyl)furan (33b)
starting with 31 (150 mg; 0.40mmol), 3-ethynyl 
toluene (23h) (0.18mL; 1.44mmol), CuI (5 mol %), 
Pd(PPh3)2Cl2 (10 mol %), and diisopropylamine 
(5mL), 33b was isolated as brown highly viscous oil 
(139 mg; 73 %). 1H-NMR (300 MHz, CDCl3): δ = 
2.40 (Brs, 9H, 3CH3), 7.20–7.32 (m, 6H), 7.41–7.45 
(m, 6H). 13C-NMR (62 MHz, CDCl3): δ = 21.2 
(3CH3), 76.9, 77.8, 77.9, 97.9, 98.2, 99.2, 108.5, 115.8, 121.2, 121.3, 122.3 (C), 128.3, 
128.4, 128.8, 128.9, 129.8, 130.3, 130.4, 132.2, 132.3 (CH), 138.1, 138.2 (C). ; IR (KBr): 
ν~ = 2919 (w), 2200 (m), 1710 (m), 1600 (m), 1481 (m), 1359 (w), 1274 (w), 1218 (w), 
O
Br
O
O
O
O
Br
 96
1086 (m), 1026 (m), 906 (w), 780 (s), 686 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 488 
(M+, [79Br], 62), 490 (M+, [81Br], 66),  447 (02), 410 (02), 381 (100), 363 (06), 350 (04), 
287 (02), 263 (09), 245 (07), 224 (02), 182 (10), 175 (15). HRMS (EI, 70 eV): calcd for 
C31H21BrO (M+, [79Br]: 488.07703; found 488.07687; calcd for C31H21BrO (M+, [81Br]: 
490.07498; found 490.07535. 
3-Bromo-2,4,5-tri(pent-1-ynyl)furan (33c)
starting with 31 (150 mg; 0.40mmol), 1-pentyne (23g) 
(0.14mL; 1.44mmol), CuI (5 mol %), Pd(PPh3)2Cl2 (10 
mol %), and diisopropylamine (5mL), 33c was isolated as 
brown highly viscous oil (86 mg; 64 %). 1H-NMR (250 
MHz, CDCl3): δ = 0.92–1.02 (m, 9H), 1.46–1.63 (m, 6H), 
2.35–2.41 (m, 6H). 13C NMR (62 MHz, CDCl3): δ = 
13.3(CH3), 13.4 (2CH3), 21.5, 21.6, 21.9, 29.6, 30.1, 31.4 (CH2), 69.1, 69.7, 70.0, 98.0, 
99.1, 99.5, 107.0, 114.7, 135.7, 139.0 (C). IR (KBr): ν~ = 2961 (m), 2224 (w), 1714 (s), 
1455 (m), 1378 (w), 1181 (w), 1077 (w), 967 (w), 799 (w) cm-1. GC-MS (EI, 70 eV): m/z
(%) = 344 (M+, [79Br], 100), 346 (M+, [81Br], 95), 317 (57), 304 (03), 281 (07), 237 (05), 
193 (14), 178 (26), 165 (21). HRMS (EI, 70 eV): calcd for C19H21BrO (M+, [79Br]: 
344.08012; found 344.08031; calcd for C19H21BrO (M+, [81Br]: 346.01215; found 
346.01166. 
2,3,4,5-Tetrakis((3-methoxyphenyl)ethynyl)furan(34a)
starting with 31 (150 mg; 0.40mmol), 3-
ethynylanisole (23c) (0.24mL; 1.92 mmol), 
CuI (5 mol %), Pd(PPh3)2Cl2 (10 mol %), 
diisopropylamine (5mL), 34a was isolated as 
brown viscous oil (191 mg; 83 %). 1H-NMR 
(300 MHz, CDCl3): δ =3.73 (s, 6H, OCH3), 
3.75 (s, 6H, OCH3), 6.82-6.89 (m, 4H), 7.02-
7.04 (m, 4H), 7.09-7.13 (m, 4H), 7.17-7.21 (m, 4H). 13C NMR (75.4 MHz, CDCl3): δ = 
55.3, 55.4 (CH3), 77.9, 78.5, 97.3, 98.5, 115.3 (C), 115.4, 116.1, 116.3, 116.5 (CH), 
O
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122.5, 123.8 (C), 124.3, 129.5, 129.6 (CH),139.3, 159.3, 159.4 (C). IR (KBr): ν~ = 2935 
(w), 1571 (s), 1426 (m), 1283 (s), 1159 (s), 1036 (s), 850 (m), 776 (s), 681 (s) cm-1.GC-
MS (EI, 70 eV): m/z (%) = 588 (100) [M]+, 529 (02), 486 (11), 429 (23), 400 (14), 294 
(06), 262 (26), 243(03), 207 (04). HRMS (EI, 70 eV): calcd. for C40H28O5 [M+] ; 
588.19313 found 588.19343. 
2,3,4,5-Tetrakis((4-tert-butylphenyl)ethynyl)furan (34b)
starting with 31 (150 mg; 0.40mmol), 4-
(tert-butyl)phenylacetylene (23a) (0.31mL; 
1.92 mmol), CuI (5 mol %), Pd(PPh3)2Cl2
(10 mol %), diisopropylamine (5mL), 34b
was isolated as brown semisolid (219 mg; 
81 %). 1H-NMR (300 MHz, CDCl3): δ
=1.24 (s, 18H, 6CH3), 1.25 (s, 18H, 6CH3), 
7.30 (d, 4H, J = 8.5 Hz) 7.32 (d, 4H, J = 8.3 
Hz) 7.42 (d, 4H, J = 8.2Hz) 7.44 (d, 4H, J = 8.6 Hz). 13C NMR (62 MHz, CDCl3): δ = 
31.1, 31.2 (CH3), 34.8, 34.9, 76.7, 77.6, 97.7, 98.2, 115.7, 118.5, 119.5 (C), 125.4, 125.5, 
131.4, 131.5 (CH), 139.5, 152.2, 152.8 (C). IR (KBr): ν~ = 2954 (m), 2199 (w), 1659 (w), 
1603 (w), 1566 (w), 1499 (m), 1460 (m), 1362 (m), 1266 (m), 1105 (m), 1015 (m), 831 
(s), 735 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 692 (100) [M]+, 677 (10), 647 (01), 632 
(10), 616 (15), 599 (03), 536 (02), 477(20), 331 (13), 293 (02). HRMS (EI, 70 eV): calcd. 
for C52H52O [M+] ; 692.40127 found 692.40322. 
2,3,4,5-Tetrakis(m-tolylethynyl)furan (34c)
starting with 31 (150 mg; 0.40mmol), 3-ethynyltoluene  
(23h) (0.24mL; 1.92 mmol),CuI (5 mol %),  
Pd(PPh3)2Cl2 (10 mol %), diisopropylamine (5mL), 34c
was isolated as brown semisolid (153 mg; 75 %). 1H-
NMR (300 MHz, CDCl3): δ = 2.28 (s, 6H, 2CH3), 2.29 
(s, 6H, 2CH3), 7.08–7.22 (m, 9H),  7.31–7.35 (m, 7H). 
13C NMR (75 MHz, CDCl3): δ = 21.2 (CH3), 77.9, 
78.6, 97.5, 98.6, 115.3, 121.5, 122.7 (C), 128.3, 128.4, 128.8, 129.6, 130.2, 132.2, 132.4 
O
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(CH), 138.0, 138.2, 139.3 (C). IR (KBr): ν~ = 2917 (w), 2197 (w), 1709 (m), 1600 (w), 
1360 (m), 1219 (m), 1058 (w), 899 (m), 874 (m), 775 (s), 683 (s) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 524 (100) [M]+, 481 (05), 464 (02), 381 (04), 329 (03), 281 (02), 262 
(08), 242 (06), 226 (05), 207 (04), 169 (02). HRMS (EI, 70 eV): calcd. for C40H28O [M+] 
; 524.21347 found 524.21434. 
2,5-Bis((4-tert-butylphenyl)ethynyl)-3,4-bis(3-methoxyphenyl)furan (35a)
starting with 32b (108 mg; 0.2mmol), 4-
methoxyphenylboronic acid (18e) (61 mg; 
0.40 mmol), Pd(PPh3)2Cl2 (10 mol %), 
K2CO3(83 mg; 0.60 mmol) Dioxane 
(5mL), 35a was isolated as light brown 
crystalline  solid (90 mg; 76 %); m.p. 
162–164 °C. 1H-NMR (300 MHz, CDCl3): δ =1.24 (s, 18H, CH3), 3.75 (s, 6H, OCH3), 
6.80(d, 4H, J = 8.8Hz), 7.23-7.41 (m, 12H). 13C-NMR (75.4 MHz, CDCl3): δ = 31.1 
(CH3), 34.9 (C), 55.2 (CH3), 79.5, 95.8 (C), 113.6 (CH), 114.2, 119.3, 123.5 (C),125.4, 
130.6, 131.1 (CH), 134.5, 152.1, 159.0 (C). IR (KBr): ν~ = 2959 (m), 2188 (m), 1729 (w), 
1608 (m), 1512 (m), 1247 (s), 1175 (m), 1034 (m), 981 (m), 832 (s) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 592 (100) [M]+, 577 (12), 562 (03), 547 (02), 532 (02), 407 (30), 391 
(19), 377 (26), 296 (05), 281 (16). HRMS (EI, 70 eV): calcd. for C42H40O3 [M+]; 
592.29720 found 592.29492. 
3,4-Bis(4-methoxyphenyl)-2,5-bis(phenylethynyl)furan (35b)
starting with 32c (90 mg; 0.2mmol), 4-methoxy 
phenylboronic acid (18e) (61 mg; 0.40 mmol), 
Pd(PPh3)2Cl2 (10 mol %), K2CO3 (83mg; 0.60 mmol) 
Dioxane (5mL), 35b was isolated as light brown 
crystalline solid (70 mg; 69 %); m.p. 146–148 °C. 1H-
NMR (250 MHz, CDCl3): δ =3.75 (s, 6H, 3OCH3),  
6.81 (d, 4H, J = 8.8Hz). 7.24-7.28 (m, 10H), 7.37-7.41 (m, 4H). 13C NMR (75 MHz, 
CDCl3): δ = 55.2 (OCH3), 80.1, 95.6 (C), 113.7 (CH), 122.3, 123.4 (C), 128.4, 128.7 
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(CH), 129.8 (C), 130.6, 131.4 (CH), 134.5, 159.1 (C). IR (KBr): ν~ = 2916 (w), 1611 (m), 
1509 (m), 1441 (m), 1395 (w), 1291 (m), 1248 (s), 1172 (m), 1108 (w), 1029 (m), 979 
(m), 825 (s), 751 (s), 689 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 480 (100) [M]+, 465 
(02), 421 (20), 351 (08), 336 (13), 308 (02), 263 (21), 240 (33), 213 (09). HRMS (EI, 70 
eV): calcd. for C34H24O3 [M+] ; 480.17200 found 480.17223. 
3,4-Bis(4-methoxyphenyl)-2,5-bis((3-methoxyphenyl)ethynyl)furan (35c)
starting with 32a (100 mg; 0.2mmol), 4-
methoxyphenylboronic acid (18e) (61 mg; 
0.40 mmol), Pd(PPh3)2Cl2 (10 mol %), 
K2CO3 (83mg; 0.60 mmol) Dioxane (5mL), 
35c was isolated as light brown crystalline  
solid (87 mg; 79 %); m.p. 144–146 °C. 1H-
NMR (250MHz, CDCl3): δ =3.73 (s, 6H, 2OCH3), 3.75 (s, 6H, 2OCH3), 6.79–6.84 (m, 
5H), 6.90–6.92 (m, 2H), 6.99 (d, 2H, J = 8.1 Hz), 7.13–7.19 (m, 3H), 7.26 (d, 4H, J = 8.7 
Hz). 13C NMR (62 MHz, CDCl3): δ = 55.2, 55.3 (CH3), 79.8, 95.6 (C), 113.7 (CH), 114.8 
(C), 115.3, 116.1 (CH), 123.2, 123.3 (C), 124.0, 129.5 (CH), 130.0 (C), 130.6 (CH), 
134.4, 159.1, 159.3 (C). IR (KBr): ν~ = 2932 (w), 1583 (m), 1507 (m), 1461 (m), 1424 
(m), 1289 (m), 1246 (s), 1177 (m), 1145 (m), 1032 (s), 984 (m), 829 (s), 772 (s), 682 (s) 
cm-1. GC-MS (EI, 70 eV): m/z (%) = 540 (100) [M]+, 481 (04), 423 (04), 381 (13), 338 
(06), 270 (06), 211 (06). HRMS (EI, 70 eV): calcd. for C36H28O5 [M+] ; 540.19313 found 
540.19213. 
2,5-Bis((6-methoxynaphthalen-2-yl)ethynyl)-3,4-dip-tolylfuran (35d)
starting with 32d (120 mg; 0.2 mmol), 
4-methylphenylboronic acid (18f) (54 
mg; 0.40 mmol), Pd(PPh3)2Cl2 (10 
mol %), K2CO3 (83 mg; 0.60 mmol) 
Dioxane (5mL), 35d was isolated as 
dark brown semisolid (92 mg; 74 %).
1H-NMR (300 MHz, CDCl3): δ =2.31 (s, 6H, 2CH3), 3.86 (s, 6H, 2OCH3), 7.07–7.11 (m, 
O
O O
O
O O
O O
 100
7H), 7.27 (d, 4H, J = 8.1Hz), 7.40 (d, 2H, J = 8.5Hz), 7.56–7.67 (m, 5H), 7.84 (Brs, 2H). 
13C NMR (75 MHz, CDCl3): δ = 21.3 (CH3), 55.4 (OCH3), 79.8, 96.3 (C), 106.0 (CH), 
117.1 (C), 119.5, 126.9 (CH), 128.4 (C), 128.5, 128.9, 129.3, 129.4 (CH), 129.8, 130.0, 
134.3, 134.9, 137.4, 158.5 (C). IR (KBr): ν~ = 2923 (m), 2180 (m), 1713 (m), 1621 (s), 
1602 (s), 1497 (m), 1480 (m), 1390 (m), 1264 (s), 1212 (s), 1163 (s), 1027 (s), 885 (m), 
851 (s), 811 (m), 736 (w) cm-1.GC-MS (EI, 70 eV): m/z (%) = 608 (12) [M]+, 549 (23), 
503 (42), 476 (29), 419 (15), 343 (100), 328 (05), 287 (28), 259 (13), 231 (03), 202 (06). 
HRMS (EI, 70 eV): calcd. for C44H32O3 [M+] ; 608.23460 found 608.23805. 
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Appendix  Crystal Data and Structure Refinement 
Table 25.  Crystal data and structure refinement for 7d
Identification code  7d 
Empirical formula  C16 H12 S 
Formula weight  236.32 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group (H.-M.)  F d d 2 
Space group (Hall)  F2 d2
Unit cell dimensions a = 26.425(15) Å α= 90.00. 
b = 31.214(15) Å β= 90.00 
c = 5.775(3) Å γ = 90.00. 
Volume 4764(4) Å3
Z 8 
Density (calculated) 1.388 Mg/m3
Absorption coefficient 0.243mm
-1
F(000) 1984 
Crystal size 0.31x 0.12x 0.11mm3
Θ range for data collection 2.02 to 30.00°. 
Index ranges -36
h
25, -43
k
39, -4
l
8 
Reflections collected 7610 
Independent reflections 2711 [R(int) = 0.0368] 
Completeness to Θ = 29.00° 99.2%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9285 and 0.9738 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2173 / 1 / 154 
Goodness-of-fit on F2 1.046 
Final R indices [I>2σ(I)] R1 = 0.0409, wR2 = 0.0901 
R indices (all data) R1 = 0.0593, wR2 = 0.0970 
Largest diff. peak and hole 0.262and -0.224e.Å-3
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Table 26.  Crystal data and structure refinement for 19f
Identification code  19f 
Empirical formula  C29 H22 O2
Formula weight  402.47 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group (H.-M.)  P 21/c 
Space group (Hall)  -P 2ybc 
Unit cell dimensions a = 9.709(8) Å α= 90.00. 
b = 9.924(7) Å β= 99.40(3). 
c = 22.922(18) Å γ = 90.00. 
Volume 2179(3) Å3
Z 4 
Density (calculated) 1.227Mg/m3
Absorption coefficient 0.076 mm-1
F(000) 848 
Crystal size 0.64x 0.50x 0.21mm3
Θ range for data collection 3.00 to 28.50°. 
Index ranges -12
h
13, -12
k
13, -30
l
20 
Reflections collected 21616 
Independent reflections 5505 [R (int) = 0.0364] 
Completeness to Θ = 29.00° 99.6%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9532 and 0.9843 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4207 / 0 / 282 
Goodness-of-fit on F2 1.078 
Final R indices [I>2σ(I)] R1 = 0.0514, wR2 = 0.1360 
R indices (all data) R1 = 0.0688, wR2 = 0.1453 
Largest diff. peak and hole 0.369 and -0.303e.Å-3
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Table 27.  Crystal data and structure refinement for 24c
Identification code  24c 
Empirical formula  C22 H14 Cl2 N2 O2
Formula weight  409.25 
Temperature  173(2) K 
Wavelength  0.71073Å 
Crystal system  orthorhombic 
Space group (H.-M.)  P b c n 
Space group (Hall)  P 2n 2ab 
Unit cell dimensions a = 3.8669(17) Å α= 90.00. 
b = 17.742(6) Å β= 90.00. 
c = 27.590(9) Å γ = 90.00. 
Volume 1892.8(12) Å3
Z 4 
Density (calculated) 1.436Mg/m3
Absorption coefficient 0.364mm-1
F(000) 840 
Crystal size 0.42x 0.08x 0.07mm3
Θ range for data collection 2.30to 22.82°. 
Index ranges -4
h
4, -19
k
19, -23
l
30 
Reflections collected 13846 
Independent reflections 1294 [R (int) = 0.0405] 
Completeness to Θ = 29.00° 99.8%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8622 and 0.9750 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 1041/ 0 / 130 
Goodness-of-fit on F2 1.042 
Final R indices [I>2σ(I)] R1 = 0.0290, wR2 = 0.0672 
R indices (all data) R1 = 0.0414, wR2 = 0.0708 
Largest diff. peak and hole 0.144and -0.193e.Å-3
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Table 28.  Crystal data and structure refinement for 28
Identification code  28 
Empirical formula  C20 H14 Cl2 N2 O 
Formula weight  369.23 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group (H.-M.)  C 2/c 
Space group (Hall)  -C 2yc 
Unit cell dimensions a = 18.9682(7) Å α= 90.00. 
b = 10.5747(3) Å β= 103.206(2) °. 
c = 17.6689(5) Å γ= 90.00°. 
Volume 3450.36(19) Å3
Z 8 
Density (calculated) 1.422Mg/m3
Absorption coefficient 0.386 mm-1
F (000) 1520 
Crystal size 0.69 x 0.64 x 0.10 mm3
Θ range for data collection 2.22 to 29.99°. 
Index ranges -26
h
26, -14
k
14, -24
l
24 
Reflections collected 34320 
Independent reflections 5012 [R(int) = 0.0239] 
Completeness to Θ = 29.00° 99.8%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7764 and 0.9624 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3954 / 0 / 228 
Goodness-of-fit on F2 1.087 
Final R indices [I>2σ(I)] R1 = 0.0449, wR2 = 0.1261 
R indices (all data) R1 = 0.0614, wR2 = 0.1364 
Largest diff. peak and hole 0.523 and -0.317 e.Å-3
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Table 29.  Crystal data and structure refinement for 29
Identification code  29 
Empirical formula  C29 H21 Cl1 N2 O2
Formula weight  464.93 
Temperature  173(2) K 
Wavelength  0.71073Å 
Crystal system  Triclinic 
Space group (H.-M.)  1P   
Space group (Hall)  -P 1 
Unit cell dimensions a = 10.4979(9) Å α= 113.847(2) °. 
b = 11.1694(5) Å β= 102.708(2) °. 
c = 11.4714(5) Å γ = 97.191(3) °. 
Volume 1165.04(12) Å3
Z 2 
Density (calculated) 1.325Mg/m3
Absorption coefficient 0.194mm-1
F(000) 484 
Crystal size 0.66x 0.23x 0.10mm3
Θ range for data collection 2.89 to 27.99°. 
Index ranges -13
h
13, -14
k
14, -15
l
14 
Reflections collected 18933 
Independent reflections 5511 [R(int) = 0.0271] 
Completeness to Θ = 29.00° 98.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8828 and 0.9809 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3816 / 0 / 321 
Goodness-of-fit on F2 1.098 
Final R indices [I>2σ(I)] R1 = 0.0482, wR2 = 0.1290 
R indices (all data) R1 = 0.0807, wR2 = 0.1397 
Largest diff. peak and hole 0.279and -0.302e.Å-3
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Table 30.  Crystal data and structure refinement for 35a
Identification code  35b 
Empirical formula  C42 H40 O3
Formula weight  592.74 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group (H.-M.)  P c 
Space group (Hall)  P y2 c 
Unit cell dimensions a = 9.8252(2) Å α= 90.00. 
b = 19.0652(4) Å β= 97.1530(10) ° 
c = 18.3191(4) Å γ = 90.00. 
Volume 3404.82(12) Å3
Z 4 
Density (calculated) 1.156Mg/m3
Absorption coefficient 0.071mm-1
F(000) 1264 
Crystal size 0.69x 0.55x 0.38mm3
Θ range for data collection 2.14 to 29.00°. 
Index ranges -13
h
13, -23
k
26, -24
l
24 
Reflections collected 34636 
Independent reflections 16746 [R(int) = 0.0282] 
Completeness to Θ = 29.00° 99.8%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9526 and 0.9735 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 11566 / 2 / 843 
Goodness-of-fit on F2 1.022 
Final R indices [I>2σ(I)] R1 = 0.0523, wR2 = 0.1152 
R indices (all data) R1 = 0.0880, wR2 = 0.1262 
Largest diff. peak and hole            0.226 and -0.160e.Å-3
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Abbreviations 
Ac  Acetyl  
Anal  Elemental Analysis  
bp  Boiling point  
calcd  Calculated  
CI  Chemical Ionization  
COSY  Correlated Spectroscopy  
DEPT  Distortionless Enhancement by Polarization Transfer  
dr  Diastereomeric ratio  
ee  Enantiomeric excess  
EI  Electron Impact   
Et2O  Diethyl ether  
EtOH  Ethanol  
GC  Gas Chromatography  
GP  General Procedure  
HMBC Heteronuclear Multiple Bond Correlation  
HPLC  High Performance Liquid Chromatography  
HRMS  High Resolution Mass Spectrometry  
IR  Infrared Spectroscopy  
MS  Mass Spectrometry  
mp  Melting point  
NaOEt  Sodium ethanolate  
nBuLi  n-Butyllithium  
NEt3  Triethylamine  
NMR  Nuclear Magnetic Resonance  
NOESY Nuclear Overhauser and Exchange Spectroscopy 
ORTEP Oak Ridge Thermal Ellipsoid Plot   
OTf  Triflate  
Ph  Phenyl  
ppm  Parts per million  
Rf  Retention factor  
Tf2O  Trifluoromethanesulfonic anhydride (triflic anhydride) 
TFA  Trifluoroacetic acid  
THF  Tetrahydrofuran  
TLC  Thin Layer Chromatography  
TMS   Tetramethylsilane  
Tol  Tolyl (p-MeC6H4)  
Tos  Tosyl (p-MeC6H4SO2 
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